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Abstract 
Glycine receptors (GlyRs) mediate fast inhibitory neurotransmission in the spinal cord and 
brainstem. Four GlyR subunits (α1 – 3, β) have been identified in humans, and their differential 
anatomical distributions result in a diversity of synaptic isoforms with unique physiological and 
pharmacological properties. However, despite their importance in controlling neuronal function, 
little is known about these properties. To address this, we developed an ‘artificial’ synapse system 
which allows to control over the synaptic GlyR subunit composition. We induced the formation of 
recombinant synapses between cultured spinal neurons and HEK293 cells expressing GlyR subunits 
of interest plus the synapse-promoting molecule, neuroligin-2A. In the heterosynapses thus formed, 
recombinant α1β and α3β GlyRs mediated fast decaying inhibitory postsynaptic currents (IPSCs) 
whereas α2β GlyRs mediated slow decaying IPSCs. These results are consistent with the 
fragmentary information available from native synapses and single channel kinetic studies. As β 
subunit incorporation is considered essential for localizing GlyRs at the synapse, we were surprised 
that α1 – 3 homomers supported robust IPSCs with β subunit incorporation accelerating IPSC rise 
and decay times in α2β and α3β heteromers only. Finally, heterosynapses incorporating α1D80Aβ and 
α1A52Sβ GlyRs exhibited accelerated IPSC decay rates closely resembling those recorded in native 
synapses from mutant mice homozygous for these mutations, providing an additional validation of 
our technique. As our model system successfully recapitulates the effects of known GlyR disease 
mutations, we employed it to investigate the effects of new GlyR disease mutations.   
 
Hyperekplexia is a human neuromotor disorder caused by mutations that impair glycinergic 
neurotransmission. We investigated the mechanism by which gain-of-function GlyR mutations 
cause hyperekplexia. We identified two new gain-of-function mutations (I43F, W170S) and 
characterised these along with the known gain-of-function mutations (Q226E, V280M, R414H) to 
identify how they cause hyperekplexia. Using ‘artificial’ synapses, we show that all mutations 
prolong the decay of IPSCs and induce spontaneous activation. As these effects may deplete the 
chloride electrochemical gradient, hyperekplexia could potentially result from reduced glycinergic 
inhibitory efficacy. However, we consider this unlikely as it should also lead to pain sensitization 
and a hyperekplexia phenotype that correlates with mutation severity, neither of which is observed 
in patients. We also rule out small increases in IPSC decay times (as caused by W170S and R414H) 
as a possible mechanism given that the clinically-important drug, tropisetron, increases glycinergic 
IPSC decay times without causing motor side effects. A recent study concluded that an elevated 
intracellular chloride concentration late during development ablates α1β glycinergic synapses but 
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spares GABAergic synapses. As this mechanism satisfies all our considerations, we propose it is 
primarily responsible for the gain-of-function hyperekplexia phenotype. 
 
GlyRs containing α2 subunits exert excitatory effects in immature neurons, and thereby modulate 
neuronal migration and synapse formation. The α2 R350L mutation has been identified in a human 
patient with autism spectrum disorder (ASD). This mutation was found to slow both the channel 
closing rate and the IPSC decay time. As mutation of R350 to Ala, Lys or Ile did not affect the 
IPSC decay time, we propose the Leu mutation specifically affects a molecular interaction 
responsible for the prolonged IPSC time courses. However, the link between the R350L and ASD 
remains to be elucidated.  
 
Zn2+ is concentrated into presynaptic vesicles at central synapses and is released into the synaptic 
cleft by nerve terminal stimulation. There is strong evidence that synaptically released Zn2+ 
modulates glutamatergic neurotransmission, although there is debate concerning its peak 
concentration in the cleft. GlyRs are potentiated by low nanomolar Zn2+ and inhibited by 
micromolar Zn2+. A mutation that ablates Zn2+ potentiation of GlyRs results in a hyperekplexia 
phenotype suggesting that Zn2+ physiologically modulates glycinergic neurotransmission. There is, 
however, little evidence that Zn2+ is stored presynaptically at glycinergic terminals and it is possible 
that the modulation is mediated by tonically bound Zn2+. We sought to estimate the peak Zn2+ 
concentration in the glycinergic synaptic cleft as a means of evaluating whether it is likely to be 
synaptically released. We generated ‘artificial’ synapses expressing α1β GlyRs with defined Zn2+ 
sensitivities. By comparing the effect of Zn2+ chelation on glycinergic IPSCs with the effects of 
defined Zn2+ plus glycine concentrations applied rapidly to recombinant GlyRs in outside-out 
patches under simulated synaptic activation conditions, we inferred that synaptic Zn2+ rises to at 
least 1 µM following a single presynaptic stimulation. Moreover, using the fast high-affinity 
chelator, ZX1, we found no evidence for tonic Zn2+ bound constitutively to high affinity GlyR sites. 
We conclude that diffusible Zn2+ reaches 1 µM or higher and is therefore likely to be phasically 
released at glycinergic synapses. 
 
Taken together, these results provide significant new insights into normal and abnormal glycinergic 
neurotransmission and the physiological modulatory mechanisms of glycinergic IPSCs. 
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Chapter 1: Introduction 
1 Glycine receptor 
 Glycine receptor structure and function 
Glycine receptor (GlyR) chloride channels play a critical role in mediating fast inhibitory 
neurotransmission in the human adult spinal cord, brain stem and retina (Lynch, 2004). They 
belong to the pentameric ligand-gated ion channels (pLGICs), which also include nicotinic 
acetylcholine, serotonin 5-hydroxytryptamine type 3 (5-HT3) and type A γ-amino-butyric acid 
(GABAA) receptors. GlyRs assemble as homopentamers from α subunits, or heteropentamers from 
α and β subunits. Heteromeric forms are thought to include three α and two β, or two α and three β 
(Durisic et al., 2012; Yang et al., 2012). Each transmembrane subunit is composed of an 
extracellular domain (ECD) harbouring a ligand-binding site, a transmembrane domain (TMD) 
made of four α-helical TM1-TM4, and a large intracellular loop domain (ILD) connecting the TM3 
and TM4 that influences the ion conductance (Carland et al., 2009) and interaction with 
intracellular proteins (Kim et al., 2006a; Del Pino et al., 2014). Fast quantal (< 1 ms) and high 
concentration (> 1 mM) release of glycine triggers the opening of channel gate (Legendre, 1998; 
Beato, 2008), resulting in a flux of anions through the channel pore that causes a rapid 
hyperpolarization and inhibition of the postsynaptic neurons. The glycinergic inhibition is 
important in many physiological processes including muscle tone, motor control and sensory 
processing, and its malfunction has been directly linked to a range of neurological disorders 
including hyperekplexia, temporal lobe epilepsy, autism, breathing disorders and chronic 
inflammatory pain. 
 
The structural related proteins provide a framework for the gating mechanism and ligand 
recognition of GlyRs. Recent reports have revealed the structures of the GlyR in complex with its 
competitive antagonist strychnine (Du et al., 2015; Huang et al., 2015), also the glycine- and 
glycine/ivermectin-bound reconstructions (Du et al., 2015) (Fig. 1). These findings enhance current 
understanding of molecular mechanisms for ligand-dependent gating in GlyRs. 
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Figure 1: The overall architecture of GlyR. a − c, 3D reconstructions of the strychnine- (blue), glycine- (yellow) and 
glycine/ivermectin- (red) bound GlyR structures determined by single-particle electron cryo-microscopy, viewed 
parallel to the plasma membrane. d − f, The cartoon models of a − c. g − i, views from the extracellular side of the 
membrane (Du et al., 2015) 
 
 Glycine receptor subunit expression 
Four isoforms of the α subunit (α1 – α4) and one isoform of β subunit are identified in mammals 
and share a > 90% amino acid sequence homology with each other. Their gene expression profiles 
are developmentally and regionally regulated. In the embryonic state, α2 transcripts are abundantly 
and widely expressed in spinal cord and brainstem (Kuhse et al., 1991). During the developmental 
period, there is a switch from α2 homomeric GlyRs to α1β heteromeric GlyRs (Lynch, 2009). 
Nonetheless, reduced densities of α2 mRNA still present in adult hippocampus, cerebral cortex and 
thalamus (Malosio et al., 1991; Sato et al., 1992; Lynch, 2004). After birth, α1 and α3 expression 
become more abundant. In situ hybridization studies reveal that α1 are prominently expressed in the 
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spinal cord, brainstem cerebellar deep nuclei, hypothalamus and colliculi (Malosio et al., 1991; 
Greferath et al., 1994). α3 subunit expression is relatively lower than α1 subunit at all 
developmental stages, and restricted to superficial laminae of the dorsal horn and respiratory 
network of the brainstem (Malosio et al., 1991; Harvey et al., 2004; Manzke et al., 2010). α4 has 
been described as an embryonic GlyR subunit isoform, which is only expressed in chick spinal 
cord, lumbosacral sympathetic ganglia and dorsal root ganglia (Harvey et al., 2000), but is 
presumed to be a pseudo-gene in humans due to a premature stop codon. In contrast, the β subunit 
gene is transcribed at all developmental stages and cannot form functional receptor alone. β subunit 
mRNA are widely and abundantly distributed in spinal cord and brain (Grenningloh et al., 1990; 
Fujita et al., 1991). This pattern of distribution is similar to that of α1 subunit mRNA. β subunit is 
considered to be indispensable for synaptic clustering by interacting with the receptor-anchoring 
protein gephrin (Meyer et al., 1995), therefore it is generally assumed that α1β isoform of the GlyR 
dominates at most “native” adult synapses in the spinal cord and brainstem (Singer et al., 1998). 
 
 Glycine receptor and disease 
Alterations in the function of GlyRs have been implicated in many human diseases, such as 
hyperekplexia, autism, pain, epilepsy, motor neuron disease and breathing disorders. 
 Hyperekplexia 
Loss of glycinergic synaptic signalling has been implicated in a rare hereditary neurological 
disorder, known as hyperekplexia, or startle disease. Hyperekplexia is characterized by neonatal 
hypertonia and an exaggerated startle reflex in response to sudden, unexpected stimuli (Bakker et 
al., 2006). Mutations in the GLRA1 or GLRB genes, which encode the α1 and β GlyR subunits 
respectively, are the major cause of hyperekplexia (Harvey et al., 2008; Bode and Lynch, 2013, 
2014).  To date, more than 50 GLRA mutations and 18 GLRB mutations have been identified in 
humans (Bode and Lynch, 2014). The vast majority of these mutations are loss-of-function in that 
they reduce the ability of GlyRs to flux chloride. Recessive hyperekplexia mutations generally 
result in the loss of α1 or β GlyR protein expression at the cell surface, whereas dominant mutations 
usually allow strong surface expression but impair channel function via reduced open probability, 
single channel conductance or glycine sensitivity (Harvey et al., 2008; Bode and Lynch, 2014). In 
addition, several GLRA1 gain-of-function hyperekplexia mutations have been detected to evoke 
spontaneous channel activity, which is paradoxical in that these mutations generated different levels 
of prolonged postsynaptic glycinergic currents but full hyperekplexia phenotype (Zhang et al., 
2016). All genetic forms of hyperekplexia are successfully treated with the benzodiazepine or 
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clonazepam (Bakker et al., 2006; Thomas et al., 2013), which acts by enhancing GABAergic 
synaptic transmission.  
 Autism 
Autism spectrum disorders (ASDs) are a group of heterogeneous neurodevelopmental disorders 
characterized by deficits in social interaction and communication. ASD is thought to result from 
dysfunctional development of multiple brain areas and to be associated with perturbed excitatory 
and inhibitory balance. Neuroligins (NLs) are postsynaptic cell-adhesion molecules that are 
essential for synapse maturation and specification. Mutations in the human NL genes NLGN3 and 
NLGN4 were detected in patients with ASDs (Mackowiak et al., 2014). Using the transgenic mice 
model, the NLGN3 mutation was found to affect the balance between inhibition and excitation with 
an increase of inhibitory neurotransmission (Tabuchi et al., 2007).  
 
GlyRs containing a2 subunits exert excitatory effects in immature neurons, and thereby modulate 
neuronal migration and synapse formation. Microdeletions and missense mutations in GLYA2 gene, 
encoding the GlyR a2 subunit, have been reported to represent a rare cause of ASDs (Piton et al., 
2011; Pilorge et al., 2015). Previous studies have demonstrated that GLYA2 mutations associated 
with ASD cause reduced surface GlyR expression and glycine sensitivity, and aberrant plasticity in 
the prefrontal cortex resulted from altered glycinergic transmission (Pilorge et al., 2015).  Further 
investigation of the precise link between GLYA2 and neuronal migration abnormalities related to 
ASDs may provide essential insights into underlying molecular mechanisms. 
 Pain 
Both a1 and a3 GlyR subunits were found to present at glycinergic synapses on pain sensory 
neurons in the spinal cord superficial laminae (Harvey et al., 2004). GlyR α3−/− mice display a loss 
of pain sensitization induced by peripheral inflammation without defects in motor coordination 
(Harvey et al., 2004). Inflammatory mediators (notably prostaglandin E2) induce chronic 
inflammatory pain by phosphorylating, and inhibiting, α3-containing GlyRs (Ahmadi et al., 2002; 
Harvey et al., 2004). A reduction of glycinergic inhibition onto superficial dorsal horn neurons 
leads to an increased transmission of nociceptive input to higher brain region. This mechanism, 
which provides a paradigm for chronic inflammatory pain sensitisation, implies that compounds 
that positively modulate α3β GlyRs should be analgesic. Given that α1β GlyRs have broader 
distribution and potentiating a1b GlyRs causes severe motor disorders and other side effects 
(Zeilhofer, 2005; Lynch and Callister, 2006), molecules with selectivity for α3β over α1β GlyRs are 
implicated as new generation treatments for chronic pain. 
	 6	
 Temporal lobe epilepsy 
In addition to processing of nociceptive signals, α3 GlyRs are also involved in hippocampal 
pathophysiology of temporal lobe epilepsy (Meier et al., 2005; Eichler et al., 2008; Eichler et al., 
2009). It has been demonstrated that post-transcriptional RNA editing produces a new gain-of-
function GlyR α3 isoform, GlyR α3P185L, resulted from cytidine 554 deamination (C554U) (Meier 
et al., 2005). The proline to leucine editing of GlyR α3 remarkably enhances sensitivity to glycine 
and remains open for longer during each synaptic events (Meier et al., 2005; Legendre et al., 2009; 
Dixon et al., 2015). Additionally, RNA editing of GlyR α2 at the corresponding position (P192L) 
was found in patients with temporal lobe epilepsy, and also produces receptors with increased 
agonist affinities (Eichler et al., 2008). 
 Motor neuron disease 
Motor neuron disease or amyotrophic lateral sclerosis (ALS) is an adult onset neurological disease 
characterized by progressive motor neuron degeneration. A loss of glycinergic innervation of spinal 
motor neurons is evident in transgenic mouse model of ALS (Chang and Martin, 2009, 2011), 
suggesting hyperexcitability of motor neurons which results from the insufficient synaptic 
inhibition could plausibly contribute to the pathogenesis of ALS. 
  Breathing disorders 
Inhibitory interactions between neurons of the brainstem respiratory network enable stable rhythmic 
breathing. A failure of glycinergic inhibitory transmission has been implicated in impairment of 
respiratory rhythm (Schmid et al., 1991; Pierrefiche et al., 1998; Busselberg et al., 2001), which 
may even lead to sudden death (Busselberg et al., 2001; Markstahler et al., 2002; Harvey et al., 
2008).  
 GlyR pharmacology  
 Competitive antagonist – strychnine 
GlyR channels can be activated by glycine, taurine and β-alanine, and efficiently antagonized by 
the plant alkaloid strychnine. Strychnine inhibits the function of GlyRs in a competitive manner, 
with a considerably high affinity (Ki = 16 nM) (Akagi et al., 1991; Brams et al., 2011). Like glycine 
and other agonist, the binding site for strychnine is located at the extracellular N-terminal domain. 
The residue Phe-63, Gly-160, Lys-200, Tyr-202 and Phe-207 have been defined the important 
determinants of strychnine binding, which are closed to agonist binding sites (Vandenberg et al., 
1992b; Vandenberg et al., 1992a; Grudzinska et al., 2005; Huang et al., 2015). The core strychnine 
binding residues are highly conserved across the GlyR subunits but not the other pLGIC members, 
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which may account for highly selective for GlyRs over any other receptor type.  Thus strychnine is 
commonly used as a unique tool in distinguishing glycinergic from GABAergic inhibition. 
 Allosteric agonist – ivermectin 
Ivermectin, a naturally occurring macrocyclic lactone, potently activates glutamate-gate chloride 
channel receptor which is present in the neurons and muscle cells of nematodes and some 
arthropods but is absent in vertebrate (McCavera et al., 2009). Hence, ivermectin commercially 
used as an antiparasitic agent in both human medicine and veterinary practice (Omura, 2008). 
Previous study from our laboratory shows that ivermectin acts as a potent agonist of GlyRs that 
irreversibly activates α1-containing GlyRs, with an EC50 of 0.39 µM (Shan et al., 2001). 
Substitution of the residue Ala-288 and Pro-230 profoundly disrupted GlyR sensitivity to 
ivermectin, suggesting that the transmembrane regions play a crucial role in influencing allosteric 
modulation by ivermectin (Lynagh et al., 2011). In addition, ivermectin was found to exert 
significant allosteric modulation effects on other pLGICs, such as α7 nAChRs and GABAARs 
(Krusek and Zemkova, 1994; Krause et al., 1998). 
 Allosteric modulators 
Zn2+ ions allosterically modulate GlyRs in a dose-dependent manner, with low micromolar 
concentrations of Zn2+ potentiate glycine-activated currents and higher concentrations (> 10 µM) of 
Zn2+ inhibit glycine-evoked currents (Bloomenthal et al., 1994; Laube et al., 1995; Miller et al., 
2005b; Miller et al., 2005a). The potentiating and inhibiting concentrations are critically determined 
by the GlyR subunit composition. The major synaptic α1β GlyR isoform is extremely sensitive to 
Zn2+, whereas other GlyR subtypes display more than 10-fold less sensitive to Zn2+ (Miller et al., 
2005b; Miller et al., 2005a). Residues involved with the potentiation and inhibition actions of Zn2+ 
appear to be localized distinct regions of the N-terminal domain of the alpha subunit. Sequence 
alignment and mutagenesis study of α1 and α2 subunits have identified residue Asp-194 in α1 
subunit (which corresponds to α2 Glu-201) is a major determinant of the differential sensitivity to 
Zn2+ potentiation (Miller et al., 2005a). However, residue His-107 in α1 subunit contributes 
significantly to the subtype-selective Zn2+ inhibition. Replacing asparagine residue at the 
homologous position in α2 and α3 subunits with histidine residue markedly increases the potency of 
Zn2+ mediated inhibition (Miller et al., 2005b). Other sites that are important determinants for Zn2+ 
inhibition of GlyR function include His-109, Ser-112 and Ser-133 of the α1 subunit (Harvey et al., 
1999; Laube et al., 2000; Nevin et al., 2003). In contrast, residues Asp-80, Glu-192, Asp-194, Thr-
151, Trp-170 and His-215 of the α1 subunit are thought to contribute to high-affinity binding sites 
and are critically for potentiation of GlyR function by low micromolar concentrations of Zn2+ 
(Lynch et al., 1998; Miller et al., 2005a; Zhou et al., 2013). Substitution mutations in the TM1-TM2 
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and TM2-TM3 domains eliminated Zn2+ potentiation of GlyR function, indicating allosteric 
connection between the Zn2+ potentiating site and the glycine binding site, or selective disruption of 
transduction pathway (Lynch et al., 1998).  
 
Furthermore, a number of different GlyR allosteric modulators have been identified, including 
cannabinoids, ethanol, anaesthetics, glutamate, neuroactive steroids, tropeines and picrotoxin 
(Hawthorne and Lynch, 2005; Yevenes and Zeilhofer, 2011). However, these modulator effects are 
not restricted to certain GlyR subtype but occur in many receptors. Due to lacking of subtype-
selective probes, it is therefore almost impossible to dissect out specific GlyR isoform functions in 
different regions of the mammalian CNS. 
2 Glycinergic synapses 
 Synaptogenesis and synapse dynamics  
 Role of GlyR α2 in cortical neuron migration 
During the early brain development, migration of newly generated neurons from their site of origin 
to their target region in a distinct brain area is an important step. Functional α2 homomers have 
been found in the developing cerebral cortex (Young-Pearse et al., 2006) and can be activated by 
paracrine release of glycine or taurine (Flint et al., 1998; Qian et al., 2014). Due to low Cl- extruder 
expression in immature neurons, intracellular Cl- concentrations are initially high.  Activation of 
GlyRs can be depolarizing and excitatory in immature neurons, leading to intracellular Ca2+ 
oscillations and Ca2+-dependent synaptogenesis (Kirsch and Betz, 1998; Avila et al., 2013). 
 
Several lines of evidence indicate that α2 subunit-containing GlyRs play a critical function in early 
development of neocortex. Deletion of GLYA2 gene in mice results in moderate microcephaly in 
newborn mice (Avila et al., 2014). Activation of GlyRs promotes tangential migration of cortical 
interneurons from the medial ganglionic eminence to the cerebral cortex in the developing brain, 
whereas genetic disruption or pharmacological inhibition of α2 GlyR expression and function 
impaired the interneuron migration abilities (Avila et al., 2013). After birth, dendrite and spine 
morphological abnormalities accompanied by the loss of glycinergic signalling were observed in 
cortical neuron of layer V in GLYA2 knockout mice, indicating α2 GlyRs also play a critical role in 
synaptogenesis (Morelli et al., 2016). The importance of GlyR α2 in neuronal migration and cortical 
network formation is highlighted by the identifying of ASD-related GLYA2 mutations. 
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 Key regulator of inhibitory synapse formation – gephyrin 
Selective clustering of GlyRs at postsynaptic regions of neuronal plasma membrane is indispensible 
for the formation of functional inhibitory synapses. In the glycinergic postsynapse, gephyrin acts as 
a bridge between GlyRs and the cytoskeleton (Fig. 2), which can regulate postsynaptic GlyR 
clustering and lateral diffusion of GlyRs enter and exit synapses (Prior et al., 1992; Charrier et al., 
2006). Targeted disruption of the gene encoding gephyrin in mice die within one day after birth and 
exhibit hypertonic phenotype similar to that of human hyperekplexia (Feng et al., 1998). Loss of 
GlyRs and most GABAAR clustering at inhibitory synapses most likely accounts for the early 
lethality of gephyrin-deficient mice (Grosskreutz et al., 2003). Antisense oligonucleotide treatment 
against gephyrin resulted in a loss of GlyR clusters in the cultured rat spinal neurons (Feng et al., 
1998). Similarly, hippocampal neurons cultured from gephyrin knockout mice lack of GlyR clusters 
(Levi et al., 2004). These findings suggest that neuronal gephyrin expression is essential for GlyR 
localization at postsynaptic membrane specializations. 
 
Immunohistochemical analysis has demonstrated that co-localization of GlyRs and gephyrin in a 
punctate pattern in the mammalian brainstem and spinal cord (Triller et al., 1985; Todd et al., 1996; 
Baer et al., 2003; Harvey et al., 2004). An 18-amino acid motif within the TM3-TM4 intracellular 
loop of the GlyR β subunit was found to bind to gephyrin with high affinity (Meyer et al., 1995). 
Insertion of gephyrin-binding motif derived from GlyR β subunit to the intracellular loop of GlyR 
α1 subunit significantly enhanced the co-localization of α1 GlyRs and gephyrin in neurons and 
nonneural cells (Meier et al., 2000; Meier et al., 2001). Incorporation of gephyrin-binding motif to 
excitatory NMDA receptor (NMDAR) cytoplasmic tail region directed NMDARs to intracellular 
gephyrin-rich domains in transfected HEK cells (Kins et al., 1999). GABAAR α6 and δ subunits 
bearing the gephyrin-binding motifs brought receptors closer to postsynaptic sites (Wu et al., 2012). 
Thus, gephyrin-binding motif in the TM3-TM4 intracellular loop of GlyR β subunit is sufficient for 
routing GlyRs to inhibitory postsynaptic sites. In contrast to the GlyR β subunit, there is no 
evidence for direct interaction of gephyrin to GlyR α subunits. 
 
Heterologous expression of recombinant gephyrin in many cell lines results in intracellular 
gephyrin aggregation. However, gephyrin clusters were only observed at the selective postsynaptic 
regions in neurons, suggesting neuron-specific molecular mechanisms exist which ensures gephryin 
postsynaptic targeting and clustering, like posttranslational modification (Tyagarajan et al., 2011), 
binding to some neuronal proteins (Kins et al., 2000; Giesemann et al., 2003) and activation of 
GlyRs (Kirsch and Betz, 1998), etc. 
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 Key regulator of synapse maturation and function – neuroligin 
Trans-synaptic interaction between postsynaptic cell adhesion protein neuroligin (NL) and its 
presynaptic counterpart neurexin is of particular importance for the assembly and function of 
synaptic specializations (Dean and Dresbach, 2006). Neuroligins are transmenrbrane proteins and 
bind neurexins via an extracellular esterase-like domain (Fig. 2). Five neuroligin isoforms exist in 
humans (NL1−3, NL4X and NL4Y), while only four isoforms were found in rodent (NL1−4). NL1 
is preferentially distributed in excitatory (glutamatergic) synapses (Song et al., 1999) whereas NL2 
and NL4 are exclusively localized to inhibitory (GABAergic/glycinergic) postsynaptic 
specializaions (Varoqueaux et al., 2004; Hoon et al., 2011). NL3 is present at both excitatory and 
inhibitory synapses (Budreck and Scheiffele, 2007), but its functional significance is less known. 
NL2 is known to directly bind gephyrin through a conserved cytoplasmic motif and simultaneously 
bind to the gephyrin-associated protein, collybistin (Poulopoulos et al., 2009). Similarly, NL4 also 
interacts with gephyrin and collybistin via intracytoplasmic domain. In contrast, NL1 and NL3 were 
found to interact with gephyrin without binding to collybistin (Hoon et al., 2011). The significance 
of the NL2-gephyrin interaction was emphasized by a study showing that knockdown of gephyrin 
expression in neuronal cultures perturbed synaptic targeting of NL2, with a significant shift of NL2 
from inhibition to excitatory synaptic contacts (Levinson et al., 2010).  
 
Expression levels of neuroligins control the number of synapses in neurons. Knockdown of NL1, 
NL2 and NL3 individually or simultaneously inhibited postsynaptic maturation, as indicated by a 
substantial reduction in the dendritic spines density on hippocampal neurons (Chih et al., 2005).  
Further insight into functional evidence for neuroligin was provided by the electrophysiological 
analysis of in vivo synaptic transmission in neuroligin knockout mice. Mice lacking NL1, NL2 and 
NL3 genes displayed disrupted brainstem respiratory networks, with reduced 
GABAergic/glycinergic and glutamatergic synaptic transmission (Varoqueaux et al., 2006). 
Deletion of NL2 in mice resulted in a loss of GABAergic and glycinergic inhibition (Poulopoulos et 
al., 2009).  
 
Neuroligin along is sufficient to induce the formation of presynaptic terminals. Cocultured NL1 or 
NL2-expressing nonneuronal cells with neurons induced synaptic vesicle clustering and 
morphological presynaptic differentiation in contacting axons, which is comparable to the real 
synapses (Scheiffele et al., 2000). 
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Figure 2: Architecture of essential proteins at glycinergic synapses.  
Adapted from (Tyagarajan and Fritschy, 2014). 
 Regulation of GlyR dynamics at synapses 
The postsynaptic components of inhibitory synapses are complex and dynamic structures. Single 
particle tracking (SPT) techniques is a powerful tool which involves real time monitoring lateral 
mobility of a small probe attached to a membrane protein of interest in living cells. The detailed 
analysis of individual molecular trajectories, such as quantifying diffusion properties, identifying 
behavioral transitions, measuring transition frequency and dwell time at synaptic or non-synaptic 
locations, advances our understanding of dynamic properties of synaptic receptors in the plasma 
membrane and their underlying mechanisms related to molecular movements (Alcor et al., 2009).  
 
For GlyRs, the first observation of receptor dynamics at synapses was using single-quantum dot 
tracking on spinal cord neurons (Dahan et al., 2003). GlyRs have been demonstrated to be more 
confined at synaptic compartments and exchange between synapses and extrasynapses within 
minutes.  Another study using SPT has revealed that cytoskeleton contributes to rapidly regulate 
GlyR levels at synapses as pharmacological disruption of cytoskeleton reduced the amount of both 
GlyR and gephyrin at synapse, associated with an increased GlyR transition between the synaptic 
and extrasynaptic sites and a decreased GlyR dwell time at synapses (Charrier et al., 2006). In 
addition, diffusion properties of synaptic GlyRs can be regulated through gephyrin-gephyrin 
interaction which can stabilize GlyRs at synapses by forming scaffolding clusters (Ehrensperger et 
al., 2007). Furthermore, some extrasynaptic GlyRs were proposed to diffuse in a gephyrin-bond 
form (Ehrensperger et al., 2007). To date, the diffusion properties of different GlyR subtypes still 
remain to be elucidated, with important implications for our understanding of the mechanisms 
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underlying the heterogeneity in inhibitory post-synaptic currents (IPSCs) kinetics and synaptic 
plasticity, and of tonic glycine currents, i.e. the dynamics and function of the extrasynaptic pool. 
 
 Glycinergic IPSCs  
 α1β GlyR -mediated IPSCs 
The distribution glycinergic synapses have been implicated in olfactory bulb, cerebellum, 
hippocampus, hypothalamus, retina and gray matter in spinal cord (van den Pol and Gorcs, 1988; 
Wassle et al., 2009). The α1β heteromer is the predominant adult synaptic GlyR isoform and 
mediates the bulk of glycinergic transmission in brainstem, spinal cord and retina (Lynch, 2009). 
Electrophysiological recordings of glycinergic IPSCs in adult neurons show that α1β GlyR 
mediates IPSCs characterized by fast IPSC kinetics. In neurons of the rat anteroventral cochlear 
nucleus, where glycinergic synapses are somatic and thus not subject to dendritic filtering, the mean 
10 – 90 % rise time was 0.42 ms and the decay time course was fitted by the sum of two 
exponentials with time constants of 3.6 and 28.4 ms (Lim et al., 1999). In rat dorsal horn neurons, 
the mean 10 – 90 % rise times and decay time constants were 0.76 and 10.2 ms, respectively 
(Takahashi et al., 1992). In rat lumbar motor neurons the values were comparable at 0.79 and 7.1 
ms, respectively (Beato, 2008). In adult hypoglossal motor neurons the 10 – 90 % rise times and 
decay time constants ranged between 0.6 – 1.8 and 4.9 – 7.7 ms, respectively (Singer et al., 1998; 
Graham et al., 2006; Hirzel et al., 2006). 
 α2β GlyR -mediated IPSCs 
The α2β GlyR predominates at glycinergic synapses in embryonic rat neurons (Lynch, 2009). 
Functional studies have presented that IPSCs mediated by α2β GlyR have slower decay times. 
Glycinergic IPSCs in embryonic day 20 rat dorsal horn neurons exhibited a mean 10 – 90 % rise 
time of 0.91 ms and a mean decay time constant of 27 ms (Takahashi et al., 1992), with comparable 
values observed in embryonic zebrafish Mauthner neurons (Ali et al., 2000), perinatal rat 
hypoglossal neurons (Singer et al., 1998) and adult rat wide-field amacrine cells (Veruki et al., 
2007) which are unusual for adult neurons in that they selectively express α2β GlyRs (Wassle et al., 
2009). 
 α3β GlyR -mediated IPSCs 
The α3β GlyR is generally sparsely expressed in vivo, although it is co-located with α1β GlyRs in 
glycinergic synapses on neurons in the superficial laminae of the spinal cord dorsal horn (Harvey et 
al., 2004). Although α3β-mediated IPSCs have yet to be recorded in isolation in native synapses, 
their kinetic properties appear indistinguishable from those of α1β GlyRs (Harvey et al., 2004). 
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 Modulation of glycinergic IPSCs 
GlyRs are targets for phosphorylation by cAMP-dependent protein kinase (PKA) and protein kinase 
(PKC) (Vaello et al., 1994). Heterologous expression experiments indicate that a PKA-dependent 
phosphorylation occurs in the intracellular loop of α3 GlyRs which induces current inhibition (Han 
et al., 2013). This finding fits nicely to observations that inhibition of PKA led to a diminution of 
prostaglandin E2 (PGE2)-mediated depression of glycinergic neurotransmission in spinal dorsal 
horn (Ahmadi et al., 2002; Harvey et al., 2004). Despite the role of PKC in suppress of glycine 
receptor function has been studied extensively in Xenopus oocytes and neurons (Nishizaki and 
Ikeuchi, 1995; Schonrock and Bormann, 1995), (Uchiyama et al., 1994; Vaello et al., 1994), no 
functional evidence has demonstrated the direct effects of phosphorylation of GlyRs by PKC on 
glycinergic transmission. In contrast, it has been reported that phosphorylation of intracellular loop 
of GlyR β subunit by PKC influences the GlyR-gephyrin interaction, resulting in an enhanced 
GlyRs diffusion and a reduced GlyR number at inhibitory synapses (Specht et al., 2011), but the 
functional consequences still need to be determined. 
 
Clinically relevant concentrations (< 100 mM) of ethanol have shown a potentiation in glycinergic 
activity with increases in the frequency and decay rates of miniature IPSC (mIPSC) in spinal 
neurons, brainstem motoneurons, and neurons in the ventral tegmental area (Eggers et al., 2000; Ye 
et al., 2001; Sebe et al., 2003; Mariqueo et al., 2014). Neurons primarily expressing mature α1-
containing synapses are more sensitive to ethanol than neonate neurons expressing primarily α2-
containing GlyRs (Eggers et al., 2000). The enhanced mIPSC frequency is due to presynaptically 
effect whereas the increased decay rate is due to ethanol modulation effects of GlyR function 
(Eggers and Berger, 2004; Mariqueo et al., 2014). 
 
In addition, inflammatory cytokine interleukin-1β has been implicated in the potentiation of 
glycinergic synaptic currents from dorsal horn neurons (Chirila et al., 2014). GlyRs are also found 
in the presynaptic nerve terminals. Exogenous application of glycine (3 µM) resulted in an 
increased frequency of glycinergic IPSCs in rat spinal sacral dorsal commissural nucleus neurons 
while their amplitudes and decay times were unaffected (Jeong et al., 2003). This indicates that 
glycine could also acts presynaptically to modulate glycine release. 
 Heterosynapses 
The subunit composition of native GlyRs varies both developmentally and regionally (Baer et al., 
2009). The heterogeneity of subunit composition underlies the heterogeneity in GlyR-mediated 
IPSC kinetics. Each GlyR isoform has unique properties that contribute to modulate neuronal 
	 14	
activity and behavior, and disruptions to these properties can result in human diseases. For example, 
hereditary mutations of GlyR α and β subunits cause human hyperekplexia by affecting subcellular 
location and intrinsic properties of receptors, finally leading to the reduced glycinergic transmission 
(Bode and Lynch, 2014). Due to the multitude of other isoforms present at the same synapse and 
the difficulty in pharmacologically or genetically isolating the receptor isoform of interest, only 
limited information is available for understand the role of specific GlyR isoform in the human 
health and disease.  
 
Although GlyRs are not currently pharmacological targets for clinically important agents, 
molecules that selectively enhance α3-containing GlyRs are considered promising as new 
generation treatments for chronic pain (Zeilhofer, 2005; Lynch and Callister, 2006). Because α1- 
and α3-containing GlyRs are both expressed in inhibitory synapses on spinal pain sensory neuron, 
with α3 possibly as the minor partner (Graham et al., 2011), any pharmacological effect of α3-
specific drugs may be diluted by the presence of other isoforms. Moreover, drugs that act non-
specifically at the GlyRs in the CNS may cause undesirable motor disorders and other side effects. 
By developing strategies that specifically target IPSCs mediated by defined GlyR isoforms, it is 
possible to evaluate drug efficacy and selectivity under realistic synaptic activation conditions. 
 
Co-culture synapses were first described more than fifteen years ago to investigate molecular 
mechanisms underlying synaptogenesis (Scheiffele et al., 2000). Neuroligins-expressing 
nonneuronal cells stimulate the formation of presynaptic structure in contacting axons of co-
cultured neurons (Scheiffele et al., 2000; Kim et al., 2006b).  Accordingly, neurexin-expressing 
nonneuronal cells induce postsynaptic differentiation in contacting dendrites of co-cultured neurons 
(Graf et al., 2004). In addition, other synaptic cell adhesion molecules including postsynaptic 
netrin-G ligand-2 (Kim et al., 2006b), SynCAM (Biederer et al., 2002; Sara et al., 2005) were found 
to be able to trigger formation of excitatory synapses by using co-culture methods. Co-culture of 
human HEK293 cells co-expressing SynCAM and GluR2 with hippocampal neurons exhibited 
postsynaptic glutamatergic transmission similar to those of neurons (Biederer et al., 2002). 
Excitatory postsynaptic currents (EPSCs) were also obtained in HEK293 cells transfected with 
neuroligins together with NMDA or AMPA receptors in a co-culture with cerebella granule cells 
(Fu et al., 2003). Later, expressing NL2 with GABAARs (Dong et al., 2007), or GABAARs along 
(Fuchs et al., 2013) in the HEK293 cell lines successfully reconstituted functional GABAergic 
synapses by co-culturing with medium spiny neurons, hippocampal neurons or hypothalamic 
neurons. Recent studies have used cortical neuron-HEK cell heterosynapse to investigate synaptic 
targeting properties of different GABAAR subunits (Wu et al., 2012; Dixon et al., 2014) with 
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GABAerigc IPSCs recorded from the ‘artificial’ synapse agree very well with those recorded from 
neurons, and to identify the structural determinant of GABAARs in synaptic contact formation 
(Brown et al., 2016). The ‘artificial’ synapse can be easily extended to investigate the impact of 
disease-related neuroligin mutations on GABAergic synaptogenesis (Chubykin et al., 2005; Sun et 
al., 2011).  
 
Viewed together, the ‘artificial’ synapse offers a best tool for investigation into the kinetic 
properties of IPSCs mediated by defined GlyR isoforms and the effects of drugs on IPSCs mediated 
by selective GlyR isoforms. Furthermore, it is also possible to examine the effects of 
posttranslational modifications (e.g., phosphorylation) and hereditary disease mutations on the 
formation and function of glycinergic synapses, and molecular mechanisms regulating the 
synaptogenesis and synaptic clustering.  
3 Zinc: role in synaptic transmission 
 Zinc modulation of glutamatergic synapses 
The free ionic form of zinc (Zn2+) plays a dynamic role in many biological processes including 
synaptic transmission (Sensi et al., 2009). At many glutamatergic synapses in the central nervous 
system (CNS), it is well known that Zn2+ is concentrated into presynaptic vesicles (Frederickson, 
1989) and is released into the synaptic cleft by nerve terminal stimulation (Assaf and Chung, 1984; 
Howell et al., 1984). The estimation of how Zn2+ concentration increase during synaptic activation 
is spanning four orders of magnitude from 10 nM (Kay, 2003) to > 100 µM (Vogt et al., 2000). The 
lower estimate stems from studies that concluded that Zn2+ is not released in a phasic manner at all, 
but rather becomes ‘externalized’ following exocytosis and then binds tightly to presynaptic 
proteins forming a ‘veneer’ (Kay, 2003; Kay and Toth, 2006, 2008). 
 
The NMDARs incorporating GluN2A subunits that populate most glutamatergic synapses are 
unique in that they inhibited by Zn2+ at low nanomolar concentrations (Paoletti et al., 1997). 
Mutation in the gene encoding GluN2A subunit led to impaired GluN2A-Zn2+ interaction in 
children with idiopathic focal epilepsy (Lemke et al., 2013), revealing an essential role of high-
affinity Zn2+ inhibition in human health. Previous experiments demonstrate that at hippocampal 
mossy fiber synapses, the presence of endogenous Zn2+ tonically occupies the high-affinity binding 
site of NMDARs, and synaptically released Zn2+ during neuronal activity occupies the lower-
affinity binding site of NMDARs, resulting in the depression of NMDAR response (Vogt et al., 
2000). However, this concept has been challenged by recent electrophysiological observations 
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under normal extracellular condition (Vergnano et al., 2014). Vergnano et al found a lack of the 
high-affinity, voltage-independent inhibition at MF-CA synapses, which are the mainly Zn2+-
enriched synapses within the brain, whereas fast repetitive stimulation unveiled Zn2+-mediated 
inhibition of EPSCs (Vergnano et al., 2014).  This indicates that ambient Zn2+ levels at resting 
conditions are insufficient to populate the high-affinity GluN2A Zn2+ binding sites, and a short 
burst of synaptic stimulation is required for Zn2+ modulation of NMDAR-mediated EPSCs. In 
contrast, another investigation using a high-affinity Zn2+ chelator at the same synapses concluded 
that synaptic release of Zn2+ in response to a single action potential is capable of modulating 
NMDAR-mediated activity (Pan et al., 2011). In addition, ambient Zn2+ levels were proposed to be 
lower at synaptic site but higher at extrasynaptic site, thus extrasynaptic NMDARs activated by 
glutamate spillover can be subjected to tonic Zn2+-mediated inhibitory modulation (Anderson et al., 
2015).  
 
Kainate and AMPA receptors are other abundant types of glutamate receptors involving in synaptic 
transmission. By using zinc chelator, endogenous Zn2+ was found to selectively inhibit kainate but 
not AMPA receptors at mossy fiber synapses (Mott et al., 2008). 
 Zinc modulation of GABAergic synapses 
Zn2+ also have potent inhibition effects on GABAAR (Westbrook and Mayer, 1987). The 
sensitivities to Zn2+ are considerably different among the GABAAR subtypes (Draguhn et al., 1990; 
Smart et al., 1991). For example, GABAARs containing the γ subunits are far less sensitive to low 
concentrations of Zn2+ (Draguhn et al., 1990; Smart et al., 1991), and Zn2+ inhibition was found 
greater in GABAARs containing α2 and α3 subunits than those containing α1 subunits (White and 
Gurley, 1995).   Ruiz et al first demonstrate that GABA and Zn2+ can be co-localized in the same 
mossy fiber varicosities and endogenous Zn2+ can inhibit GABAergic response in CA3 pyramidal 
neurons in guinea pig hippocampal slices (Ruiz et al., 2004). In this study, Ruiz et al also suggest 
extracellular Zn2+ associated with mossy fibers inhibit GABAAR in a tonic fashion, with little 
dynamic modulation of inhibition by synaptically released Zn2+ with physiological patterns of 
stimuli. Furthermore, it is demonstrated that endogenous Zn2+ not only depresses monosynaptic 
GABAergic synaptic transmission though direct binding to GABAARs, but also inhibits di-synaptic 
GABAergic signalling by regulating the excitability of presynaptic interneurons (Grauert et al., 
2014).  
 Zinc in the glycinergic synaptic cleft 
GlyRs have been identified as one of the potential synaptic targets for zinc effects on inhibitory 
transmission. As discussed above, the positive or negative modulatory effects of Zn2+ on GlyRs 
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depends on its concentration. The major synaptic a1b GlyR isoform is extremely sensitive to Zn2+, 
with low (10 – 1000 nM) Zn2+ concentrations potentiating EC50 glycine-gated currents and higher 
Zn2+ concentrations (3 – 300 µM) eliciting a dose-dependent inhibition (Bloomenthal et al., 1994; 
Laube et al., 1995; Miller et al., 2005b; Miller et al., 2005a). In experiments with membrane-
impermeant Zn2+ buffers and chelators, it has been shown that glycinergic IPSCs are positively 
modulated by tonic Zn2+ (Suwa et al., 2001; Hirzel et al., 2006; Perez-Rosello et al., 2015). The 
knock-in mice carrying a point mutation (a1D80A) that selectively ablated the sensitivity of a1 
GlyRs to Zn2+ potentiation displayed a severe motor phenotype with symptoms resemble those 
observed in human hypereplexia (Hirzel et al., 2006). Electrophysiological recordings from the 
brainstem hypoglossal neurons detected a reduced amplitude and a accelerated decay time of 
glycinergic IPSCs in knock-in mice, consistent with a loss of Zn2+ potentiation. Since no changes 
were observed in glycine sensitivity, GlyR expression levels, synaptic localization, and glycinergic 
IPSC kinetics when neurons predominately expressed a2 instead of a1 subunits, it was concluded 
that the hyperekplexia-type phenotype in α1D80A GlyR knock-in mice is due to the impaired Zn2+ 
potentiation (Hirzel et al., 2006). As to the action of synaptic Zn2+, a tonic and/or a phasic manner 
for Zn2+-mediated potentiation of glycinergic IPSCs has been proposed by Kay et al (Kay et al., 
2006). 
 
Figure 3: The proposed mechanisms for Zn2+-mediated modulation of glycinergic transmission. In the phasic 
model, Zn2+ is co-released with other neurotransmitter into glycinergic synaptic cleft upon exocytosis, and rapidly 
pumped back into cells. However, in the tonic model, only a few Zn2+ could be released into the extracellular space, and 
most Zn2+ would tonically bind to proteins on the pre- and postsynaptic membranes, forming a veneer layer of Zn2+. 
Alternatively, spillover of Zn2+ from the vicinity of synapses (e.g. glutamatergic synapses) could be another source 
(Kay et al., 2006). 
Despite a co-localization of Zn2+ and glycine has been reported at presynaptic terminals in the 
spinal cord of the lamprey (Birinyi et al., 2001), there is currently no direct evidence for the co-
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localization of Zn2+, glycine and vesicular Zn2+ transporter (ZnT3) at glycinergic presynaptic 
terminals in the mammalian brainstem or spinal cord. Thus, the origin of Zn2+ in glycinergic 
synapses remains enigmatic. A recent study reported that tonic Zn2+-mediated potentiation of 
glycinergic neurotransmission decreased spontaneous firing in mice auditory brainstem nucleus, 
and the increase in spontaneous firing frequency by removal of Zn2+ in ZnT3 knock-out mice was 
comparable to the increase observed in wild-type mice (Perez-Rosello et al., 2015). The authors 
proposed that Zn2+-mediated modulation of neuronal excitability probably in the areas that are not 
closed to the sites of synaptically released Zn2+. 
 
At physiological concentrations, Zn2+ can also modulate a variety of ion channel in CNS, including 
voltage-gated calcium channels, voltage-gated potassium channels, acid-sensing ion channels, P2X 
receptors, 5HT3R and nAChRs, etc (Marger et al., 2014). As Zn2+ can have very different 
(sometimes opposite) effects on the function of potential targets depending on the concentrations, 
quantitative estimation of zinc concentration in the synaptic cleft will help us to understand both the 
synaptic targets and action of synaptically released Zn2+. 
 
Aims of the thesis 
The overall aim of this thesis was to establish glycinergic ‘artificial’ synapse system which can 
provide some aspects of normal and abnormal glycinergic neurotransmission in health and disease. 
Aim 1: Establish the methods for reliably generating recombinant glycinergic synapses that 
incorporate defined GlyR isoforms of interest. 
Aim 2: Investigate the mechanism by which gain-of-function GLRA1 mutations cause 
hyperekplexia by using ‘artificial’ synapse. 
Aim 3: Investigate the effects of α2 GlyR autism mutations on glycinergic synaptic function. 
Aim 4: Estimate the free zinc concentration in the glycinergic synaptic cleft following a single 
presynaptic stimulation. 
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Abstract 
 
Glycine receptor (GlyR) chloride channels mediate fast inhibitory neurotransmission in the 
spinal cord and brainstem. Four GlyR subunits (α1 – 3, β) have been identified in humans, and their 
differential anatomical distributions result in a diversity of synaptic isoforms with unique 
physiological and pharmacological properties. To improve our understanding of these properties, 
we induced the formation of recombinant synapses between cultured spinal neurons and HEK293 
cells expressing GlyR subunits of interest plus the synapse-promoting molecule, neuroligin-2A. In 
the heterosynapses thus formed, recombinant α1β and α3β GlyRs mediated fast decaying inhibitory 
postsynaptic currents (IPSCs) whereas α2β GlyRs mediated slow decaying IPSCs. These results are 
consistent with the fragmentary information available from native synapses and single channel 
kinetic studies. As β subunit incorporation is considered essential for localizing GlyRs at the 
synapse, we were surprized that α1 – 3 homomers supported robust IPSCs with β subunit 
incorporation accelerating IPSC rise and decay times in α2β and α3β heteromers only. Finally, 
heterosynapses incorporating α1D80Aβ and α1A52Sβ GlyRs exhibited accelerated IPSC decay rates 
closely resembling those recorded in native synapses from mutant mice homozygous for these 
mutations, providing an additional validation of our technique. Glycinergic heterosynapses should 
prove useful for evaluating the effects of drugs, hereditary disease mutations or other interventions 
on defined GlyR subunit combinations under realistic synaptic activation conditions. 
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Introduction 
 
Glycine receptor (GlyR) chloride channels mediate fast inhibitory neurotransmission in the 
brainstem and spinal cord, and disruptions to their function underlie a range of disorders including 
chronic inflammatory pain (Lynch and Callister, 2006; Zeilhofer, 2005), hyperekplexia (Bode and 
Lynch, 2014), tinnitus (Wang et al., 2009), temporal lobe epilepsy (Eichler et al., 2008) and 
neuropsychiatric disorders (Winkelmann et al., 2014). GlyRs are pentameric ligand-gated ion 
channels comprizing either homomeric assemblies of α subunits or heteromeric assemblies of α and 
β subunits in either 2α:3β or 3α:2β stoichiometries (Durisic et al., 2012; Grudzinska et al., 2005; 
Yang et al., 2012). The β subunit is considered essential for clustering GlyRs at synapses due to its 
direct interaction with the cytoplasmic clustering protein, gephyrin (Fritschy et al., 2008; Kneussel 
and Loebrich, 2007; Meyer et al., 1995). In humans, four GlyR subunits (α1 – 3 and β) have been 
identified and their distribution varies both developmentally and regionally (Baer et al., 2009). This 
underlies a heterogeneity in inhibitory postsynaptic current (IPSC) kinetics and synaptic plasticity 
mechanisms that provide appropriately nuanced influences on network behavior in the central 
nervous system.  
Because it is often not possible to ascertain which GlyR subunits are present in a particular 
synapse, our understanding of the synaptic properties of different GlyR isoforms is incomplete. For 
example, although α3 immunoreactivity suggests it is strongly expressed in synapses on spinal 
nociceptive neurons (Harvey et al., 2004), there is doubt as to whether α3β GlyRs contribute 
significantly to the function of these synapses (Graham et al., 2011).  
A related issue is that it is difficult to validate the effects of drugs on defined GlyR isoforms 
under synaptic activation conditions. For example, compounds that potentiate α3-containing GlyRs 
but do not affect other GlyRs are considered potential leads for analgesic development (Lynch and 
Callister, 2006; Zeilhofer, 2005). Because α1- and α3-containing GlyRs are both expressed in 
inhibitory synapses on spinal pain sensory neuron, with α3 possibly as the minor partner (Graham 
et al., 2011), any pharmacological effect of α3-specific drugs may be diluted by the presence of 
other isoforms. 
It has proved routinely possible to reconstitute GABAergic synapses between cultured 
GABAergic neurons (that provide the presynaptic terminals) and HEK293 cells that express the 
desired GABA-A subunits plus neuroligin 2 (NL2) (Dixon et al., 2014; Dong et al., 2007; Fuchs et 
al., 2013; Wu et al., 2012). We refer to these as ‘heterosynapses’. Postsynaptic NL2 is key to 
generating such synapses due to its ability to promote synapse formation by binding to trans-
synaptic neurexins (Lise and El-Husseini, 2006). Because NL2 is also important for glycinergic 
synapse maturation (Poulopoulos et al., 2009), we reasoned that it should be feasible to induce 
glycinergic heterosynapse formation between cultured spinal glycinergic neurons and HEK293 cells 
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expressing NL2 plus the GlyR subunits of interest. In the present study, we show that this is indeed 
feasible and we employ this approach to characterize heterosynaptic IPSCs mediated by a variety of 
wild type and mutant GlyR subunit combinations.  
 
 
Materials and methods 
 
Cell culture and molecular biology 
Plasmid DNAs encoding the human α1 (pCIS), human α2 (pCIS), rat α3 (pcDNA3.1) and 
human β (pcDNA3.1) GlyR subunits were transfected into HEK293 cells via calcium phosphate-
DNA coprecipitation. We transfected α cDNA with β cDNA at different ratios from 1:1 to 1:100. 
Homomeric GlyRs were produced by transfecting α subunit only. In addition, the mouse NL2A 
splice variant (pNice) and rat gephyrin (pCIS) were co-transfected along with GlyR subunits, which 
facilitated the formation of heterosynapses. eGFP, which acted as expression marker was also 
transfected. The total amount of the final cDNA mixture per 35-mm petri dish was kept at 1 – 2 µg. 
Site-directed mutagenesis was performed using the QuikChange mutagenesis kit, and the successful 
incorporation of mutation was confirmed by DNA sequencing. 
Primary cultures of spinal cord neurons were prepared as previously described (Hoch et al., 
1989; Levi et al., 1998) from embryonic day 15 rat pups. Cells were plated at a density of ~80000 
cells per 18 mm poly-D-lysine coated coverslip in DMEM medium with 10% fetal bovine serum. 
After 24 hours, the plating medium was changed to Neurobasal medium supplemented with 2% 
B27 and 1% glutamax, and a second feed after one week replaced half of this medium. Neurons 
were grown for 1 – 4 weeks in vitro and the heterosynaptic co-cultures were prepared by directly 
introducing transfected HEK293 cells onto the primary neuronal cultures 1 – 3 days prior to 
recordings. 
 
Electrophysiology 
Whole-cell recordings were performed under voltage-clamp mode using a HEKA EPC10 
amplifier (HEKA Electronics, Lambrecht, Germany) and Patchmaster software (HEKA), at room 
temperature. Series resistance was routinely compensated to 60% of maximum and was monitored 
throughout the recording. Both spontaneous and action potential-evoked glycinergic IPSCs in HEK 
cells were recorded at a holding potential −60 mV and signals were filtered at 4 kHz and sampled at 
10 kHz.  Patch pipettes (4 − 8 MΩ resistance), made from borosilicate glass (GC150F-7.5, Harvard 
apparatus), were filled with an intracellular solution containing the following (in mM): 145 CsCl, 2 
CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA and 2 MgATP, adjusted to pH 7.4 with NaOH. Cells were 
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continuously perfused with extracellular solution comprizing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with NaOH.  
In the pharmacological studies, lindane, strychnine or tricine (all from Sigma-Aldrich) were 
applied by bath perfusion. After waiting 2 min for drug effects to stabilize, we compared at least 3 
min of spontaneous activity before and after drug application. 
  
Analysis 
Analyses of IPSC amplitude, 10 − 90% rise time, and decay time constant (single-
exponential) were performed using Axograph X (Axograph Scientific). Only cells with a stable 
series resistance of < 25 MΩ throughout the recording period were included in the analysis. Single 
peak IPSCs with amplitudes of at least three times above the background noise were detected using 
a semiautomated sliding template. Each detected event was visually inspected and only well-
separated IPSCs with no inflections in the rizing or decay phases were included. The kinetics of 
IPSCs were determined by averaging the selected currents. These averages from multiple recording 
days were then pooled to obtain group data. Statistical analysis and plotting were performed with 
Prism 5 (GraphPad Software). All data are presented as mean ± SEM. One-way and two-way 
ANOVA were employed for multiple comparisons. Drug group comparisons were made using 
paired Student’s t-tests. For all tests, the number of asterisks corresponds to level of significance: 
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.  
 
Results 
 
Establishing the conditions for reliable β subunit expression in heterosynapses 
As synaptic GlyRs are considered to comprise heteromers of α and β subunits (Lynch, 2009), 
it is important to verify that αβ heteromeric GlyRs are predominantly expressed in our system. This 
is a particular concern given that a recent single channel study reported difficulty in reliably 
expressing heteromers of α3 and β subunits (Marabelli et al., 2013). As a negative control for 
β subunit incorporation, we first tested whether α1, α2 or α3 subunits could form synaptic-like 
currents in the absence of the β subunit. These experiments involved transfecting HEK293 cells 
with the relevant α subunit plus NL2A and gephyrin. Sample recordings of IPSCs from HEK293 
cells expressing these constructs suggest markedly different decay kinetics for α1, α2 and α3 GlyRs 
(Fig. 1A). Next, we transfected α and β cDNAs at different ratios (ranging from 1:1 to 1:100) to 
identify the conditions required to achieve a high level of heteromeric receptor expression (Fig. 1B, 
C). In Fig. 1B, each data point represents the average of all IPSCs recorded from a single cell. 
Examples of IPSCs recorded from cells expressing the indicated heteromeric GlyRs are shown in 
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Fig. 1C. To pharmacologically verify β subunit incorporation into recombinant GlyRs, we applied 
30 µM lindane which completely inhibits homomeric GlyRs but does not affect α1β heteromeric 
GlyRs (Islam and Lynch, 2012). As expected, lindane completely inhibited IPSCs in cells 
expressing homomeric GlyRs but had no significant effect on those expressing heteromeric GlyRs 
(Fig. 1C, D). We also confirmed that heterosynaptic IPSCs mediated by all subunit combinations 
were completely inhibited by 10 µM strychnine (e.g., Fig. 1D), a potent but nonspecific GlyR 
antagonist (Legendre, 2001; Lynch, 2004). 
 
 
Figure 1. Homomeric and heteromeric GlyR-mediated IPSCs in heterosynapses. A. Representative recordings of 
glycinergic IPSCs in HEK293 cells expressing the indicated homomeric GlyRs at three different temporal resolutions. 
B. Distribution of decay time constants for IPSCs recorded with the indicated transfection ratios, showing the effects of 
incorporation of β subunit on IPSC decay times. Data were obtained in the absence and presence of extracellular 
lindane (LIN, 30 µM). Each data point represents the mean of all events recorded in a single cell. C. Representative 
glycinergic IPSCs recorded from HEK293 cells expressing the indicated heteromeric GlyRs. α and β GlyR cDNA were 
transfected at different ratios (1α:50β for α1β and α2β, 1α:10β for α3β) to minimize contamination by homomeric α 
receptors. D. Sample recordings illustrating the effect of lindane and strychnine on HEK293 cells expressing the 
indicated subunits. A transfection ratio of 1α:50β was used to generate α1β GlyRs. Mean results for lindane are shown 
in panel B. 
 
With increasing β subunit expression, we observed a trend toward faster IPSC decay time 
constants in α2 and α3-containing cells, but not in α1-containing cells (Fig. 1B). When α2 and β 
cDNAs were cotransfected at 1:1 and 1:10 ratios, decay time constants were broadly distributed, 
suggesting that the heterosynapses contained a mixed population of α2 homomeric and α2β 
heteromeric GlyRs. Lindane selectively eliminated the slower events, demonstrating that they were 
indeed mediated by homomeric α2 GlyRs (Fig. 2B). Lindane had no effect at α2:β transfection 
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ratios of 1:50 and 1:100, suggesting that a reasonably pure population of heteromeric GlyRs had 
been attained. Co-expression with the β subunit also reduced decay time constants in HEK293 cells 
expressing the α3 subunit (Fig. 1A – C). However, the impact of increasing the proportion of β 
cDNA on mean decay time constants was less variable. With an α3:β transfection ratio of 1:10, all 
heterosynapses appeared to exclusively express α3β GlyRs (Fig. 1B). Thus, the optimal transfection 
ratios for generating heteromeric IPSCs were 1:50 for α2:β and 1:10 for α3:β (Fig. 1C). These ratios 
were used throughout the remainder of this study. 
We could not distinguish α1 from α1β GlyR-mediated IPSCs according to their decay 
kinetics (Fig. 1A – C). For the remainder of this study we employed a 1:50 transfection ratio for 
α1:β, consistent with previous studies that verified the incidence of heteromer formation by 
monitoring single channel conductance (Burzomato et al., 2004; Pitt et al., 2008).  
 
Kinetic properties of glycinergic heterosynapses  
We characterized the mean amplitudes, 10 – 90 % rise times and decay time constants of 
IPSCs mediated by recombinant α1, α2, α3, α1β, α2β and α3β GlyRs (Fig. 2). Intriguingly, 
heterosynapses incorporating α1β and α3β GlyRs exhibited similar IPSC characteristics (Fig. 2A), 
with mean amplitudes of 58.6 ± 6.4 pA and 53.7 ± 10.1 pA (p > 0.05), mean 10 – 90 % rise times of 
1.6 ± 0.1 ms and 2.0 ± 0.1 ms (p > 0.05) and mean decay time constants of 7.2 ± 0.4 ms and 9.7 ± 
0.5 ms (p > 0.05), respectively. Conversely, α2β GlyR-mediated heterosynapses exhibited IPSCs 
with dramatically slower decay time constants (25.7 ± 1.5 ms) than those mediated by α1β or α3β 
GlyRs (Fig. 2A, right panel). As noted above, α1 is the only subunit that supports identical 
homomeric and heteromeric IPSC kinetics. In contrast, decay time constants measured from α2 and 
α3 homomeric heterosynapses were considerably longer than their heteromeric counterparts (Fig. 
2A). A two-way ANOVA indicated that both α and β subunits had high significantly effects on 
current decay time constants (p < 0.0001). 
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Figure 2. Comparison of the kinetics of heteromeric and homomeric GlyR-mediated IPSCs. A. Mean values for the 
amplitude, 10 – 90% rise time and decay time constant of IPSCs recorded from homomeric and heteromeric GlyRs 
(transfection ratios- 1α:50β for α1β and α2β, 1α:10β for α3β). Each data point represents the mean of all events 
recorded in a single cell. B. Distribution histograms of IPSC decay time constants plotted against normalized number of 
events (n = 6 cells for each subtype). Inset shows homomer and heteromer averages for comparison (n > 30 events for 
homomers; n > 150 events for heteromers), normalized to peak amplitude. Scale bar, 50 ms. *p < 0.05, **p < 0.01, 
****p < 0.0001; #p < 0.05, ####p < 0.0001 relative to corresponding homomers. ns, not significant. 
 
The event distribution histograms (Fig. 2B), which pooled the decay time constants of all 
individual events in six cells selected at random expressing the indicated homomeric and 
heteromeric GlyRs, confirms that the β subunit had little effect on the distribution of events in α1 
GlyR-containing heterosynapses. In contrast, incorporation of the β subunit into α2 and α3-
containing GlyRs shifted the distribution in the decay time constants to much lower values (Fig. 
2B). Finally, we found that 10 – 90 % rise times and decay time constants were not significantly 
correlated for any of the six GlyR isoforms (all linear correlation coefficients < 0.33). Together 
these results suggest that events mediated by each individual isoform cannot be segregated into 
different categories (e.g., synaptic vs. peri-synaptic). 
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In summary, the kinetics of α1β and α3β GlyR-mediated IPSCs were similar to each other 
but faster than α2β GlyR-mediated IPSCs. In addition, the β subunit enhanced the decay rate of 
IPSCs mediated by α2- and α3-containing GlyRs only. 
 
Comparison of heterosynaptic and native synapses incorporating mutant α1 subunits 
Low (10 – 300 nM) zinc concentrations rapidly potentiate α1 GlyRs whereas higher 
concentrations (3 – 300 µM) elicit a dose-dependent, slowly-developing inhibition (Bloomenthal et 
al., 1994). Zinc exerts broadly similar effects at all GlyR subtypes (Miller et al., 2005a) and the 
molecular determinants of both potentiation and inhibition are spatially distinct and have been well 
characterized (Grudzinska et al., 2008; Harvey et al., 1999; Laube et al., 1995; Laube et al., 2000; 
Lynch et al., 1998; Miller et al., 2005a; Miller et al., 2005b; Nevin et al., 2003). Zinc is released 
from presynaptic glycinergic terminals upon nerve stimulation (Birinyi et al., 2001) and modulates 
glycinergic synaptic transmission in vivo by binding to and potentiating GlyRs. Given that the 
glycine concentration in the native synaptic cleft is saturating (Beato, 2008), the physiological 
effect of zinc is to prolong IPSC duration. The α1D80A mutation is one of several mutations known 
to selectively eliminate zinc potentiation (Hirzel et al., 2006; Lynch et al., 1998). Consistent with 
this, a genetically modified mouse harbouring the homozygous α1D80A mutation exhibited rapidly 
decaying glycinegic IPSCs in adult hypoglossal motor neurons that predominantly express α1β 
GlyRs (Hirzel et al., 2006).  
We performed two experiments to evaluate whether endogenous zinc prolongs the duration 
of IPSCs in α1β GlyR-mediated heterosynapses. The first involved applying a 10 mM concentration 
of the zinc chelator, tricine. Fig. 3A displays sample recordings before and after tricine application, 
with the respective averaged, normalized IPSCs shown in Fig. 3B. As summarized in Fig. 3C, 10 
mM tricine significantly reduced the decay time constant (from 7.6 ± 0.7 to 6.2 ± 0.8 ms; p < 0.01, 
paired t test; n = 6 cells), but had no effect on current amplitude (from 40.0 ± 6.3 to 37.1 ± 7.4 pA; 
p > 0.05, paired t test; n = 6 cells).  
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Figure 3. Tricine shortens IPSC duration. A. 
Representative traces recorded from an α1β GlyR-
expressing cell before (black trace) and after 10 mM 
tricine (grey trace). B. Superimposed averaged 
traces of IPSCs (n > 200 events) recorded before 
(black trace) and after tricine treatment (grey trace), 
normalized to peak amplitude. C. Mean IPSC 
amplitude and decay time constants in α1β GlyR-
expressing cells before (filled black symbols) and 
after tricine treatment (unfilled grey symbols, n = 6). 
ns, not significant. 
 
 
 
 
 
 
We next compared the IPSCs recorded in vitro from homozygous α1D80A mice with those 
from heterosynapses incorporating recombinant α1D80Aβ GlyRs. Sample recordings from α1β and 
α1D80Aβ GlyRs are shown in Fig. 4A, with the respective averaged, normalized IPSCs shown in Fig. 
4B. We observed no significant difference in amplitude but a dramatic reduction in decay time 
constants (α1β, 7.2 ± 0.4 ms vs. α1D80Aβ, 3.1 ± 0.3 ms; p < 0.0001; Fig. 4B, C). These results 
correspond remarkably well with those observed in native glycinergic IPSCs from α1D80A mice (see 
Fig. 7E and F in (Hirzel et al., 2006)), implying similar zinc concentrations in the respective 
synaptic clefts.  
The α1A52S mutation occurs naturally in the Spasmodic mouse where it reduces GlyR 
sensitivity to glycine, thereby accelerating IPSC deactivation and causing a hyperekplexia 
phenotype (Plested et al., 2007; Ryan et al., 1994). Consistent with this, IPSCs recorded from 
hypoglossal motor neurons and spinal dorsal horn neurons of homozygous adult Spasmodic mice 
exhibit reduced amplitudes and accelerated decay rates (Graham et al., 2006; Graham et al., 2011). 
To assess whether the glycine concentration in the synaptic cleft of our heterosynapses is 
comparable with that found in native synapses, we investigated the effect of the A52S mutation. 
Figure. 4A shows examples of IPSCs recorded from heterosynapses containing α1A52Sβ GlyRs. As 
summarized in Fig. 4B and C, the mutation resulted in significant reductions in both IPSC 
amplitude (α1β, 58.6 ± 6.4 pA vs. α1A52Sβ, 33.8 ± 4.3 pA; p < 0.05) and decay time constants (α1β, 
7.2 ± 0.4 ms vs. α1A52Sβ, 3.6 ± 0.4 ms; p < 0.0001). As these changes closely mirror those of 
glycinergic IPSCs recorded in vitro from homozygous Spasmodic mice (Graham et al., 2006; 
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Graham et al., 2011) they imply that a molecular perturbation affecting GlyR agonist sensitivity 
exerts similar effects in native synapses and heterosynapses. 
  
Figure 4. Effects of the D80A and A52S α1 
subunit mutations on IPSCs mediated by α1β 
GlyRs A. Representative glycinergic IPSCs 
recorded from HEK cells expressing α1β, 
α1A52Sβ and α1D80Aβ GlyRs. B. Superimposed 
averaged glycinergic IPSCs (n > 150 events) 
mediated by α1β (red), α1A52Sβ (orange) and 
α1D80Aβ (purple) GlyRs, normalized to peak 
amplitude. C. Averaged amplitude and decay 
time constants of α1β (n = 13), α1A52Sβ (n = 8) 
and α1D80Aβ (n = 8) receptor-mediated IPSCs. 
 
 
 
 
 
 
Comparison of heterosynaptic IPSC kinetics with the intrinsic kinetic properties of their component 
GlyRs 
 Table 1 provides a summary of the mean 10 – 90 % rise times and decay time constants for 
IPSCs mediated by all six wild type GlyR isoforms. Knowledge of the intrinsic activation and 
deactivation time courses of the GlyRs populating these heterosynapses would enable us to infer 
whether IPSC kinetics are determined by the intrinsic channel properties or by extrinsic factors such 
as the neurotransmitter concentration and time course. Intrinsic channel kinetic properties can be 
quantitated by single channel kinetic analysis. To date, this analysis has been employed to derive 
activation mechanisms for recombinant α1, α2 and α3 homomeric and α1β heteromeric GlyRs 
(Beato et al., 2004; Burzomato et al., 2004; Krashia et al., 2011; Marabelli et al., 2013). Figure 5 
presents examples of simulated IPSCs reconstituted using the optimal activation mechanism that 
was derived in each of these four studies. The relevant parameters from these simulations are also 
included in Table 1. For α1, α1β and α2 GlyRs, the IPSC decay rate and the intrinsic channel 
closing rate are in reasonable accord, but for α3 GlyRs the IPSC decay rate is 3-fold slower than 
predicted by the intrinsic closing rate. In contrast, the rise times of heterosynaptic IPSCs are all 
much slower than the intrinsic channel activation rates, suggesting delayed activation by 
neurotransmitter in the synaptic cleft. 
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Table 1: GlyR kinetic properties 
Number of cells in parentheses 
na, not available  
 
 
Figure 5. Ensemble current simulations based on intrinsic receptor activation properties. Simulated ensemble currents 
(shown as colored traces) for homomeric α1, α2, α3, and heteromeric α1β receptors were generated using functional 
activation mechanisms derived from single channel analysis. Accompanying the traces are the activation times (10 –
90%) and deactivation time constants from either a single, or weighted sum of two exponential fits. The simulations 
were generated in QuB (Nicolai and Sachs, 2013) for 1000 receptors in response to a 1 ms application of agonist using 
‘flip’ mechanisms. The mechanisms and rate constants employed in these simulations were obtained as follows: α1 
 α1β α2β α3β α1 α2 α3 
10-90% 
Rise time (ms) 
Heterosynapses 1.6 ± 0.1 (n = 13) 
2.7 ± 0.3 
(8) 
1.9 ± 0.1 
(20) 
1.7 ± 0.1 
(18) 
4.4 ± 0.3 
(13) 
2.6 ± 0.2 
(10) 
Simulation 0.1 na na 0.1 0.2 0.2 
Deactivation 
time constant 
(ms) 
Heterosynapses 7.2 ± 0.4 25.7 ± 1.5 9.7 ± 0.5 7.9 ± 0.5 88.8 ± 6.0 27.9 ± 2.0 
Simulation 10 na na 11 163 6.3 
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homomeric GlyRs – scheme 5 from (Burzomato et al., 2004); α2 homomeric GlyRs – scheme 2 from (Krashia et al., 
2011); α3 homomeric GlyRs – scheme 3 from (Marabelli et al., 2013); α1β heteromeric GlyRs – scheme 5 of 
(Burzomato et al., 2004). Corresponding mean recorded IPSCs, reproduced from Fig. 2B, are included for comparison. 
 
Discussion  
 
Here we present a simple, robust method for inducing synapse formation between native 
glycinergic presynaptic terminals and HEK293 cells that recombinantly express the GlyR subunits 
of interest. This system was developed to provide a tractable means of evaluating the effects of 
drugs, hereditary disease mutations or other interventions on defined GlyR subunit combinations 
under realistic synaptic activation conditions. In the present study we sought to validate this method 
by comparing the influence of different GlyR subunits, both wild type and mutant, with information 
obtained by others in native glycinergic synapses.  
The α1β heteromer is the predominant adult synaptic GlyR isoform (Lynch, 2009). 
Allowing for variations in rise and decay times due to variations in dendritic filtering and 
intracellular chloride concentrations (Pitt et al., 2008), electrophysiological recordings of native 
glycinergic IPSCs in acute spinal cord or brain stem slices exhibit similar rise and decay times as 
observed in our heterosynapses. For example, in neurons of the rat anteroventral cochlear nucleus, 
where glycinergic synapses are somatic and thus not subject to dendritic filtering, the mean 10 – 90 % 
rise time was 0.42 ms and the decay time course was fitted by the sum of two exponentials with 
time constants of 3.6 and 28.4 ms (Lim et al., 1999). In rat dorsal horn neurons, the mean 10 – 90 % 
rise times and decay time constants were 0.76 and 10.2 ms, respectively (Takahashi et al., 1992). In 
rat lumbar motor neurons the values were comparable at 0.79 and 7.1 ms, respectively (Beato, 
2008). In adult hypoglossal motor neurons the 10 – 90 % rise times and decay time constants 
ranged between 0.6 – 1.8 and 4.9 – 7.7 ms, respectively (Graham et al., 2006; Hirzel et al., 2006; 
Muller et al., 2006; Singer et al., 1998). The α1β GlyR isoform is likely to predominate at all these 
synapses (Lynch, 2009). The mean decay time constant for α1β GlyRs measured in our 
heterosynapses (7.2 ms) fits well with these data, although our 10 – 90 % rise time (1.6 ms) is 
slower by a factor of two.  
A striking finding was that α1- and α1β-mediated IPSCs exhibit identical kinetic profiles 
(Fig. 2). Since the IPSC decay time constants correspond well with the intrinsic channel 
deactivation time constants (Fig. 5, Table 1), we infer that both α1 and α1β GlyRs are activated by 
transmitter pulses briefer than their respective intrinsic channel closing rates. This implies that α1 
GlyRs can mediate synaptic transmission as efficiently as α1β GlyRs. This is a surprising result 
given that the β subunit is considered essential for synaptic clustering via its specific interaction 
with gephyrin (Fritschy et al., 2008; Kneussel and Loebrich, 2007; Meyer et al., 1995). However, 
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immunolabeling studies have found that GlyR α1 and α2 subunits can form small cell surface 
clusters independently of gephyrin (Meier et al., 2000) and an electrophysiological study has found 
evidence for IPSCs mediated by α1 homomeric GlyRs in embryonic zebrafish neurons (Legendre, 
1997).  
The α2β GlyR predominates at glycinergic synapses in embryonic rat neurons (Lynch, 
2009). Glycinergic IPSCs in embryonic day 20 rat dorsal horn neurons exhibited a mean 10 – 90 % 
rise time of 0.91 ms and a mean decay time constant of 27 ms (Takahashi et al., 1992), with 
comparable values observed in embryonic zebrafish Mauthner neurons (Ali et al., 2000), perinatal 
rat hypoglossal neurons (Singer et al., 1998) and adult rat wide-field amacrine cells (Veruki et al., 
2007) which are unusual for adult neurons in that they selectively express α2β GlyRs (Wassle et al., 
2009).  The mean decay time constant recorded in the present study (26 ms) fits well with these 
data although our 10 – 90 % rise time (2.4 ms) is dramatically slower. The intrinsic deactivation 
properties of recombinant α2β GlyRs have yet to be investigated. 
The mean decay time constant of homomeric α2 GlyR-mediated IPSCs was very slow (~89 
ms) but consistent with the intrinsic closing rate of these receptors (Fig. 5). Given this close 
correspondence, we infer that their respective channel closing rates governs the decay rates of 
recombinant α2 and α2β-mediated IPSCs. 
The α3β GlyR is generally sparsely expressed in vivo, although it is co-located with α1β 
GlyRs in glycinergic synapses on neurons in the superficial laminae of the spinal cord dorsal horn 
(Harvey et al., 2004). Although α3β-mediated IPSCs have yet to be recorded in isolation in native 
synapses, their kinetic properties appear indistinguishable from those of α1β GlyRs (Harvey et al., 
2004). This fits well with the results of the present study (Fig. 2).  
The rise and decay times of homomeric α3 GlyR-mediated IPSCs were significantly slower 
than those of α3β GlyRs (Fig. 2). Importantly, the homomeric decay time constants were also 
significantly slower than predicted by the intrinsic channel closing rate (Fig. 4). This suggests that 
the kinetic properties of α3-mediated IPSCs are governed by slow agonist access and removal. The 
fact that the rise times of α3β-mediated IPSCs are dramatically faster could indicate an impact on 
receptor gating, or could imply they are located closer to synaptic release sites, which would be 
consistent with the role of the β subunit in gephyrin-dependent clustering.   
Chelation of synaptic zinc by tricine reduced the IPSC decay time constant from 7.6 ± 0.7 to 
6.2 ± 0.8 ms, consistent with a reduction in zinc potentiation. However, the D80A mutation, 
accelerated the decay rate by a much greater margin (7.2 ± 0.4 to 3.1 ± 0.3 ms). There are several 
possible reasons for this discrepancy. First, 10 mM tricine may not have completely chelated 
synaptic zinc. Second, the D80A mutation may have had a secondary accelerating effect on the 
intrinsic channel deactivation rate. Third, the complete elimination of zinc potentiation by the 
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D80A mutation may have uncovered a high potency zinc inhibitory effect that may have 
contributed to the enhanced decay rate.  
 To summarise the main points, the decay rates of IPSCs mediated by α1β, α2β and α3β 
GlyRs in our heterosynapses are in close accord with those observed in native synapses comprizing 
the same subunits. These results, along with the close correspondence in the effects of the A52S 
and D80A mutations between native and heterosynapses, provide an important validation of our 
technique. However, IPSC rise times in our heterosynapses were relatively slow, implying either a 
greater distance between presynaptic release sites and postsynaptic GlyRs or a reduced 
neurotransmitter diffusion rate in the cleft (Nielsen et al., 2004). Our results also suggest that the 
decay rates of IPSCs mediated by α1 and α2 homomeric GlyRs are governed by the intrinsic 
channel closing rate, whereas those mediated by α3 homomeric GlyRs are governed by the slow 
rate of agonist access and removal. A possible explanation could be that α1, α1β and α3β GlyRs are 
clustered (or at least localized relatively close) to synaptic release sites and α3 GlyRs are either 
unclustered or located further away from release sites. Finally, α2-containing GlyRs deactivate so 
slowly that it is difficult to infer their location although their slow rise times imply they are located 
a substantial distance from presynaptic terminals.  
  Specific GlyR isoforms are emerging as therapeutic targets for a range of disorders. For 
example, drugs that selectively potentiate α3-containing GlyRs are candidate lead compounds for 
chronic inflammatory pain (Lynch and Callister, 2006; Xiong et al., 2012; Zeilhofer, 2005). One of 
our motivations for developing the glycinergic heterosynaptic system was to validate the efficacy of 
α3 GlyR-specific drugs under synaptic activation conditions. It is difficult to do this in native 
synapses due to the co-localisation of α1β and α3β GlyRs in individual synapses on nociceptive 
neurons (Harvey et al., 2004), the similarity in their kinetic and pharmacological properties (Lynch, 
2009) and the apparent low abundance of α3β versus α1β expression (Graham et al., 2011). The 
heterosynapse system not only avoids these problems but offers the opportunity of investigating 
GlyR clustering mechanisms, and the effects of posttranslational modifications (e.g., 
phosphorylation) and hereditary disease (e.g., hyperekplexia) mutations on the formation and 
function glycinergic synapses. 
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ABSTRACT  
Hyperekplexia is a rare human neuromotor disorder caused by mutations that impair the efficacy 
of glycinergic inhibitory neurotransmission. Loss-of-function mutations in the GLRA1 or GLRB 
genes, which encode the a1 and b glycine receptor (GlyR) subunits, are the major cause. 
Paradoxically, gain-of-function GLRA1 mutations also cause hyperekplexia, although the 
mechanism is unknown. Here we identify two new gain-of-function mutations (I43F, W170S) and 
characterize these along with known gain-of-function mutations (Q226E, V280M, R414H) to 
identify how they cause hyperekplexia. Using artificial synapses, we show that all mutations 
prolong the decay of inhibitory postsynaptic currents (IPSCs) and induce spontaneous GlyR 
activation. As these effects may deplete the chloride electrochemical gradient, hyperekplexia could 
potentially result from reduced glycinergic inhibitory efficacy. However, we consider this unlikely 
as the depleted chloride gradient should also lead to pain sensitization and to a hyperekplexia 
phenotype that correlates with mutation severity, neither of which is observed in patients with 
GLRA1 hyperekplexia mutations. We also rule out small increases in IPSC decay times (as caused 
by W170S and R414H) as a possible mechanism given that the clinically important drug, 
tropisetron, significantly increases glycinergic IPSC decay times without causing motor side effects. 
A recent study on cultured spinal neurons concluded that an elevated intracellular chloride 
concentration late during development ablates a1b glycinergic synapses but spares GABAergic 
synapses. As this mechanism satisfies all our considerations, we propose it is primarily responsible 
for the hyperekplexia phenotype.  
_____________________________________ 
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Glycine receptor (GlyR) chloride channels mediate fast inhibitory neurotransmission in the 
spinal cord, brainstem and retina, and are thus essential for controlling motor and sensory function 
(1-3). Like other members of the pentameric ligand-gated ion channel family, GlyRs are assembled 
from five subunits arranged around a central water-filled pore. Each GlyR subunit is composed of 
an N-terminal extracellular domain, a transmembrane domain containing four a-helical domains 
(termed M1−M4) and a long intracellular domain linking M3 and M4. Synaptic GlyRs are formed 
as heteromers of a1-3 and b subunit isoforms with a stoichiometry of 2a:3b or 3a:2b (4,5). The 
dominant native synaptic isoform is the a1b heteromer, with the b subunit responsible for 
anchoring GlyRs at postsynaptic densities by directly binding to the cytoplasmic clustering protein, 
gephyrin (6-8).  
Human hereditary hyperekplexia, or startle disease, is a rare neurological disorder characterized 
by neonatal hypertonia and an exaggerated startle reflex in response to sudden, unexpected stimuli 
(9). It is most commonly caused by mutations that reduce the efficacy of glycinergic synaptic 
signalling. Mutations in the GLRA1 or GLRB genes, which encode the a1 and b GlyR subunits 
respectively, are the major cause of hyperekplexia	 (9-12). The vast majority of these mutations are 
loss-of-function in that they reduce the ability of GlyRs to flux chloride. Recessive hyperekplexia 
mutations generally result in the loss of a1 or b GlyR protein expression at the cell surface, whereas 
dominant mutations usually allow strong surface expression but impair channel function via 
reduced open probability, single channel conductance or glycine sensitivity (11,13). Despite 
recessive mutations often resulting in the complete loss of a1 subunit expression (14) and dominant 
negative mutations often involving only moderate disruption to a1 subunit function, there is no 
evidence for ‘major’ or ‘minor’ forms of hyperekplexia and no evidence for a correlation between 
inheritance mode and phenotype (12). Thus, it appears that as long as the deleterious effect of a 
GLRA1 mutation exceeds a certain threshold, a common hyperekplexia phenotype will result. All 
genetic forms of hyperekplexia are successfully treated with the benzodiazepine, clonazepam	
(9,12). This works by potentiating GABA type-A receptor (GABAAR) chloride channels to 
compensate for the loss of glycinergic inhibition (15).  
Hyperekplexia can also be caused by gain-of-function GLRA1 mutations (16,17). To date four 
such mutations have been identified (Y128C, Q226E, V280M and R414H). All of these result in 
spontaneous channel activation, whereas Y128C and V280M also significantly enhance glycine 
sensitivity (16,17). While characterizing a range of other GLRA1 hyperekplexia mutations, we 
discovered that spontaneous activity is also induced by the recently characterized W170S mutation 
(18,19) and by the as yet uncharacterized I43F mutation (20). From the clinical descriptions, it is 
evident that the hyperekplexia phenotype induced by gain-of-function mutations is no different to 
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that caused by loss-of-function mutations and clonazepam remains an effective treatment 
(16,18,20).  
In this study we sought to provide insight into the mechanism by which gain-of-function 
mutations cause hyperekplexia. We have recently developed an ‘artificial’ synapse system that 
allows control over the subunit composition of GlyRs in glycinergic synapses	 (21). We inserted 
heteromeric a1b GlyRs incorporating each mutation in turn to evaluate the properties of the 
inhibitory postsynaptic currents (IPSCs) mediated by each mutant isoform. We then evaluated 
whether the hyperekplexia phenotype is likely to result from the change in IPSC properties or from 
the spontaneous channel activity. 
 
EXPERIMENTAL PROCEDURES 
Cell culture and molecular biology - The human GlyR a1 (pCIS) and b (pCIS) plasmid DNAs 
were combined in a ratio of 1a:50b (artificial synapse and macropatch recordings) or 1a:100b 
(single channel recordings) and transfected into HEK293 cells via calcium phosphate-DNA co-
precipitation. This resulted in the expression of a1b heteromeric GlyRs (21). For artificial synapse 
experiments, mouse neuroligin-2A (pNice) and rat gephyrin (pCIS) were co-transfected along with 
GlyR plasmids to facilitate the formation of artificial synapses. Empty pEGFP plasmid was also 
transfected as an expression marker. Mutagenesis was performed using the QuikChange 
mutagenesis kit, and the successful incorporation of mutations was confirmed by DNA sequencing.  
Artificial synapse formation - E15 timed-pregnant rats were euthanized via CO2 inhalation in 
accordance with procedures approved by the University of Queensland Animal Ethics Committee. 
Primary cultures of embryonic spinal cord neurons were prepared as previously described (21,22). 
Cells were plated at a density of ~80,000 cells per 18 mm poly-D-lysine coated coverslip in DMEM 
medium with 10% fetal bovine serum. After 24 h, the plating medium was changed to Neurobasal 
medium supplemented with 2% B27 and 1% glutamax, and a second feed after one week replaced 
half of this medium. Neurons were grown for 1 − 4 weeks in vitro and the heterosynaptic co-
cultures were prepared by directly introducing transfected HEK293 cells onto the primary neuronal 
cultures 1 − 3 days prior to recordings. 
Electrophysiology - Whole-cell recordings were performed in voltage-clamp mode using a 
HEKA EPC10 amplifier (HEKA Electronics, Lambrecht, Germany) and Patchmaster software 
(HEKA), at room temperature. Cells were continuously perfused with extracellular solution 
comprizing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted 
to pH 7.4 with NaOH. Patch pipettes (1 − 3 MΩ resistance), made from borosilicate glass 
(GC150F-7.5, Harvard apparatus), were filled with an intracellular solution containing the 
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following (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA and 2 MgATP, adjusted to 
pH 7.4 with NaOH. Glycine-gated currents were recorded at a holding potential of −40 mV, 
digitized at 2.9 kHz and filtered at 10 kHz. For IPSC recordings, the patch pipette resistance was 
adjusted to 4 − 6 MΩ and filled with the same internal solution. Series resistance was routinely 
compensated to 60% of maximum and was monitored throughout the recording. Spontaneous 
glycinergic IPSCs in HEK293 cells were recorded at a holding potential −60 mV and signals were 
filtered at 4 kHz and sampled at 10 kHz. As these IPSCs were completely abolished by 1 µM 
tetrodotoxin (not shown), we infer they were induced by spontaneous action potentials. 
Single-channel currents were recorded from outside-out excised patches at a clamped potential 
of −70 mV. Glass electrodes were pulled from borosilicate glass (G150F-3; Warner Instruments), 
coated with a silicone elastomer (Sylgard-184; Dow Corning) and heat-polished to a final tip 
resistance of 8 – 15 MΩ when filled with an intracellular solution containing (in mM) 145 CsCl, 2 
MgCl2, 2 CaCl2, 10 HEPES, and 5 EGTA, pH 7.4. Excised patches were directly perfused with 
extracellular solution by placing them in front of one barrel of a double-barreled glass tube. Single 
channel currents were either recorded while the patch was exposed to extracellular solution (without 
added glycine) or elicited by exposing the patch continuously to glycine (100 µM) containing 
solution. Experiments were recorded using an Axopatch 200B amplifier (Molecular Devices), 
filtered at 5 kHz and digitized at 20 kHz using Clampex (pClamp 10, Molecular Devices) via a 
Digidata 1440A digitizer. The currents were filtered off-line at 3 kHz for making figures.  
In the pharmacological studies, tropisetron (Sigma-Aldrich) was applied by bath perfusion. After 
waiting 2 min for drug effects to stabilize, we compared at least 3 min of spontaneous activity 
before, during and after drug application. 
Macropatch recordings were performed in the excised outside-out patch clamp 
configuration. Patch pipettes were fired-polished to a resistance of approximately 10 MΩ and filled 
with the same internal solution. Macroscopic currents in outside-out patches pulled from transfected 
HEK293 cells were activated by brief (<1ms) exposure to agonists using a piezo-electric translator 
(Siskiyou). We regularly calibrated the speed of the solution exchange system by rapidly switching 
the solution perfusing an open patch pipette between standard extracellular solution and an 
extracellular solution that had been diluted by 50% with distilled water. By monitoring the resulting 
pipette current, we were able to ensure that the solution perfusing the macropatch was completely 
exchanged within 200 µs (23). Recordings were performed using a Multiclamp 700B amplifer and 
pClamp9 software (Molecular Devices), filtered at 4 kHz and sampled at 10 kHz. 
Analysis - Analyses of IPSC amplitudes, 10 − 90% rise times, and weighted decay time constants 
were performed using Axograph (Axograph Scientific). Only cells with a stable series resistance of 
<25 MΩ throughout the recording period were included in the analysis. Single peak IPSCs with 
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amplitudes of at least three times above the background noise were detected using a semi-
automated sliding template. Each detected event was visually inspected and only well-separated 
IPSCs with no inflections in the rising or decay phases were included. To calculate macroscopic 
current decay time constants, averaged macroscopic traces were fitted with double-exponential 
functions in Axograph X, and a weighted time constant was calculated from individual time 
constants (τ1, τ2) and their relative amplitude (A1, A2) as followings: τweighted = 
(τ1×A1+τ2×A2)/(A1+A2). The averaged data from individual cells were then pooled to obtain 
group data. Statistical analysis, and plotting were performed with Prism 5 (GraphPad Software). 
The fitting of single Gaussian functions to IPSC amplitude and decay time constant distributions 
was also performed using Prism 5. All data are presented as mean ± SEM. Student's t-tests or one-
way ANOVAs, as appropriate, were employed for comparisons. For all tests, the number of 
asterisks corresponds to level of significance: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001.  
Single channel recordings were analysed with pClamp 10 (Clampfit) or QuB software. Segments 
of single channel activity separated by long periods of baseline were idealized into noise-free open 
and shut events using a temporal resolution of 70 µs. Single channel activations were separated 
using a shut period ranging between 6 – 30 ms. 
 
RESULTS 
Properties of GlyRs measured by whole cell recording – The locations of the mutations 
investigated in this study are shown in Fig. 1. The glycine EC50 and Imax values for GlyRs 
incorporating the Y128C, W170S, Q226E, V280M and R414H mutations have previously been 
characterized by whole cell recording (16,17,19). The Y128C mutation was found to induce a 
sufficiently large spontaneous leak current as to degrade HEK293 cell viability (17) and thus we did 
not study it further. The V280M mutation significantly reduced both the glycine EC50 and the Imax 
values, although the W170S, Q226E and R414H mutations had little effect of these parameters 
(16,19). The Q226E, V280M and R414H mutations have previously been shown to induce 
spontaneous single channel activity (16,24). In this study we filled in the gaps by quantifying the 
glycine EC50 and Imax values of a1I43Fb GlyRs by whole cell recording. We also employed outside-
out patch clamp recording to characterize the properties of spontaneous single channel events 
mediated by a1I43Fb and a1W170Sb GlyRs.  
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Figure 1. Model of the a1 GlyR viewed from within the membrane. The model is based on the cryoEM structure of 
zebrafish a1 GlyR in the glycine-bound conformation (PDB access code: 3JAE) (40). One subunit is depicted in gold 
with gain-of-function hyperekplexia mutations (red) shown in stick form.   
 
Examples of whole cell currents activated by increasing glycine concentrations at a1b and 
a1I43Fb GlyRs are shown in Fig. 2A. Averaged glycine dose-response relationships for a1, a1I43F, 
a1b and a1I43Fb GlyRs shown in Fig. 2B, with mean parameters presented in Table 1. In both 
homomeric and heteromeric GlyRs, the I43F mutation resulted in a drastically increased sensitivity 
to glycine.  
Figure. 2. Effect of the a1 subunit I43F mutation examined by 
whole cell patch clamp recording. Recordings were performed 
at −60 mV. A. Sample whole cell recordings for heteromeric 
a1b and a1I43Fb GlyRs in the presence of indicated glycine 
concentrations. B. Averaged whole cell glycine dose-response 
curves for a1, a1b, a1I43F and a1I43Fb GlyRs. Mean parameters 
of best fit are provided in Table 1. 
 
 
Table 1. Effect of the I43F mutation on GlyR functional 
properties 
 
 α1β α1 α1I43Fβ α1I43F 
EC50 
(µM) 
29.5 ± 
3.7 
52.8 ± 
8.3 
2.8 ± 
1.3*** 
1.3 ± 
0.3**** 
Hill slope 1.4 ± 0.3 2.0 ± 0.4 1.2 ± 0.2 1.8 ± 0.7 
Imax (nA) 1.1 ± 0.2 1.2 ± 0.1 1.0 ± 0.2 0.7 ± 0.2 
n 6 6 9 6 
***p < 0.001 and ****p < 0.0001 relative to the corresponding 
homo- or heteromeric wild type GlyR via unpaired t test. 
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Spontaneous channel activity in a1W170Sb and a1I43Fb GlyRs - To investigate the presence of 
spontaneous activity, 100 µM picrotoxin alone was applied to whole cells expressing either the 
a1W170Sb GlyR (Fig. 3A) or the a1I43Fb GlyR (Fig. 3B). We observed small but consistent upward 
current deflections in the presence of picrotoxin, which was particularly prominent for the a1I43Fb 
GlyR. To quantify the level of spontaneous activity in both receptors we carried out single channel 
measurements in excised outside out patches. 
In the absence of applied glycine, the a1W170Sb GlyR exhibited brief spontaneous openings of 
1.4 ms mean duration, the majority of which were simple open-shut events (Fig. 3C). We 
determined the frequency of these openings by dividing their occurrence over time by an estimate 
of the number of channels contained in each recorded patch (between 3-6 channels). This yielded an 
open frequency of 0.2 Hz per channel. Wild-type a1b GlyRs under the similar recording conditions 
exhibit negligible spontaneous activity	(10,24-26). 
In the presence of 100 µM glycine, single channel currents mediated by a1W170Sb GlyRs 
occurred in clusters of tightly spaced open-shut transitions (Fig. 3D). The mean duration of the 
clusters was 621 ± 69 ms (n = 3), which is only 1.2-fold longer than wild type a1b GlyRs (~ 500 
ms at saturating glycine (24)). The mean single channel amplitude measured at -70 mV was 3.31 ± 
0.06 pA (n = 4), yielding a conductance of 41.6 ± 0.7 pS. This is similar to that of 45.9 ± 1.4 pS for 
wild type receptors (24) and suggests that the a1W170S mutation has no appreciable effect on 
conductance. 
Similar experiments were carried out using the a1I43Fb GlyR. This receptor also exhibited 
spontaneous openings, but their mean duration was 11.2 ms, which is 8-fold greater than that of the 
a1W170Sb GlyR. Moreover, the activity consisted of brief, single open-shut bursts in addition to a 
significant number of more complex bursts, where the receptor oscillated between open and shut 
configurations multiple times before terminating (Fig. 3E). The calculated spontaneous open 
frequency of this receptor, from patches containing 1-5 channels, was 0.5 Hz. This receptor 
exhibited a greater level of spontaneous activity than the a1W170Sb GlyR, with longer, more 
complex bursts and a 2.5-fold higher frequency of occurrence. 
A 100 µM concentration of glycine elicited long clusters of activity that had a mean duration of 
1030 ± 73 ms (n =3), similar to those of the a1Q226Eb GlyR (24). The single channel mean 
amplitude the a1I43Fb GlyR was 3.64 ± 0.05 pA (n = 3), producing a conductance at -70 mV of 
45.7 ± 0.7 pS. This value is also close to that of wild type a1b GlyRs, suggesting that this mutation 
also has little effect on channel conductance. 
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Figure 3.  Spontaneous activity in a1W170Sb and a1I43Fb GlyRs. Whole-cell steady-state currents showing the effect of 
100 µM picrotoxin (PTX) on a1W170Sb (A) and a1I43Fb (B) GlyRs. Paired single channel recordings of the a1W170Sb 
GlyR in the absence of applied glycine (C) and in the presence of 100 µM glycine (D). The patch contained an estimate 
of 6 channels. Paired single channel recordings of the a1I43Fb GlyR in the absence of applied glycine (E) and in the 
presence of 100 µM glycine (F). The patch contained an estimate of 4 channels. 
 
Hyperekplexia mutations prolong the duration of IPSCs - Next we characterized the mean 
amplitudes, 10−90% rise times and decay time constants of spontaneous IPSCs mediated by 
recombinant a1b, a1I43Fb, a1W170Sb, a1Q226Eb, a1V280Mb and a1R414Hb GlyRs (Fig. 4). Sample 
recordings from artificial synapses incorporating each isoform are shown at three progressively 
increasing temporal resolutions in Fig. 4A with a globally averaged, normalized IPSC shown for 
each isoform in Fig. 4B. The averaged IPSC amplitudes, 10−90% rise times and decay time 
constants for each isoform are presented in Fig. 4C and Table 2. Relative to a1b GlyRs, IPSCs 
mediated by a1I43Fb and a1V280Mb GlyRs exhibited significantly larger amplitudes, whereas those 
mediated by a1W170Sb, a1Q226Eb and a1R414Hb GlyRs exhibited no significant change (Fig. 4C). All 
five mutations resulted in either modest (W170S and R414H) or dramatic (I43F, Q226E and 
V280M) increases in the mean IPSC decay time constant (Fig. 4C). The a1I43Fb and a1V280Mb 
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GlyRs also exhibited significantly slower rise times relative to the a1b GlyR (Fig. 4C). As 
illustrated in Fig. 5, the IPSC amplitudes and decay time constants were monotonically distributed 
for all isoforms, suggesting a single postsynaptic GlyR population in each case. It is likely that the 
prolonged IPSC rise and decay times in the mutant GlyRs is due either to altered intrinsic channel 
gating or to altered geometric factors within the synapse (e.g., synaptic cleft width, GlyR clustering 
propensity) that may slow access of neurotransmitter to the receptors. Our next experiments sought 
to distinguish between these possibilities by comparing the IPSC rise and decay rates with the 
intrinsic channel opening and closing rates for each mutant GlyR. 
 
Table 2. Comparison of 10-90 % rise times and decay time constants of IPSCs and macropatch currents mediated by 
the indicated wild type and mutant GlyRs. 
 
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 relative to the wild type α1β GlyR via one-way ANOVA 
followed by Bonferroni’s post-hoc correction. 
For IPSCs, the n values refer to the total number of cells from which data were collected. For each cell, parameters were 
analyzed from a single IPSC waveform that was digitally averaged from >50 individual events. 
 
 
 α1β α1R414Hβ α1W170Sβ α1Q226Eβ α1I43Fβ α1V280Mβ 
10-90% 
rise time (ms) 
IPSCs 1.6 ± 0.1
 
(n=17) 
1.2 ± 0.1  
(7) 
2.6 ± 0.3  
(12) 
2.7 ± 0.4  
(5) 
5.1 ± 
0.6**** 
 (13) 
7.0 ± 
0.9**** 
(10) 
macropatch 
currents 
0.8 ± 0.1 
(11) 
0.9 ± 0.2 
(8) 
1.2 ± 0.2 
(6) 
0.8 ± 0.1 
(11) 
0.7 ± 0.1 
(7) 
0.5 ± 0.1 
(9) 
deactivation 
time constant 
(ms) 
IPSCs 7.2 ± 0.5 10.9 ± 0.8 18.7 ± 1.5 102 ± 5*** 96 ± 12**** 
181 ± 
31**** 
macropatch 
currents 
26.2 ± 
3.4 32.4 ± 4.1
. 30.4 ± 3.1. 221 ± 23**** 
311 ± 
46**** 139 ± 21
*** 
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Figure 4. Properties of spontaneous IPSCs mediated by wild type and mutant GlyRs in artificial synapses. Recordings 
were performed at −60 mV.  A. Representative recordings of glycinergic IPSCs in HEK293 cells expressing the 
indicated heteromeric GlyRs at three different temporal resolutions. B. Averaged, normalized IPSCs each averaged 
from >50 events from the corresponding cell in A.  C. Comparison of mean IPSC amplitude, decay time constant and 
10-90% rise time for the indicated GlyRs. Statistical significance was determined via one-way ANOVA followed by 
Bonferroni’s post-hoc correction with significance represented by **p < 0.01, ***p < 0.001 and ****p < 0.0001 
relative to a1b GlyRs. 
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Figure 5. Distribution histograms for the peak amplitude and decay time constants of IPSCs recorded from wild type 
and mutant GlyRs (n = 6 cells for each subtype). Curves represent single Gaussian functions of best fit to the data.  
 
Characterization of intrinsic channel closing rates - The peak synaptic glycine concentration has 
been estimated to reach 1 – 3 mM in embryonic zebrafish neurons (27) and 2.2 – 3.5 mM in adult 
rat spinal neurons	 (25). Glycine is removed from the cleft with a time constant of 0.6 – 0.9 ms	 (25).	
Considering these parameters, we simulated synaptic activation conditions by rapidly applying 1 
mM glycine for a period of ~1 ms to outside-out macropatches expressing each receptor. We 
regularly calibrated the speed of the solution exchange system by rapidly switching the solution 
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perfusing an open patch pipette between standard extracellular solution and an extracellular solution 
that had been diluted by 50% with distilled water. By monitoring the resulting pipette current, we 
were able to ensure that the solution perfusing the macropatch was completely exchanged within 
200 µs (23). Under these conditions, the a1b GlyR activated robustly with a mean 10-90% rise time 
of 0.8 ± 0.1 ms and mean decay time constant of 26.2 ± 3.4 ms (Fig. 6, Table 2). This rise time was 
conserved for all five mutant GlyRs, which is surprising given that the mean IPSC rise times for the 
mutant GlyRs were all significantly slower than the wild type a1b GlyR value (Table 2). We also 
observed a systematic discrepancy between the IPSC decay time constants and the macropatch 
current deactivation time constants for the wild type and mutant GlyRs (Fig. 6, Table 2). With the 
exception of the a1V280Mb GlyR, the intrinsic channel deactivation time constants were a factor of 
1.7 – 3.6 slower than the IPSC decay time constants. The discrepancies between the macropatch 
and synaptic rise and decay times are presumably caused by factors specific to the synapse. One 
possibility is that synaptic GlyRs are clustered by a binding interaction with a protein that alters 
their gating properties. It is also possible that we have made an incorrect assumption about the 
temporal profile and/or peak glycine concentration in the synaptic cleft. However, given the strong 
correlation between IPSC decay time constants and macropatch deactivation time constants in the 
a1I43Fb, a1Q226Eb and a1V280Mb GlyRs, we infer that the dramatic slowing in their IPSC decay rates 
is dominated by changes in their intrinsic channel gating properties. Indeed, we have characterised 
the molecular basis of these gating changes in the a1Q226Eb and a1V280Mb GlyRs	(10,24). 
 
Figure 6. Comparison of the IPSC decay rate with the 
corresponding intrinsic receptor deactivation rate. 
Averaged macropatch currents recorded from outside-
out patches containing the indicated GlyR. The 
currents were activated by brief (~1 ms) exposure to 
saturating (1 mM) glycine. Recordings were 
performed at −60 mV. Corresponding averaged IPSCs 
(right panel, black traces), reproduced from Fig. 3B, 
are included for comparison. 
 
 
 
Tropisetron significantly increased α1β GlyR-mediated IPSC decay time constant - The R414H 
mutation results in a full hyperekplexia phenotype (16) despite causing a relatively small increase in 
IPSC decay time constant (from 7.2 to 11.4 ms). Can a small increase in the IPSC decay time 
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constant alone result in a motor impairment? We addressed this question by investigating the effects 
1 nM tropisetron on IPSCs mediated by a1b GlyRs.  
Tropisetron, a 5-hydroxytryptamine type-3 receptor (5-HT3R) antagonist, is clinically important 
for the treatment of postoperative and chemotherapy induced emesis and, importantly, it causes no 
motor side effects (28). As tropisetron inhibits the 5HT3R with an IC50 near 1 nM (29,30), we 
assume this concentration	 is clinically relevant. This concentration is also known to potentiate 
recombinant a1b GlyRs activated by a low (e.g., EC20) glycine concentration (4,31), although its 
effect on glycinergic IPSCs has never been reported. Sample recordings of a1b GlyR-mediated 
IPSCs in the absence and presence of 1 nM tropisetron are shown in Fig. 7A. The globally averaged 
and normalised IPSCs suggest that 1 nM tropisetron exerted a prolonging effect on IPSC decay 
times (Fig. 7B). The averaged data presented in Fig. 7C reveal that 1 nM tropisetron had no 
significant effect on IPSC amplitude or 10 – 90 % rise times, although it significantly increased the 
decay time constant from 5.8 ± 0.3 to 7.6 ± 0.4 ms (p < 0.05, paired t test; n = 6 cells). The 
percentage increase (32 %) in the IPSC decay time constant in 1 nM tropisetron was modestly 
lower than that caused by either the R414H or W170S mutations (59% and 56%, respectively).  
 
 
Figure 7. A clinically relevant concentration of tropisetron prolongs the IPSC duration. A. Representative IPSC 
recordings from an a1b GlyR-expressing cell before, during and after the application of 1 nM tropisetron. Recordings 
were performed at −60 mV. B. Superimposed averaged traces of IPSCs (n > 200 events) recorded in control (black 
trace), 1 nM tropisetron exposure (red trace), and 5 min after the tropisetron washout (grey trace). Currents have been 
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normalised. C. The decay time constant of IPSCs mediated by a1b GlyRs was significantly prolonged by 1 nM 
tropisetron whereas the amplitude and 10-90% rise times were unchanged.	*p < 0.05 relative to drug-free control. 
 
DISCUSSION 
Validation of the artificial synapse technique - We have previously validated our artificial 
synapse system by showing that the decay rates of IPSCs mediated by a1b, a2b and a3b GlyRs in 
artificial synapses are similar to those mediated by the same isoforms in native neuronal synapses 
(21). We have also compared the effects of a1 GlyR subunit mutations in artificial and native 
synapses. The a1 GlyR subunit loss-of-function D80A and A52S mutations have previously been 
shown to cause hyperekplexia-like phenotypes in mice (32,33). Artificial synapses incorporating 
recombinant a1D80Ab and a1A52Sb mutant GlyRs exhibited accelerated IPSC decay rates that were 
quantitatively similar to those recorded in native synapses in mutant mice homozygous for the same 
mutations (21). The main trends in our artificial synapse data are also supported by the fast agonist 
application experiments (Fig. 6). Thus, the possible existence of ultrastructural or protein 
expression differences between native and artificial synapses are unlikely to seriously affect the 
IPSC decay rates as reported here.  
Summary of results - We have identified two new GLRA1 gain-of-function hyperekplexia 
mutations, I43F and W170S. The I43F mutation resulted in prolonged bursts of spontaneous 
channel activity (Fig. 3E) similar to that previously demonstrated for the Q226E mutation (24). 
These bursts most likely underlie the observed slow IPSC decay rates. Indeed, synaptic currents 
mediated by other ligand-gated ion channels have also been shown to deactivate as a function of the 
durations of single channel burst activity	 (23,34-37). Conversely, the short-lived spontaneous bursts 
induced by a1W170Sb and a1R414Hb GlyRs most likely underlie their faster IPSC decay rates, 
compared to those mediated by a1I43Fb and a1Q226Eb GlyRs.  
The original electrophysiological characterisation of the a1W170Sb GlyR showed that zinc 
potentiation was	 abolished (19). Physiological levels of zinc potentiate GlyRs (38,39), and the loss 
of zinc potentiation via the a1D80A mutation accelerated the IPSC decay rate and thus caused 
hyperekplexia in a knock-in mouse model (32). Thus, it was reasonable to hypothesise that the 
W170S-mediated hyperekplexia phenotype was due to a diminished capacity of IPSCs to transfer 
chloride ions (19). However, in the present study we found that the decay time constant of IPSCs 
mediated by a1W170Sb GlyRs was actually longer than that of a1b GlyRs (Fig. 4C). Thus, the loss 
of zinc potentiation does not explain the hyperekplexia phenotype.  
It seems surprising that the R414H mutation also resulted in a full hyperekplexia phenotype, 
especially given its autosomal dominant inheritance mode	 (16). This mutation resulted in a modest 
level of spontaneous channel activity (16) and a modestly prolonged IPSC duration (Fig. 4C), 
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similar to that induced by W170S. Due to its inheritance mode, the magnitudes of these effects in 
heterozygote patients may be further reduced by the equivalent levels of expression of mutant and 
wild type a1 subunits. 
Molecular mechanisms of the mutations -Q226 lies at the top of the M1 domain (Fig. 1). As the 
channel opens, Q226 moves closer to R271 at the top of M2 (40). We have previously demonstrated 
that channel activation is facilitated by an energetic interaction between these residues (10,24). This 
interaction is strengthened by the Q226E mutation, resulting in the longer active periods that 
underlie the gain-of-function startle phenotype (10,24). V280 is located in the M2-M3 loop (Fig. 1) 
where it is closely apposed to I225 at the top of M1. We previously concluded that the bulky 
V280M substitution exerts a steric repulsion against I225, thereby tilting the M2 outwards to 
facilitate spontaneous channel opening (10,24). I49 and W170 lie in close proximity in the inner 
and outer b-sheets, respectively, of the extracellular domain (Fig. 1). It is possible that mutations to 
either of these residues disrupt the relative orientations of the b-sheets and this could lead to 
allosteric defects including aberrant receptor activation. The molecular mechanism of R414H, 
which lies at the extracellular C-terminus of M4 (Fig. 1), remains elusive.  
Proposed mechanism of hyperekplexia by gain-of-function GLRA1 mutants - Synaptic inhibition 
in adult spinal motor neurons is mediated exclusively by glycine (41,42) or by a combination of 
glycine and GABA (43,44). The chloride concentration in adult neurons is normally very low, and 
as a result small increases in the chloride influx rate can have a significant effect on the strength, or 
even polarity, of glycinergic signalling	 (45). If a tonic increase in intracellular chloride 
concentration in otherwise healthy adult spinal motor neurons causes hyperekplexia, then the I43F, 
Q226E or V280M mutations should cause a more severe phenotype than the W170S or R414H 
mutations, due to the large disparity in their rates of spontaneous and glycine-mediated chloride 
influx (45). Furthermore, if spontaneous GlyR activity results in increased chloride accumulation in 
spinal motor neurons then it should do likewise in spinal dorsal horn nociceptive neurons that also 
receive glycinergic inputs	 (46), and this should result in chronic pain (45). As neither chronic pain 
nor a correlation between GLRA1 mutation severity and startle phenotype have ever been reported 
in hyperekplexia patients (12), we consider it unlikely that hyperekplexia is predominantly due to 
an elevated chloride concentration in adult motor neurons. 
Another possibility is that the mutation-induced increase in IPSC decay time constant directly 
elicits hyperekplexia, perhaps by a presynaptic effect on an excitatory or inhibitory input onto 
motor neurons. We demonstrate that a clinically relevant (1 nM) concentration of tropisetron 
significantly prolongs the decay time constant of a1b-mediated IPSCs (Fig. 7). This is notable 
because tropisetron has never been reported to cause hyperekplexia or other motor side effects 
(28,47). As the tropisetron-induced increase in IPSC decay time constant almost reaches the levels 
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induced by the W170S and R414H mutations, it is unlikely that the modest slowing in the IPSC 
decay rate induced by these mutations could cause hyperekplexia. 
Prenatally in the rat, the a2 subunit is the predominant GlyR isoform. However, a developmental 
switch occurs during the first three postnatal weeks, whereby most of the a2 subunits are replaced 
by a1 (3).  Simultaneously, the intracellular chloride concentration is reduced due to chloride 
extrusion by the KCC2 and KCC3 chloride-potassium co-transporters to the point where it supports 
efficient synaptic inhibition	 (48). A recent study that inhibited KCC2 function in cultured spinal 
neurons during this period found that the elevated chloride concentration reduced the number and 
size of a1 GlyR dendritic clusters without affecting neighbouring a2 GlyR clusters (49). 
Concomitantly, glycinergic miniature IPSCs were reduced in amplitude and frequency although 
GABAergic IPSCs were not affected. This mechanism, which is thought to be active during the 
final maturation stage of spinal motor neurons (49), provides a mechanism for explaining how gain-
of-function hyperekplexia mutations can cause a single common hyperekplexia phenotype without 
necessarily requiring an elevated chloride concentration in adult neurons.  
Relevance of findings to pain drug development - Glycinergic synapses on pain sensory neurons 
in the spinal cord superficial laminae are unique in that they incorporate both a1 and a3 GlyR 
subunits (50). Inflammatory mediators (notably prostaglandin E2) induce chronic inflammatory 
pain by phosphorylating, and inhibiting, a3-containing GlyRs (50,51). This reduces the magnitude 
of IPSCs in spinal pain sensory neurons, which in turn ‘disinhibits’ them and thereby increases the 
rate of transmission of pain impulses to the brain. This mechanism, which provides a paradigm for 
chronic inflammatory pain sensitisation, implies that drugs that selectively potentiate (i.e., restore) 
a3b GlyR-mediated IPSCs should be analgesic. It is generally assumed that such drugs should 
avoid potentiating a1b GlyRs due to their broader distribution and the consequent risk of motor and 
other side effects (46,52). However, developing drugs specific for a3-containing GlyRs has proved 
difficult (53), due largely to the high amino acid sequence identity of a1 and a3 subunits, 
particularly in the known ligand binding sites. Our demonstration that a clinically relevant 
tropisetron concentration potentiates a1b GlyR-mediated IPSCs without causing motor or other 
side effects suggests the policy of avoiding a1 potentiation during analgesic drug development may 
be overemphasized.  
Conclusion - Given that hyperekplexia is normally associated with a loss of glycinergic 
inhibitory tone, it seems paradoxical that an increase in glycinergic tone elicits an identical 
phenotype. We demonstrate here that all known GLRA1 gain-of-function hyperekplexia mutations 
act similarly to induce spontaneous GlyR activity and slow the decay rate of glycinergic IPSCs. We 
argue that mutations with modest IPSC prolonging effects (W170S, R414H) are unlikely to cause 
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hyperekplexia by simply slowing the IPSC decay rate. We also argue that intracellular chloride 
accumulation in otherwise healthy adult neurons is unlikely to be solely responsible, although it 
may contribute to the phenotype. It has been shown that an elevated intracellular chloride 
concentration late in development selectively ablates a1b GlyR-containing synapses on spinal 
neurons. We consider this provides a plausible mechanism for gain-of-function GLRA1 
hyperekplexia mutations because the loss of synapses would result in a single common 
hyperekplexia phenotype without requiring significant chloride accumulation in adult neurons.    
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Effects of alpha2 GlyR autism mutations on glycinergic synaptic function 
 
Abstract 
 
Autism spectrum disorder (ASD), characterized by deficits in social interaction and 
communication, is thought to result from dysfunctional development of neural circuits and is 
associated with perturbed excitatory-inhibitory balance. Glycine receptors (GlyRs) are postsynaptic 
ligand-gated ion channel receptors mediating fast inhibitory neurotransmission in the mature brain. 
The α2 GlyR is the dominant isoform expressed in neurons during neurodevelopment. As the 
activity of α2 GlyRs in immature neurons is essential for neuronal migration and synapse 
formation, they play an important role in neurodevelopment. Defects in the GLYA2 gene, which 
encode the α2 GlyR subunit, have been identified in human patients with ASD. Using artificial 
synapse and macroscopic current recording techniques, we found that the newly identified ASD-
causing mutation, R350L, in the TM3-TM4 intracellular loop, altered postsynaptic performance by 
significantly increasing IPSC rise and decay times. Interestingly, R350L also exhibited reduced 
glycine sensitivity. To test the role of the arginine in normal GlyR function, we replaced R350 with 
alanine (reduced side-chain), lysine (retains the positive charge of arginine) or isoleucine (an 
analogous residue of leucine) residues. Replacement of alanine, lysine and isoleucine at this domain 
yielded IPSCs with similar kinetic properties to those of wild-type GlyRs.  
 
1. Introduction 
Autism spectrum disorders (ASDs) are a group of heterogeneous neurodevelopmental disorders 
centered on three core deficits: communication impairment, social impairment and restricted 
interests often accompanied by repetitive behaviours (Geschwind, 2009). Typically, ASD 
symptoms are manifested in early childhood and persist through adulthood. Abnormalities in the 
genes encoding glutamatergic receptors (Tarabeux et al., 2011; Uzunova et al., 2014) and GABA-A 
receptors (Bundey et al., 1994; Schroer et al., 1998; Hogart et al., 2007), or cell-adhesion molecules 
such as neurexin (Kim et al., 2008; Gauthier et al., 2011; Bena et al., 2013) and neuroligins (Jamain 
et al., 2003; Laumonnier et al., 2004; Yan et al., 2005) have been reported in ASD patients, 
suggesting a proportion of ASDs are synaptopathies. 
 
The glycine receptor (GlyR) is a member of pentameric ligand-gated ion channel (pLGIC) family 
that mediates inhibitory signalling by conducting chloride ion flux in response to the binding of 
glycine. The superfamily also includes the nicotinic acetylcholine receptor (nAChR), 5-
hydroxytryptamine type-3 receptor (5-HT3R) and γ-aminobutyric acid type-A receptor (GABAAR), 
each of which is comprised of five subunits surrounding a central ion-conducting pore. Each 
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subunit shares a common topology contains three domains, N-terminal extracellular domain (ECD) 
that harbours the ligand-binding site, four transmembrane domains (TM1-TM4) and a large 
intracellular loop domain (ILD) connecting TM3 and TM4. The intracellular TM3 - TM4 loop of 
the GlyR harbours phosphorylation sites (Han et al., 2013), and plays an important role in channel 
gating (Breitinger et al., 2009), conductance (Carland et al., 2009), modulation (Burgos et al., 
2015), intracellular sorting (Melzer et al., 2010) and interactions with intracellular proteins (Kim et 
al., 2006; Del Pino et al., 2014). Three functional isoforms of the α subunit and one isoform of β 
subunit are found in humans (Lynch, 2009). Pentameric GlyRs can be formed as homomers consist 
of α subunits only, or as heteromers comprising α and β subunits in the form of 3α:2β or 2α:3β 
(Grudzinska et al., 2005; Durisic et al., 2012; Yang et al., 2012). The β subunit is important for 
synaptic localization as it interacts directly with gephyrin, an intracellular protein essential for 
clustering GlyRs at synapses (Sola et al., 2004; Maric et al., 2014). The maturation of glycinergic 
synapses is associated with changes in the composition and functional properties of GlyRs. During 
early CNS development, the α2 subunit is broadly expressed throughout the brain, well before the 
formation of synaptic contacts. Glycine acts as an excitatory depolarising transmitter due to an 
inverted chloride gradient in immature neurons (Flint et al., 1998). After birth, GlyR α2 expression 
is gradually decreased accompanied by markedly increased α1 and α3 expression (Akagi et al., 
1991; Malosio et al., 1991; Watanabe and Akagi, 1995). The glycinergic synaptic currents decay 
rates were observed to be much faster after a progressive replacement of α2 by α1 and α3 subunits 
(Takahashi et al., 1992), thereby allowing efficient synaptic transmission.  
 
Dysfunction of glycinergic signaling has been implicated in neurological disorders known as 
hyperekplexia (Bode and Lynch, 2014). Recently, microdeletions and missense mutations in 
GLYA2 gene, encoding the GlyR α2 subunit, have been reported to represent a rare cause of ASDs 
(Piton et al., 2011; Pilorge et al., 2015). To date, three missense mutations (N136S, R153Q and 
R350L) have been identified. Previous studies have characterized the functional defects of N136S 
and R153S mutations through whole-cell patch-clamp analysis (Pilorge et al., 2015). The marked 
reduction in the glycine sensitivity caused by N136S and R153Q mutations would prevent them 
from responding appropriately to the physiological levels of glycine, thereby reducing the efficacy 
of glycinergic inhibitory neurotransmission. The Arg-350 to Leu-350 (R350L) substitution, which 
alters a conserved residue located near the C-terminal end of TM3 in the ILD (Fig. 1A), has yet to 
be functionally characterised. The aim of this this study is to examine the molecular mechanism by 
which R350L mutation contributes to ASD pathogenesis.  
 
2. Materials and method 
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2.1. Cell culture and molecular biology 
The human GlyR α2 (pCIS) and β (pCIS) plasmid DNAs were combined in a 1α:50β ratio (for 
artificial synapse and macropatch recordings) and transfected into HEK293 cells via calcium 
phosphate-DNA co-precipitation. This resulted in a high level of expression of α2β heteromeric 
GlyRs (Zhang et al., 2015). For artificial synapse experiments, the mouse NL2A splice variant 
(pNice), rat gephyrin (pCIS) were co-transfected along with GlyR plasmids to facilitate the 
formation of artificial synapses. Empty pEGFP plasmid was also transfected as an expression 
marker. Mutagenesis was performed using the QuikChange mutagenesis kit, and the successful 
incorporation of mutations was confirmed by DNA sequencing.  
 
2.2. Artificial synapse formation 
Primary cultures of spinal cord neurons were prepared as previously described (Dixon et al., 2015; 
Zhang et al., 2015). E15 timed-pregnant rats were euthanized via CO2 inhalation in accordance with 
procedures approved by the University of Queensland Animal Ethics Committee. Cells were plated 
at a density of ~80,000 cells per 18 mm poly-D-lysine coated coverslip in DMEM medium with 
10% fetal bovine serum. After 24 h, the plating medium was changed to Neurobasal medium 
supplemented with 2% B27 and 1% glutamax, and a second feed after one week replaced half of 
this medium. Neurons were grown for 1 − 4 weeks in vitro and the heterosynaptic co-cultures were 
prepared by directly introducing transfected HEK293 cells onto the primary neuronal cultures 1 − 3 
days prior to recordings. 
 
2.3. Electrophysiology 
Whole-cell recordings were performed on transfected HEK293 cells under voltage-clamp mode 
using a HEKA EPC10 amplifier (HEKA Electronics, Lambrecht, Germany) and Patchmaster 
software (HEKA), at room temperature. Cells were placed in an external solution comprising (in 
mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with 
NaOH. Patch pipettes (1−3 MΩ resistance), were pulled from borosilicate glass (GC150F-7.5, 
Harvard apparatus), and filled with an intracellular solution containing the following (in mM): 145 
CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA and 2 MgATP, adjusted to pH 7.4 with NaOH. 
Glycine-gated currents were recorded at a holding potential of −40 mV, digitized at 2.9 kHz and 
filtered at 10 kHz. For IPSC recordings, patch pipettes resistance were adjusted to 4 − 6 MΩ and 
filled with the same internal solution. Series resistance was routinely compensated to 60% of 
maximum and was monitored throughout the recording. Both spontaneous and action potential-
evoked glycinergic IPSCs in HEK cells were recorded at a holding potential −60 mV and signals 
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were digitally sampled at 10 kHz and filtered at 4 kHz. As these IPSCs were completely abolished 
by 1 µM tetrodotoxin (not shown), we infer they were induced by spontaneous action potentials. 
 
Macropatch recordings were performed in the excised outside-out patch clamp configuration. Patch 
pipettes were fired-polished to a resistance of approximately 10 MΩ and filled with the same 
internal solution. Macroscopic currents in outside-out patches pulled from transfected HEK293 
cells were activated by brief (<1ms) exposure to agonists using a piezo-electric translator 
(Siskiyou). We regularly calibrated the speed of the solution exchange system by rapidly switching 
the solution perfusing an open patch pipette between standard extracellular solution and an 
extracellular solution that had been diluted by 50% with distilled water. By monitoring the resulting 
pipette current, we were able to ensure that the solution perfusing the macropatch was completely 
exchanged within 200 µs (Dixon et al., 2014). Recordings were performed using a Multiclamp 
700B amplifer and pClamp9 software (Molecular Devices), filtered at 4 kHz and sampled at 10 
kHz. 
 
2.4. Analysis 
Analyses of IPSC amplitudes, 10 − 90% rise times, and weighted decay time constants were 
performed using Axograph (Axograph Scientific). Only cells with a stable series resistance of < 25 
MΩ throughout the recording period were included in the analysis. Single peak IPSCs with 
amplitudes of at least three times above the background noise were detected using a semi-
automated sliding template. Each detected event was visually inspected and only well-separated 
IPSCs with no inflections in the rising or decay phases were included. To calculate macroscopic 
current decay time constants, averaged macroscopic traces were fitted with double-exponential 
functions in Axograph X, and a weighted time constant was calculated from individual time 
constants (τ1, τ2) and their relative amplitude (A1, A2) as followings: τweighted = 
(τ1×A1+τ2×A2)/(A1+A2). The averaged data from individual cells were then pooled to obtain 
group data. Statistical analysis, and plotting were performed with Prism 5 (GraphPad Software). All 
data are presented as mean ± SEM. Student's unpaired t-tests or one-way ANOVAs, as appropriate, 
were employed for comparisons. For all tests, the number of asterisks corresponds to level of 
significance: *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.  
 
3. Results 
Effects of the ASD-causing α2R350L mutation on channel properties  
The R350 is highly conserved among GlyR subunits (Fig. 1A). To determine the functional effects 
of ASD-causing α2R350L mutation, we first analyzed the efficacy of glycine in activating 
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recombinant homomeric α2R350L GlyRs and heteromeric α2R350Lβ receptors. Fig. 1B illustrates 
whole-cell currents recorded in response to increasing concentrations of glycine in HEK293 cells 
expressing wild-type or mutated α2 receptors. The glycine dose-response curve of the homomeric 
and heteromeric α2R350L-containing receptors was modestly right-shifted relative to that of the 
corresponding wild-type GlyR (Fig. 1C) with mean parameters of best fit to the concentration-
response curves presented in Fig. 1D.  In both homomeric and heteromeric GlyRs, the R350L 
mutation resulted in an apparent decrease in glycine sensitivity. This suggests that the R350L 
mutation in M3-M4 loop may induce a global conformational change that propagates to the 
glycine-binding site. 
 
Fig. 1. Effect of the a2 subunit R350L mutation examined 
by whole cell patch clamp recording. A. Alignments of 
various GlyR α2 subunit amino acid sequences. The 
conserved arginine residue at position 350 in human GlyR α2 
subunit is boxed in red. B. Sample whole cell recordings for 
heteromeric α2β and α2R350Lβ GlyRs in the presence of 
indicated glycine concentrations. C. Averaged whole cell 
glycine dose-response curves for α2, α2β, α2R350L and 
α2R350Lβ GlyRs. D. Summary of dose-response analysis data. 
*p < 0.05 relative to the corresponding homo- or heteromeric 
wild type GlyR via unpaired t test. 
 
 
 
 
 
 
 
 
 
Effects of the ASD-causing α2R350L mutation on intrinsic channel gating 
The peak glycine concentrations in the synaptic cleft are thought to reach 1 − 3 mM in embryonic 
zebrafish neurons (Legendre, 1998) and 2.2 − 3.5 mM in adult rat spinal neurons (Beato, 2008). 
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The clearance of the glycine away from the cleft was estimated on a 0.6 − 0.9 ms time scale (Beato, 
2008). Based on these parameters, we examined intrinsic channel properties by rapidly applying 
saturating glycine (3 mM) for a period of ~1 ms to excised outside-out HEK cell patches expressing 
the wild-type and α2R323Lβ receptors. Sample macroscopic currents are shown in Fig. 2A. The time 
course of desensitisation was fitted by a double exponential function with a mean time constant 
value of 61.8 ± 7.9 ms (n = 15) for wild-type and a mean time constant value of 88.0 ± 9.3 ms (n = 
17) for α2R323Lβ (Fig. 2B). The deactivation time constant in the α2R323Lβ receptors was ~1.5-fold 
slower compared to wild-type receptors (p < 0.05), but the rise time did not differ from the wild-
type receptors (α2β, 1.3 ± 0.1 ms; α2R323Lβ, 1.4 ± 0.2 ms; p > 0.05), indicating that the R350L 
mutation in M3-M4 loop altered intrinsic channel properties by significantly slowing channel 
closing rate. 
 
 
Fig. 2. Glycine-evoked α2R350Lβ currents had slower intrinsic kinetic properties, compared to wild-type currents. A. 
Averaged macropatch currents recorded from outside-out patches containing the α2β (black trace) and α2R350Lβ (red 
trace) GlyRs. The currents were activated by brief (~1 ms) exposure to saturating (3 mM) glycine. To allow comparison 
the kinetic properties, the currents were normalized to the same peak amplitude. B. Comparison of mean macropatch 
currents decay time constant and 10-90% rise time. *p < 0.05 relative to a2b GlyRs via unpaired t test. 
 
Effects of the ASD-causing α2R350L mutation on glycinergic IPSC kinetics 
To test whether the impairment of GlyR channel function altered glycinergic transmission, we used 
an ‘artificial’ synapse system that allows control over the subunit composition of GlyRs in 
glycinergic synapses (Zhang et al., 2015). We inserted wild-type and mutant α2β GlyRs in turn into 
these synapses to evaluate the properties of the IPSCs mediated by α2R323Lβ receptors. Sample IPSC 
recordings from artificial synapses incorporating wild-type and α2R323Lβ isoforms are shown at two 
different temporal resolutions in Fig. 3A with a globally averaged normalised averaged normalised 
IPSC presented in in colour on the right. Mean IPSC amplitudes, decay time constants and rise 
times are shown in Fig. 3B. The averaged IPSC amplitudes, 10 – 90% rise times and decay time 
constants for wild-type and mutant receptors are presented in Fig. 3C. We observed that IPSCs 
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mediated by α2R323Lβ receptors display 2-fold slower rise and decay time than those mediated by 
wild-type GlyRs (10-90% rise time: α2β, 2.6 ± 0.3 ms, n = 7; α2R323Lβ, 4.9 ± 0.8 ms, n = 6, p < 
0.01; decay time: α2β, 27.0 ± 1.5 ms; α2R323Lβ, 60.8 ± 4.9 ms, p < 0.0001), while the mean IPSC 
amplitude did not differ significantly (α2β, 32.8 ± 2.5 pA; α2R323Lβ, 34.0 ± 11.9 pA; p >0.05). As 
the change in IPSC decay rates corresponds well with the fast application data presented in Fig. 2, 
we infer that the slower decay of IPSCs is dominated by the slowed intrinsic channel deactivation 
rates. 
 
 
Fig. 3. Leucine substitution at Arg-350 position is indeed responsible for the prolonged IPSCs. A. Representative 
recordings of glycinergic IPSCs in HEK293 cells expressing the α2β and α2R350Lβ GlyRs at different temporal 
resolutions. Averaged, normalized IPSCs each averaged from > 50 events from the corresponding cell are shown in the 
right panel (color traces). B. Comparison of mean IPSC amplitude, decay time constant and 10 – 90% rise time for the 
indicated GlyRs. C. Representative recordings of glycinergic IPSCs in HEK293 cells expressing the α2R350Aβ, α2R350Kβ 
and α2R350Iβ GlyRs at different temporal resolutions. Recordings were performed at −60 mV. Statistical significance 
was determined via one-way ANOVA followed by Bonferroni’s post-hoc correction with significance represented by 
**p < 0.01 and ****p < 0.0001 relative to a2b GlyRs. 
 
The side chain of leucine dominates the time-course of glycinergic IPSCs 
The TM3-TM4 inctracellular loop is the region of lowest amino acid sequence identity among 
different pLGIC subunits, but the Arg-350 residue is highly conserved in all α-subunits of the 
human GlyRs and GLRA2 across a wide range of vertebrates (Fig. 1A). The disturbance of 
glycinergic transmission is caused by the substitution of a positively charged arginine residue for an 
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uncharged leucine residue. We next sought to investigate whether the side chain charge or the steric 
characteristics of the residue contributes directly to the normal function or dysfunction of 
glycinergic signaling. The arginine residue was first mutated to alanine (R350A), whose side chain 
only contains a methyl group and is absent of both bulk and charge. We also investigated the lysine 
substitution, which retains the arginine’s positive charge but has a slightly reduced volume, and 
isoleucine, which retains the hydrophobicity of leucine. We then characterized the effects each 
mutation on the kinetics of IPSCs. Fig. 3C shows sample recordings from artificial synapses 
incorporating three mutated constructs, and averaged normalised IPSCs are presented in the right 
panel. Interestingly, the R350A, R350K and R350I mutations all produce IPSCs that have kinetics 
similar to those of the wild-type receptors (Table 1). This suggests that loss of either the bulky side 
chain or the positive charge at position 350 are not responsible for the effects of the R350L 
mutation on IPSC time course. 
 
 
 
 
 
 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 	
 
 
 
 
 
 
 
 
 	
Table 1. Comparison of 10 – 90 % rise times and decay time constants of IPSCs and macropatch currents mediated by 
the indicated wild type and mutant GlyRs.  
 
*p < 0.05, **p < 0.01 and ****p < 0.0001 relative to the wild type α1β GlyR, unpaired t-test for comparisons between 
two groups and one-way ANOVA followed by Bonferroni’s post-hoc correction for multiple comparisons. For IPSCs, 
the n values refer to the total number of cells from which data were collected. For each cell, parameters were analyzed 
from a single IPSC waveform that was digitally averaged from > 50 individual events. 
 
4. Discussion 
In this study we have characterized a new ASD-causing mutation R350L located in the ILD of 
GlyR α2 subunit, and used a combination of rapid glycine application and artificial synapse 
recordings to investigate the intrinsic channel kinetic and IPSC kinetic properties of α2R350Lβ 
GlyRs. We have shown that the R350L mutation reduced the glycine sensitivity, but led to dramatic 
decreases in channel closing rate and IPSC decay rate. These findings provide new evidence that 
 α2β α2R350Lβ α2R350Aβ α2R350Kβ α2R350Iβ 
10-90% 
rise time (ms) 
IPSCs 2.6 ± 0.3
 
(n = 7) 
4.9 ± 0.8** 
(6) 
2.5 ± 0.3 
(4) 
2.3 ± 0.3 
(7) 
2.4 ± 0.1 
(5) 
macropatch 
currents 
1.3 ± 0.2 
(15) 
1.4 ± 0.1 
(17)    
deactivation 
time constant 
(ms) 
IPSCs 27.0 ± 1.5 60.8 ± 4.9**** 37.1 ± 6.8 32.3 ± 2.8 32.0 ± 2.5 
macropatch 
currents 61.8 ± 7.9 88.0 ± 9.3
*    
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intracellular regions of the GlyRs also contribute to determining agonist action, channel 
conductance, intrinsic channel gating and IPSC kinetics.  
 
In contrast to the extracellular and membrane spanning domains, the TM3-TM4 loop of 
intracellular domain has lowest conservation in amino acid sequence and length across either the 
wide range of pLGIC family members or different subunits of the same receptors. Residues in the 
TM3-TM4 loop domain have been shown to contribute to the ion permeation pathway in some 
closely related pLGIC family members. Modifications of ILD length of human recombinant α3 
GlyRs resulted in drastic changes in current responses while surface protein expression levels were 
unaltered (Breitinger et al., 2009). Truncation of ILD in GABAAR α1 subunits maintained their 
functionality, but remarkably altered both channel conductance and agonist apparent affinity 
(O'Toole and Jenkins, 2011), suggesting the ILD plays an important role in receptor activation. 
However, replacement of 5HT3R, GABAρ1R or α1 GlyR subunit sequence with a shorter TM3-
TM4 linker displayed channel properties similar to those of wild-type channel (Jansen et al., 2008; 
Moroni et al., 2011; Papke and Grosman, 2014), implying that the functional significance of ILD 
may depend on the pLGIC member. The effects of mutations to the ILD on single channel 
conductance have been examined in GlyRs. Mutation of eight positively charged residues within 
the α1 GlyR ILD to negatively charged residues simultaneously gave rise to a non-functional 
channel. Inverting the charge at the Arg-377, Lys-378, Lys-385 and Lys-386 position had the 
greatest reduction in the channel conductance (Carland et al., 2009). An earlier study reported that 
disruptions to membrane insertion and transport from endoplasmic reticulum occurred when a 
cluster of positively charged residues in GlyR α1 ILD, 316RFRRKRR (Arg-316 in α1 subunit 
corresponding to Arg-350 in α2 subunit) was neutralized causing an aberrantly folded TM3-TM4 
loop (Sadtler et al., 2003).  
 
Substitution of Arg-350, which is conserved in all α-subunits of the human GlyRs and in GlyR 
subunits across species, to leucine in GLRA2 dramatically slowed down the IPSC time course. This 
provided a strong rationale to investigate its functional importance. We chose to assess the relative 
significance of the side-chains from the arginine and leucine residues by mutating arginine to 
alanine, lysine and isoleucine, and measuring the direct effects on heterosynaptic IPSCs. 
Substitution of positively charged arginine for the neutralized and smaller amino acid alanine 
(R350A) exhibits wild-type IPSC kinetics, suggests that the positive charge or steric properties of 
the residue at position 350 of α2 GlyR are not major determinants of synaptic current kinetics. 
Positive charge substitutions at Arg-350 (R350K) likewise preserved wild-type IPSC 
characteristics. α-amino groups are not critical to achieve longer IPSC duration, as suggested by the 
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functional equivalence of leucine residue at this position (R350I). This indicates that electrostatic 
properties of Arg-350 have no significant impact on glycinergic IPSCs. Altogether, our findings 
demonstrated that both charges and structural modifications at Arg-350 position are not the critical 
elements responsible for prolonged IPSCs. We suggest that the R350L may either specifically 
generate or disrupt an interaction with some cytoplasmic factor essential for normal GlyR function. 
 
Variations in GLRA1 and GLRB genes have been associated with hyperekplexia, which is a rare 
neurological disorder characterized by neonatal hypertonia and an exaggerated startle reflex in 
response to sudden, unexpected stimuli (Bode and Lynch, 2014). Hyperekplexia is generally 
considered to be associated with a loss of glycinergic inhibitory tone. Both GLRA1 loss- and gain-
of-function hyperekplexia mutations have been identified in patients with identical phenotypes. For 
GLRA2 linked with autism, some examples of microdeletion such as GLRA2Δex8−9 that results in 
loss of transmembrane domains TM3 and TM4, and missense mutations such as N136S and R153Q 
have been reported (Pilorge et al., 2015). The previous reports show that deleted and mutated 
channels have loss-of-function defects with disrupted surface expression or dramatically decreased 
agonist sensitivity (Pilorge et al., 2015). We observed that R350L increased the IPSC time course, 
whereas no significant effect on the amplitude of IPSCs was observed. These findings suggested 
R350L mutation is a gain-of-function mutation.  
 
During embryogenesis, α2 GlyRs are functionally expressed in the cerebral cortex (Young-Pearse et 
al., 2006) where they were suggested to play a critical function in early development of neocortex. 
Deletion of GLYA2 gene in mice results in moderate microcephaly in newborn mice (Avila et al., 
2014). Moreover, activation of GlyRs promotes tangential migration of cortical interneurons from 
the medial ganglionic eminence to the cerebral cortex in the developing brain, whereas genetic 
disruption or pharmacological inhibition of α2 GlyR expression and function impaired the 
interneuron migration abilities (Avila et al., 2013). After birth, dendrite and spine morphological 
abnormalities accompanied by the loss of glycinergic signaling were observed in cortical neuron of 
layer V in GLYA2 knockout mice, supporting the idea that α2 GlyRs also play an important role in 
synaptogenesis (Morelli et al., 2016). It is not surprising that mutations affecting GLYA2 gene, 
which contribute to the generation and migration of cerebral cortical neurons, may cause severe 
brain malfunctions leading to the symptoms observed in individuals with ASDs.  
 
Here, we show that R350L mutation identified from ASD patients have major defects in glycinergic 
inhibitory synaptic transmission arising from altered intrinsic channel gating. Future work to further 
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investigate the link between R350L mutation and autism could involve studying the morphological 
and functional changes in cortical neurons. 
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Abstract: Zn2+ is concentrated into presynaptic vesicles at many central synapses and is released into 
the synaptic cleft by nerve terminal stimulation. There is strong evidence that synaptically released 
Zn2+ modulates glutamatergic neurotransmission, although there is debate concerning the peak 
concentration it reaches in the synaptic cleft. Glycine receptors (GlyRs), which mediate inhibitory 
neurotransmission in the spinal cord and brainstem, are potentiated by low nanomolar Zn2+ and 
inhibited by micromolar Zn2+. Mutations that ablate Zn2+ potentiation of GlyRs result in 
hyperekplexia phenotypes suggesting that Zn2+ physiologically modulates glycinergic 
neurotransmission. There is, however, little evidence that Zn2+ is stored presynaptically at glycinergic 
terminals and an alternate possibility is that GlyRs are modulated by constitutively bound Zn2+. We 
sought to estimate the peak Zn2+ concentration in the glycinergic synaptic cleft as a means of 
evaluating whether it is likely to be synaptically released. We employed ‘artificial’ synapses because 
they permit the insertion of engineered a1b GlyRs with defined Zn2+ sensitivities into synapses. By 
comparing the effect of Zn2+ chelation on glycinergic IPSCs with the effects of defined Zn2+ and 
glycine concentrations applied rapidly to the same recombinant GlyRs in outside-out patches under 
simulated synaptic activation conditions, we inferred that synaptic Zn2+ rises to at least 1 µM 
following a single presynaptic stimulation. Moreover, using the fast high-affinity chelator, ZX1, we 
found no evidence for tonic Zn2+ bound constitutively to high affinity GlyR binding sites. We 
conclude that diffusible Zn2+ reaches 1 µM or higher and is therefore likely to be phasically released 
in artificial glycinergic synapses. 
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INTRODUCTION  
 
The free ionic form of zinc (Zn2+) is present in the extracellular CNS solution at low nM 
concentrations	(Frederickson et al., 2006). We define this as ‘tonic’ Zn2+. It is also concentrated into 
presynaptic vesicles at many brain glutamatergic synapses (Frederickson, 1989) and is released into 
the synaptic cleft by nerve terminal stimulation (Assaf and Chung, 1984; Howell et al., 1984). The 
GluN2A-containing NMDA receptor (NMDAR) cation channels that populate these synapses are 
inhibited by Zn2+ at low nM concentrations (Paoletti et al., 1997). Recent studies have found evidence 
for the transient modulation of synaptic NMDARs by phasically released Zn2+ (Vergnano et al., 2014; 
Anderson et al., 2015) and for the constitutive modulation of extrasynaptic NMDARs by tonic Zn2+ 
(Anderson et al., 2015). A major unresolved question concerns the concentration to which Zn2+ rises 
during synaptic activation, with estimates spanning four orders of magnitude from 10 nM (Kay, 2003) 
to > 100 µM (Vogt et al., 2000). It is important to resolve this because many neuronal membrane 
proteins are modulated by Zn2+ at high concentrations (Marger et al., 2014), and a knowledge of the 
peak Zn2+ concentration would permit the identification of potential physiological targets of 
synaptically-released Zn2+.  
It is also unclear whether tonic or synaptically-released Zn2+ modulates neurotransmission at other 
synapses. Glycine receptor (GlyR) chloride channels, which mediate inhibitory neurotransmission in 
the spinal cord and brainstem (Lynch, 2004), are a likely candidate for Zn2+ modulation for several 
reasons. First, the major synaptic a1b GlyR isoform is extremely sensitive to Zn2+, with low (10 – 
1000 nM) Zn2+ concentrations potentiating EC50 glycine-gated currents and higher Zn2+ 
concentrations (3 – 300 µM) eliciting a dose-dependent inhibition (Bloomenthal et al., 1994; Laube 
et al., 1995; Miller et al., 2005a; Miller et al., 2005b). Second, selectively ablating the sensitivity of 
a1 GlyRs to Zn2+ potentiation led to impaired glycinergic inhibition and a hyperekplexia-type 
phenotype in a1D80A GlyR knock-in mice (Hirzel et al., 2006). Third, by eliminating free Zn2+ from 
the synaptic cleft via Zn2+ buffers and chelators, it has been shown that glycinergic inhibitory 
postsynaptic currents (IPSCs) are positively modulated by either tonic or synaptically-released Zn2+ 
(Suwa et al., 2001; Hirzel et al., 2006; Perez-Rosello et al., 2015). Fourth, there is strong evidence 
for the co-localization of Zn2+ and glycine at presynaptic terminals in the spinal cord of the lamprey 
(Birinyi et al., 2001) although the evidence for their co-localization at glycinergic presynaptic 
terminals in the mammalian spinal cord is less clear cut	(Wang et al., 2001). However, to date there 
has been no investigation into the possibility that Zn2+ may be phasically released at glycinergic 
synapses.  
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 Since glycine reaches a saturating concentration in the cleft during synaptic stimulation (Legendre, 
1998; Beato, 2008), potentiating concentrations of Zn2+ cannot further increase the IPSC magnitude, 
and as a result Zn2+ potentiation is manifest as a slowing in the IPSC decay rate (Suwa et al., 2001; 
Laube, 2002; Hirzel et al., 2006; Eto et al., 2007). However, miniature IPSCs, which are mediated by 
the stochastic release of single glycine vesicles and thus involve sub-saturating glycine concentrations, 
are increased in magnitude by potentiating concentrations of Zn2+ (Suwa et al., 2001; Hirzel et al., 
2006; Perez-Rosello et al., 2015).  
We have recently developed an ‘artificial’ synapse system whereby glycinergic synapses are 
induced to form between presynaptic terminals of cultured spinal glycinergic interneurons and 
HEK293 cells expressing recombinant heteromeric GlyRs (Dixon et al., 2015; Zhang et al., 2015). 
This system has two main advantages over neuronal synapses. First, it allows control over the subunit 
composition of postsynaptic GlyRs. Second, the electrotonically compact shape of HEK293 cells 
avoids problems associated with dendritic filtering, allowing IPSC waveforms to be resolved with 
high fidelity. In the present study, we engineered the Zn2+ sensitivities of the recombinant GlyRs so 
that they could act as reporters of synaptic Zn2+ over different concentration ranges. By comparing 
the effect of Zn2+ chelation on IPSCs with the effects of buffered Zn2+ plus glycine concentrations 
applied rapidly to the same recombinant GlyRs to simulate synaptic activation, we sought to provide 
an estimate of the concentration to which Zn2+ rises in response to a single presynaptic stimulation. 
We also sought to determine whether Zn2+ inhibition is physiologically relevant. 
 
MATERIALS AND METHODS 
 
Molecular biology and HEK293 cell transfection 
We employed plasmid DNAs encoding the human a1 (pCIS), rat a3L (pcDNA3.1) and human b 
(pcDNA3.1) GlyR subunits, plus mouse neuroligin 2A (pNice) and rat gephyrin P1 (pCIS). Empty 
pEGFP plasmid was also transfected as an expression marker. Site-directed mutagenesis was 
performed using the QuikChange mutagenesis kit (Agilent Technologies) according to manufacturers’ 
instructions and the successful incorporation of mutations was confirmed by DNA sequencing. The 
plasmid DNAs were transfected into HEK293 cells via a calcium phosphate-DNA co-precipitation 
protocol. When expressing a1b GlyRs, we transfected the following DNA quantities into each 35 
mm culture dish of HEK293 cells: 0.03 µg a1 GlyR, 1.5 µg b GlyR, 0.2 µg neuroligin 2A, 0.2 µg 
gephyrin, 0.1 µg EGFP. When expressing a3b GlyRs, we transfected the following DNA quantities 
into each 35 mm culture dish: 0.15 µg a3L GlyR, 1.5 µg b GlyR, 0.2 µg neuroligin 2A, 0.2 µg 
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gephyrin, 0.1 µg EGFP. We have previously validated that these transfection conditions result in a 
high level of expression of heteromeric a1b and a3b GlyRs, respectively (Zhang et al., 2015). 
 
Artificial synapse formation 
Details of this method have recently been published (Dixon et al., 2015; Zhang et al., 2015). 
Briefly, E15 timed-pregnant rats were euthanized via CO2 inhalation in accordance with procedures 
approved by the University of Queensland Animal Ethics Committee (approval number: 
QBI/203/13/ARC). Embryos were surgically removed and placed into ice cold Ca2+-Mg2+-free 
Hank’s Balanced Salt Solution under sterile conditions. The spinal cords were then dissected out and 
pinned at the wider proximal end while meninges were carefully detached. The dissected neurons 
were then triturated, centrifuged and resuspended in Dulbecco’s Modified Eagles Medium 
supplemented with 10 % fetal bovine serum. The cells were then counted and between 40,000 - 
80,000 neurons were plated onto each 12 mm poly-D-lysine-coated coverslip in 4-well plates. 
Neuronal cultures were always maintained in a 5 % CO2 incubator at 37 oC. After incubation for 24 
h the entire Dulbecco’s Modified Eagles Medium supplemented plus 10 % fetal bovine serum 
medium was replaced with Neurobasal medium including 2 % B27 and 1 % GlutaMAX supplements. 
A second (and final) feed 1 wk later replaced half of this medium. Neurons were used in co-culture 
experiments 1 – 4 wk later. Heterosynaptic co-cultures were prepared by directly introducing 
transfected HEK293 cells onto the primary neuronal cultures 1 − 3 d prior to electrophysiological 
recording. 
 
Electrophysiology 
All experiments were performed at 20 – 22 oC at a holding potential of −60 mV. Whole-cell 
recordings were obtained with a HEKA EPC10 amplifier (HEKA Electronics, Lambrecht, Gremany) 
and Patchmaster software (HEKA), with currents filtered at 4 kHz and sampled at 10 kHz. Series 
resistance was compensated to 60% and monitored throughout the recording. Patch pipettes (4 - 8 
MΩ) made from thick-walled borosilicate glass (GC150F-7.5, Harvard Apparatus) were filled with 
an internal solution comprising (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA and 2 
MgATP, pH 7.4 with NaOH. Cells were perfused with extracellular solution comprising (in mM): 
140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, pH 7.4 with NaOH. 
For outside-out recordings, pipettes were fired-polished to a resistance of ~10 MΩ and filled with 
the same internal solution. Macroscopic currents in outside-out patches pulled from transfected 
HEK293 cells were activated by brief (< 1 ms) exposure to agonists using a piezoelectric translator 
(Siskiyou). Currents were recorded using a Multiclamp 700B amplifer and pClamp9 software 
(Molecular Devices), filtered at 4 kHz and sampled at 10 kHz.  
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In accordance with standard practice in the field, solutions containing buffered concentrations of 
free Zn2+ were made by adding 10, 100, 500 and 1000 µM free Zn2+ to the standard extracellular 
solution + 10 mM tricine (Sigma-Aldrich) to produce buffered Zn2+ concentrations of 0.1, 1, 5 and 
10 µM, respectively (Paoletti et al., 1997; Low et al., 2000; Miller et al., 2005b; Vergnano et al., 
2014). The added Zn2+ concentration was aliquoted from a 10 mM aqueous ZnCl2 stock solution on 
the day of the experiment. ZX1 (Strem Chemicals) was dissolved as a 100 mM stock in water and 
added to the control solution on the day of the experiment. 
 
Data Analysis 
Analyses of IPSC amplitudes, 10−90% rise times and decay time constants were performed using 
Axograph X (Axograph Scientific). Single peak IPSCs with amplitudes of at least three times the 
background noise were detected using a semi-automated sliding template. Events were visually 
inspected and only well-separated IPSCs with no inflections in the rising or decay phases were 
included. Current decay phases were fitted with double-exponential functions and a weighted time 
constant was calculated from individual time constants (τ1, τ2) and their relative amplitudes (A1, A2) 
as follows: τweighted = (τ1×A1+τ2×A2)/(A1+A2). Statistical comparisons were performed using non-
parametric tests in Prism 6 (GraphPad Software Inc.). For multiple comparisons we used the 
Friedman test or the Wilcoxon matched-pairs signed rank test and for single comparisons we used 
the Mann-Whitney U test. In all tests we took p < 0.05 to be statistically significant. 
 
RESULTS  
 
Zn2+-sensitivity of IPSCs mediated by a1b, a1H107Nb and a1W170Sb GlyRs  
The a1b GlyR is the main synaptic isoform (Lynch, 2009). Zn2+ potentiates EC50 glycine-gated 
currents in recombinant a1b GlyRs with an EC50 near 40 nM (Miller et al., 2005b) and inhibits with 
an IC50 near 13 µM (Miller et al., 2005a). We also investigated the a1H107Nb and the a1W170Sb GlyRs. 
The H107N mutation eliminates Zn2+ inhibition and increases the Zn2+ potentiation EC50 to 0.8 µM 
(Miller et al., 2005b). We reasoned that this receptor should respond only to high nanomolar or 
micromolar concentrations of Zn2+. The W170S mutation, which occurs naturally in a sporadic case 
of human hyperekplexia (Al-Futaisi et al., 2012), eliminates Zn2+ potentiation but leaves Zn2+ 
inhibition intact with an IC50 near 5 µM (Zhou et al., 2013). We employed this mutant as both a 
negative control for the potentiating effect of Zn2+ and to determine whether Zn2+ inhibition (when 
isolated from potentiation) is capable of affecting IPSC parameters.    
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In order to precisely control the extracellular Zn2+ concentration, we buffered it with 10 mM tricine 
as described in Materials and Methods. We also applied 10 mM tricine with no added Zn2+ to buffer 
the free Zn2+ concentration to virtually zero, although as recently demonstrated, this may not remove 
tonic Zn2+ that is bound strongly to low nanomolar affinity Zn2+ binding sites (Anderson et al., 2015). 
Thus, our starting hypothesis is that 10 mM tricine ablates freely diffusing Zn2+ but not constitutively 
bound Zn2+.  
Sample recordings of spontaneous IPSCs from HEK293 cells expressing each of these constructs 
are shown in Figure 1A. As IPSCs were almost entirely abolished by 1 µM tetrodotoxin (not shown), 
we infer they were induced by spontaneous action potentials. The remaining miniature IPSCS were 
too small to analyse. Figure 1A (left) shows sample recordings of spontaneous IPSCs recorded from 
single cells expressing either the a1b GlyR (top), the a1H107Nb GlyR (middle) or the a1W170Sb GlyR 
(bottom). The left panels show control recordings in tricine-free extracellular solution, the centre 
panels show the effect of 10 mM tricine and the right panels show the effect of adding 5 µM free 
Zn2+. Individual IPSCs from the recordings in A were normalised and digitally averaged to produce 
the global mean IPSC waveforms as displayed in Figure 1B. The mean IPSC amplitudes, decay time 
constants and 10 – 90 % rise times for each construct recorded in tricine-free extracellular solution 
are presented in Figure 1C. We found that IPSCs mediated by a1W170Sb GlyRs exhibited significantly 
larger amplitudes, longer decay time constants and slower rise times relative to those mediated by 
a1b GlyRs. This indicates that the W170S mutation affects intrinsic receptor gating or synaptic 
clustering properties in addition to ablating Zn2+ potentiation. 
Figure 1D-F summarises the effects of adding either 10 mM tricine alone or 5 µM free Zn2+ to 
IPSCs mediated by the three constructs. We observed no effect 10 mM tricine on the IPSC amplitude 
mediated by any construct (Figure 1D). However, the removal of free Zn2+ significantly accelerated 
the decay rate of a1b GlyRs (Figure 1E) indicating that the free Zn2+ concentration is high enough 
to positively modulate these receptors. In contrast, 10 mM tricine had no effect on the IPSC decay 
rate mediated by a1W170Sb GlyRs. This not only provides a control for the GlyR-specificity of the 
Zn2+ potentiating effect, but also indicates that the low affinity inhibitory effect of Zn2+ does not 
appreciably affect IPSC parameters. All these findings are reinforced by the converse experiment 
whereby increasing free Zn2+ to 5 µM significantly slowed the decay rate in a1b GlyRs and a1H107Nb 
GlyRs but had no effect on a1W170Sb GlyRs (Figure 1E). The removal free Zn2+ also accelerated the 
rise times of IPSCs mediated by a1b GlyRs only (Figure 1F). 
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Figure 1. Effects of synaptic Zn2+ on spontaneous IPSCs mediated by a1b, a1H107Nb and a1W170Sb GlyRs. (A) 
Representative recordings of IPSCs mediated by the indicated constructs are shown in the presence of tricine-free solution 
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(black traces), 10 mM added tricine (red traces) and 10 mM added tricine + 500 µM added Zn2+ (= 5 µM free Zn2+: blue 
traces). (B) Superimposed, digitally averaged, normalized IPSCs from the corresponding cell in (A). The total number of 
events included in each averaged IPSC was as follows:  a1b GlyR (control: 86; 10mM added tricine: 63; 10 mM added 
tricine + 500 µM added Zn2+: 92), a1H107Nb GlyR (control: 72; 10mM added tricine: 56; 10 mM added tricine + 500 µM 
added Zn2+: 89), a1W170Sb GlyR (control: 53; 10mM added tricine: 61; 10 mM added tricine + 500 µM added Zn2+: 68). 
(C) Comparison of mean IPSC amplitude, decay time constant and 10 – 90 % rise time for the three constructs in tricine-
free solution. Statistical significance was determined by Mann-Whitney U test. The distributions in WT and W170S 
values differed significantly for amplitude (U = 11, *p < 0.05), decay time constant (U = 0, ***p < 0.001) and 10 – 90 % 
rise time (U = 10, *p < 0.05).  (D) Comparison of the effects of the indicated solutions on IPSC amplitude, decay time 
constant and 10 – 90 % rise time for the three constructs. Comparisons between the constructs are not shown. Statistical 
significance was determined by Friedman test with significance represented by *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. Relative to their values in 10 mM tricine, the decay time constants for  a1b and a1H107Nb GlyRs increased 
by 74 ± 13 % and 50 ± 24 %, respectively, in standard extracellular solution and by 109 ± 15 % and 101 ± 28 %, 
respectively, in 5 µM free Zn2+. In panels (C) and (D), we analyzed 12 cells expressing a1b GlyRs, 7 cells expressing 
a1H107Nb GlyRs and 5 cells expressing a1W170Sb GlyRs. 
 
Zn2+-sensitivity of IPSCs mediated by a3b GlyRs 
In an attempt to generalize our findings, we investigated the Zn2+-sensitivity of the other major 
adult synaptic GlyR isoform, the a3b, which mediates synaptic inhibition onto nociceptive neurons 
in superficial laminae of the adult spinal cord dorsal horn (Zeilhofer et al., 2012). Despite their 
importance in pain signal processing mechanisms and their relevance as novel therapeutic targets for 
inflammatory pain	(Lynch, 2009; Zeilhofer et al., 2012), the Zn2+ sensitivity of a3b GlyRs has never 
been investigated. We thus repeated the experiment of Figure 1A on spontaneous IPSCs mediated by 
a3b GlyRs. Examples of normalized, averaged IPSCs recorded from one cell exposed sequentially 
to standard extracellular solution containing no tricine, 10 mM tricine or 10 mM tricine plus 5 µM 
free Zn2+ are shown in Figure 2A, with averaged results summarized in Figure 2B – D. According to 
the non-parametric Friedman test, these data reveal that the removal of free Zn2+ by 10 mM tricine 
had no significant effect on any IPSC parameter. However, as all data distributions in Figure 2B 
satisfied the D’Agostino-Pearson omnibus test for normality (using p < 0.05 as cutoff), we performed 
a repeated measures one-way ANOVA on decay time constants of the control versus 10 mM tricine 
and 10 mM tricine plus 5 µM free Zn2+ experimental conditions. As 10 mM tricine significantly 
accelerated the IPSC decay rate according to this test (p < 0.05, n = 8), we conclude that the 
endogenous levels of Zn2+ in artificial synapses significantly prolong the decay time constant of α3β 
GlyR-mediated IPSCs. 
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Figure 2. Effects of synaptic Zn2+ on IPSCs 
mediated by a3b GlyRs. (A) Superimposed 
averaged, normalized IPSCs each averaged 
from > 50 events from the same cell. 
Recordings were made in the presence of 
tricine-free solution (black trace; averaged 
from 52 events), 10 mM added tricine (red 
trace; averaged from 55 events) and 10 mM 
added tricine + 500 µM added Zn2+ (= 5 µM 
free Zn2+: blue trace; averaged from 83 events). 
(B – D) Comparison of the effects of the 
indicated solutions on IPSC amplitude, decay 
time constant and 10 – 90 % rise time for a3b-
mediated IPSCs. All results were averaged 
from 8 cells. Statistical significance was 
determined by Friedman test with significance 
represented by ***p < 0.001. 
 
 
Calibrating the Zn2+-sensitivity of a1b, a1H107Nb and a1W170Sb GlyRs under simulated synaptic 
activation conditions 
The a1b GlyR Zn2+ EC50 and IC50 values cited above were obtained under steady-state 
applications of Zn2+ and EC50 glycine (Miller et al., 2005a; Miller et al., 2005b). As these conditions 
do not apply to the synapse, we calibrated the Zn2+ sensitivity of the GlyR constructs using fast 
solution exchange to mimic synaptic activation conditions. The glycine concentration in the synaptic 
cleft has been estimated to reach a peak of 1 – 3 mM in embryonic zebrafish hindbrain neurons 
(Legendre, 1998) and 2.2 – 3.5 mM in adult rat spinal motor neurons (Beato, 2008). Glycine is cleared 
from the cleft with a time constant of 0.6 – 0.9 ms (Beato, 2008). Considering these parameters, we 
simulated synaptic activation conditions by applying 1 mM glycine with or without free Zn2+ for 0.5 
– 1 ms to outside-out macropatches expressing the GlyR isoform of interest. To calibrate and optimize 
the solution application system, we rapidly switched the solution perfusing an open patch pipette 
between standard extracellular solution and an extracellular solution that had been diluted by 50 % 
with distilled water. Figure 3A shows an example of an open pipette response, indicating the typical 
solution exposure profile. We performed this control regularly to ensure that the solution switching 
rate remained constant within and between experiments. 
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Figure 3. Control experiments 
employing rapid solution exchange 
over macropatches expressing a1b 
GlyRs. (A) (Left) Image of the 
double-barrelled q-tube used to 
perform the rapid solution exchange 
experiments on macropatches. The 
image also shows an open recording 
pipette and the position of the 
solution interface (broken line). 
(Right) Open pipette response 
obtained by switching the solution over the electrode tip from the standard extracellular solution to one diluted to 10% 
with water. The rise and decay times are approximately 300 µs. (B) Overlayed macropatch recordings (averages of 6 – 
20 sweeps) of control (black, 1 mM glycine) and co-application of 1 mM glycine with either 10 mM tricine (red) or 100 
µM ZX1 (green). (C) Summary bar plots of the weighted decay time constant for control and the two Zn2+ chelators. (D) 
Summary bar plots of the rise times for control and the two Zn2+ chelators. Mann Whitney U test revealed no significant 
differences in the distributions of either the decay or rise times, p > 0.05 for both, n = 3 – 8 macropatches for each 
condition. 
 
Contaminating Zn2+ released into solution from plastic and glass laboratory ware is thought to 
reach concentrations as high as 100 nM (Kay, 2004), which is high enough to modulate steady-state 
GlyR currents activated by low glycine concentrations (Miller et al., 2005b; Cornelison and Mihic, 
2014). We determined whether Zn2+ contamination might have contributed to the results of Figures 
1 and 2 via two sets of control experiments. The first involved switching rapidly between a control 
(putatively Zn2+-contaminated) solution and a Zn2+-chelating solution. In this experiment the control 
and test solutions both comprised our standard extracellular solution plus 1 mM glycine, although the 
test solution also contained either 10 mM tricine or 100 µM ZX1 (Perez-Rosello et al., 2015). A 
sample recording from a single macropatch containing a1b GlyRs suggests the chelators had little 
effect on decay rate (Figure 3B) and the averaged result confirms the lack of a significant effect on 
either the decay or rise times (Figure 3C, D). It is evident, however, that ZX1 showed a tendency to 
decrease the decay time constant that may become significant with a larger number of observations. 
If so, this effect could be due to either (1) a direct allosteric inhibitory effect on the GlyR or (2) the 
removal of tonically-bound Zn2+ from the GlyR. The second possibility will be investigated below.  
In a second control experiment, we initially exposed macropatches to a buffered 100 nM Zn2+ 
solution and switched this rapidly to either a control (putatively Zn2+-contaminated) solution (n = 10 
macropatches) or to a Zn2+-chelating solution (i.e., control + 10 mM tricine, n = 3 macropatches). 
Again, no significant differences in rise times or decay rates were observed in either experiment (p > 
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0.05 by Mann-Whitney U test). Together, these results strongly suggest that contaminating Zn2+ in 
our extracellular solution had no significant effect on IPSC rise or decay rates.  
 To mimic synaptic activation, we employed standard extracellular solution without added tricine 
as the control solution to replicate the conditions employed in Figures 1 and 2. Test solutions had the 
same composition except that we added 1 mM glycine either alone or together with 10 mM tricine 
and 100 nM, 1 µM or 10 µM free Zn2+. Examples of current responses to the sequential application 
of each of these four solutions to a1b, a1H107Nb and a1W170Sb GlyRs are shown in Figure 4A, with 
averaged weighted deactivation time constants shown in Figure 4B. The averaged individual time 
constants (τ1, τ2) and their relative amplitudes (A1, A2) for each experimental condition are 
presented in Table 1. For the a1b GlyR, we observed no change in the deactivation rate or 10 – 90 % 
rise time at 100 nM Zn2+. We observed a statistically significant slowing in the deactivation rate at 1 
µM and a dramatic slowing in deactivation rate at 10 µM free Zn2+. We also observed a statistically 
significant slowing in the deactivation rate at 10 µM free Zn2+at the a1H107Nb GlyR. At 10 µM Zn2+, 
the percentage increase in the macropatch current deactivation time constant at both receptors (a1b: 
76 ± 41 %; a1H107Nb: 76 ± 19 %) was comparable to the magnitude of the IPSC decay time constant 
increase from 10 mM tricine-containing to standard extracellular solution (a1b: 74±13 %, a1H107Nb: 
50 ± 24 %). In contrast, at the a1W170Sb GlyR we observed no change in IPSC magnitude, decay rate 
or rise time at free Zn2+ concentrations up to 10 µM (Figure 4A – C). Together, these results suggest 
that the free synaptic Zn2+ concentration reaches a concentration of at least 1 µM following a single 
synaptic stimulation. The lack of an inhibitory effect of 10 µM Zn2+ on a1W170Sb GlyRs is most likely 
due to the slow onset of Zn2+ inhibition and the brief exposure time to Zn2+ in our experiments.  
We next considered the possibility that the magnitude of the Zn2+ effect may depend on the 
synaptic glycine concentration. We therefore repeated the experiment of Figure 4A at a1b GlyRs 
using 3 mM glycine, in line with the maximum predicted	synaptic glycine concentration (Legendre, 
1998; Beato, 2008). Sample recordings reveal that 10 µM Zn2+ exerts a diminished prolonging effect 
on deactivation rate of currents activated by brief applications of 3 mM glycine (Figure 4C). This 
trend is supported by the averaged data shown in Figure 4D. Thus, if the concentration of glycine in 
the synaptic cleft is 3 mM or higher, our results imply that Zn2+ must rise to concentrations greater 
than 10 µM during synaptic transmission to account for the effect of 10 mM tricine on the IPSC decay 
rate.  
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Figure 4. Calibration of the Zn2+-sensitivity of  a1b, a1H107Nb and a1W170Sb GlyRs under simulated synaptic activation 
conditions. (A) Representative macropatch currents mediated by indicated constructs upon switching from control 
extracellular solution to one containing 1 mM glycine plus 10 mM tricine plus the indicated concentration of free Zn2+. 
Traces were averaged from >10 sweeps each and normalized. (B) Mean values for weighted decay time constants and 10 
– 90 % rise times for the three constructs. See Supplementary Table 1 for a full breakdown of n values, mean t1 and t2 
values and their relative proportions. Statistical significance was determined by Mann-Whitney U test. The distributions 
in WT (glycine only) and WT (glycine + 1 µM Zn2+) values differed significantly for decay time constant (U = 63, *p < 
0.05, n1 = 17 macropatches, n2 = 13 macropatches).  The distributions in WT (glycine only) and WT (glycine + 10 µM 
Zn2+) values also differed significantly for decay time constant (U = 20, ***p < 0.001, n1 = 17 macropatches, n2 = 10 
macropatches).  The distributions in H107N (glycine only) and H107N (glycine + 10 µM Zn2+) values also differed 
significantly for decay time constant (U = 16, **p < 0.01, n1 = 13 macropatches, n2 = 8 macropatches). (C) Representative 
macropatch currents mediated by a1b GlyRs upon switching from control extracellular solution to one containing 3 mM 
glycine plus 10 mM tricine plus the indicated free Zn2+ concentration. Traces were averaged from >10 sweeps each and 
normalized. (D) Mean values for weighted decay time constant and 10 – 90 % rise time for two glycine concentrations. 
Statistical significance was determined by Mann-Whitney U test. The distributions in the 1 and 3 mM glycine 10 – 90 % 
rise time values differed significantly for Zn2+ concentrations of 0, 100 nM and 1 µM (U = 9 – 15, *p < 0.05, n1 = 10 – 
17 macropatches, n2 = 5 macropatches).   
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Effect of a fast, high-affinity Zn2+ chelator on IPSC parameters 
ZX1 is a fast, high affinity Zn2+ chelator (Radford and Lippard, 2013). When applied at a 
concentration of 100 µM, it has been shown to efficiently remove tonic Zn2+ bound constitutively to 
NMDARs (Anderson et al., 2015). Given that GlyRs and NMDARs both have high affinity Zn2+ sites 
with similar nanomolar affinities, it is reasonable to hypothesize that ZX1 should have the same effect 
on GlyRs. Indeed, a recent study has suggested that ZX1 does remove tonic Zn2+ bound to synaptic 
GlyRs (Perez-Rosello et al., 2015). We investigated the effects of 100 µM ZX1 on IPSCs mediated 
by a1b GlyRs both as a control for possible nonspecific (e.g., pharmacological) effects of tricine and 
to investigate the possibility that tonic Zn2+ might be bound tightly to synaptic GlyRs. Figure 5A 
shows examples of normalized, averaged IPSCs recorded from one cell before, during and after 
exposure to 100 µM ZX1. Results averaged from nine cells recorded under identical conditions reveal 
that 100 µM ZX1 had no significant effect on IPSC amplitude (Figure 5B) or 10 – 90 % rise time 
(Figure 5C) although it significantly reduced the IPSC decay time constant (Figure 5D). However, 
there was no significant difference in the magnitude of the effect of 10 mM tricine and 100 µM ZX1 
on the IPSC decay time constant (Figure 5E – G). Moreover, in five cells where we quantitated the 
effects of 10 mM tricine and 100 µM ZX1 sequentially in the same cell, we found the ZX1 exerted 
no significant additional effect on the IPSC decay time constant (not shown). Thus, if tonic Zn2+ is 
bound with high affinity to synaptic a1b GlyRs in our artificial synapses, then its removal has no 
functional consequence. We thus infer that the effect of tricine and ZX1 on glycinergic IPSCs is 
mediated by freely diffusing Zn2+.  
In a final experiment, we quantitated the recovery time course of IPSC decay time constant 
following ZX1 washout (Figure 5H). In this experiment we digitally averaged all events within each 
30 s interval during the recovery phase and fitted a single decay time constant to the averaged data. 
Results were averaged from five cells. As seen in Figure 5H, complete recovery from ZX1 application 
required around 1 min, although the decay time constant eventually stabilized at a value that was 
significantly higher than the initial control IPSC decay time constant (Figure 5D, H). This suggests 
that the concentration of free synaptic Zn2+ is not depleted over time under our experimental 
conditions. 
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Figure 5. Effects of 100 µM ZX1 on IPSCs mediated by a1b GlyRs. (A) Superimposed averaged, normalized IPSCs 
each averaged from > 50 events from the same cell. Recordings were made in the presence of control solution (black 
trace; averaged from 79 events), after addition of 100 µM ZX1 (red trace; averaged from 61 events) and after 5 min 
washout (pink trace; averaged from 52 events). (B – D) Effects of 100 µM ZX1 on IPSC amplitude, decay time constant 
and 10 – 90 % rise time for a1b-mediated IPSCs. All results were averaged from 10 cells. Statistical significance in D 
was determined by Friedman test with significance represented by *p < 0.05, and ****p < 0.0001. (E - G) Comparison 
of the effects of 10 mM tricine and 100 µM ZX1 on IPSC amplitude, decay time constant and 10 – 90 % rise time for 
a1b-mediated IPSCs. There was no significant difference in the decay time constants in either condition. Statistical 
significance in G was determined by two-tailed Wilcoxon matched-pairs signed rank test, with significance represented 
by **p < 0.01 and ***p < 0.001. (H) Time course of washout of the ZX1 effect on decay time constant. ZX1 was applied 
for 3 min. All data points were averaged from five cells.  
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DISCUSSION 
 
The main advantage of our artificial synapse system is that it allows control over the GlyR subunit 
composition. However, a potential limitation is that artificial synapses may not faithfully replicate 
real synapses, especially in terms of synaptic cleft geometry or the location and density of Zn2+ and 
glycine transporters. Although such factors could affect Zn2+ and glycine concentrations in the 
synaptic cleft, we think they are unlikely to seriously compromise our conclusions for several reasons. 
First, IPSCs from artificial synapses containing a1b and a2b GlyRs exhibit decay times that are 
remarkably similar to those from native neuronal synapses expressing the same isoforms (Zhang et 
al., 2015). Second, the decay time constants of IPSCs recorded in vitro from homozygous a1D80A 
knock-in mice (where Zn2+ potentiation is abolished) or from homozygous Spasmodic a1A52S mice 
(where glycine sensitivity is reduced 10-fold) were quantitatively similar to those recorded from 
artificial synapses incorporating the same mutant subunits (Graham et al., 2006; Hirzel et al., 2006; 
Zhang et al., 2015). These results suggest a reasonably close correspondence in the concentration 
profiles of Zn2+ and glycine between artificial and real glycinergic synapses. Turning to the present 
study, tricine-mediated buffering of extracellular Zn2+ significantly accelerated the decay rate of 
IPSCs mediated by a1b and a1H107Nb GlyRs. However, no change in IPSC amplitude was observed. 
Together these results imply that the Zn2+ concentration in the synaptic cleft is high enough to 
modulate IPSCs, and that the glycine concentration is saturating. These observations fit well with 
previous studies on neuronal glycinergic synapses. For example, a study that investigated glycinergic 
IPSCs in zebrafish neurons found that 10 mM tricine reduced IPSC duration to a similar extent as 
observed here (Suwa et al., 2001). In addition, studies by Legendre (1998) and Beato (2008) found 
that the synaptic glycine concentration reaches > 1 mM, which is saturating at a1b GlyRs. 
By comparing the effects of 10 mM tricine on IPSCs to the effects of co-applied glycine plus free 
Zn2+ to macropatches, we infer that the free synaptic Zn2+ rises to at least 1 µM following a single 
action potential. The dramatic slowing in the IPSC decay rate that we observed in the presence of 5 
µM free added Zn2+ (Figure 1E) is probably due to the total (tonic plus synaptically-released) free 
Zn2+ rising to ≥ 6 µM. In addition, the absence of any effect of Zn2+ at concentrations up to 10 µM in 
the a1W170Sb GlyR suggests that the well-characterized inhibitory effect of Zn2+ (Laube et al., 1995; 
Nevin et al., 2003; Miller et al., 2005a) is not physiologically relevant, at least at low synaptic 
stimulation rates. Finally, given the similarity in the effects of 10 mM tricine and 100 µM ZX1 on 
the IPSC decay rate (Figure 5G), we find no evidence for tonic Zn2+ binding tightly to high affinity 
sites on the GlyR (Perez-Rosello et al., 2015). 
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It is yet to be demonstrated that Zn2+ is co-released with glycine in a phasic manner. However, in 
the absence of a phasic release mechanism it is difficult to explain how a ≥ 1 µM Zn2+ concentration 
could be maintained in the cleft for periods typically exceeding 20 min (Figure 5H) when the bulk 
extracellular (tonic) concentration is presumably in the low nM range (Frederickson et al., 2006).  
A similar type of analysis of synaptic Zn2+ concentration was recently performed on glutamatergic 
synapses (Vergnano et al., 2014). GluN2A-containing NMDARs exhibit both high affinity Zn2+ 
inhibition in the 10 – 20 nM range and low affinity inhibition in the 10 – 50 µM range (Paoletti et al., 
1997). Vergnano et al compared the effect of 10 mM tricine on GluN2A-mediated synaptic currents 
from control mice to those from knock-in mice that overexpressed a mutant GluN2A deficient in high 
affinity Zn2+ binding (Vergnano et al., 2014). They found no effect of tricine on single action 
potential-mediated excitatory postsynaptic currents (EPSCs) in either case, although fast repetitive 
stimulation unveiled Zn2+-mediated inhibition of EPSCs in control animals only. From this they 
concluded that synaptic Zn2+ does not rise high enough to bind to the low affinity sites. It is 
noteworthy that a1b GlyRs and GluN2A-containing NMDARs have similar high affinities to Zn2+. 
Given that a single action potential releases sufficient Zn2+ to modulate glycinergic IPSCs but not 
NMDAR-mediated EPSCs, we infer that Zn2+ rises to significantly higher concentrations in the 
glycinergic synaptic cleft. Indeed, high affinity chelation of Zn2+ by 100 µM ZX1 to remove tonic 
Zn2+ bound to NMDARs is needed to detect an effect of Zn2+ released by a single action potential 
(Anderson et al., 2015). This implies that the Zn2+ concentration increase in the glutamatergic 
synaptic cleft response to a single action potential is in the low nM range.  
GlyRs are also potentiated by La3+, Pb2+ and Co2+ and inhibited by Cu2+ and Ni2+ (Lynch, 2004).  
As tricine is a low affinity chelator with poor specificity among heavy metals (Ferreira et al., 2015), 
it is possible that its effect of GlyRs may be due to the chelation of other metal contaminants in the 
recording solution. Since tricine inhibits glycinergic currents, we infer that any metal contaminant 
must be a GlyR potentiator. However, the three known potentiators (La3+, Pb2+ and Co2+) are unlikely 
to be present as contaminants in our recording solutions at concentrations high enough (100 µM) to 
positively modulate GlyRs. Thus, it is highly likely that the effects of tricine on a1b GlyR-mediated 
IPSCs is mediated by Zn2+. 
Human hyperekplexia, or startle disease, is most commonly caused by hereditary mutations in a1 
or b GlyR subunits that disrupt glycinergic neurotransmission (Bode and Lynch, 2014). Most startle 
mutations result in the complete or partial loss of glycinergic inhibitory function (Chung et al., 2010; 
Bode et al., 2013; Bode and Lynch, 2014). Given that the human a1W170S startle mutation abolished 
Zn2+ potentiation, it was originally concluded that the startle phenotype was due to a diminished IPSC 
magnitude or duration (Zhou et al., 2013). In support of this, a startle phenotype	had previously been 
 	 98	
demonstrated in a knock-in mouse overexpressing a mutant a1D80A GlyR subunit in which Zn2+ 
potentiation had been eliminated (Hirzel et al., 2006). Our fast application experiments demonstrate 
that the inherent deactivation rates of a1b and a1W170Sb GlyRs in the absence of Zn2+ are similar 
(Figure 4B), implying that the loss of Zn2+ potentiation in a1W170Sb GlyRs may indeed lead to a net 
diminished current carrying capacity. However, in artificial synapses we found that both the mean 
amplitude and decay rate of IPSCs mediated by a1W170Sb GlyRs were comparable to those of a1b 
GlyRs that had been maximally positively modulated by Zn2+ (Figure 1C, E). This effect could either 
be due to altered gating properties or differential clustering at the synapse. We have recently shown 
that the a1W170Sb GlyR also exhibits spontaneous activation (Zhang et al., 2016) and suggested that, 
like other gain-of-function startle disease mutations, W170S may cause startle disease via a 
developmental defect that prevents the maturation of a1b GlyR synapses (Zhang et al., 2016). 
 
CONCLUSION 
 
In conclusion, we infer that the free Zn2+ concentration in the artificial glycinergic synaptic cleft 
reaches at least 1 µM following a single presynaptic stimulation. As this concentration at least an 
order of magnitude higher than the tonic Zn2+ concentration, we assume that diffusible Zn2+ is 
somehow concentrated in the synaptic cleft. The most likely explanation is that Zn2+ is phasically 
released from presynaptic terminals. It is noteworthy that this peak concentration is significantly 
higher than that reached under similar conditions in the glutamatergic synaptic cleft. We also found 
no evidence for tonic Zn2+ binding to high affinity GlyR sites. Similarly, we found no evidence for 
Zn2+ inhibition in response to a single action potential in synapses where GlyR Zn2+ potentiation had 
been eliminated. These results provide new insights into the physiological modulatory mechanisms 
of glycinergic IPSCs.  
 
Supplementary information: Supplementary Table 1. 
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Supplementary Table 1. Summary of the fast and slow deactivation time constants, and their relative amplitudes, 
measured in response to the rapid application of 1 mM glycine to macropatches expressing the indicated GlyR isoforms. 
Parameters: t1 – fast decay time constant; A1 – relative amplitude of t1; t2 – slow decay time constant; A2 – relative 
amplitude of t2. 
n values for each experiment are given in brackets. 
**p < 0.01 by nonparametric Mann-Whitney U test.	
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Chapter 6: General Discussion 
The overall aim of my PhD project was to develop and validate a protocol for efficiently generating 
functional glycinergic ‘artificial’ synapses incorporating defined glycine receptor subunit 
combinations. Secondary aims were to use this assay to investigate the effects of startle disease and 
autism mutations on glycinergic IPSCs and to probe the Zn2+ concentration in the glycinergic 
synaptic cleft. Here, I will summarise the major findings as presented in each chapter and propose 
some future directions on the basis of current research. 
 
1. The ‘artificial’ synapse is a reliable means of generating functional recombinant 
glycinergic synapses that selectively incorporate the GlyR isoform of interest. 
The main advantage of the artificial synapse preparation is that it allows control over the subunit 
composition of postsynaptic GlyRs. It is critical to establish that the spontaneous IPSCs generated 
from the artificial synapses exhibit similar characteristics to those mediated by native synapses 
incorporating the same subunits. Glycinergic IPSCs recorded from artificial synapses containing 
α1β and α2β GlyRs exhibit decay times that correspond remarkably closely to those from native 
neuronal synapses expressing the same isoforms. Additionally, the accelerated IPSC decay rates 
recorded from homozygous a1D80A knock-in mice or from homozygous spasmodic a1A52S mice 
closely resemble those recorded from artificial synapses incorporating the same mutant subunits 
(Graham et al., 2006; Hirzel et al., 2006). These results provide an important validation of our 
technique. However, potential limitations of the ‘artificial’ synapse approach include the possibility 
of different geometries of the synaptic microenvironment, or the possible lack of essential 
transporters or clustering proteins in the postsynaptic cells, which may be reflected in slower 
glycinergic IPSC rise times in artificial synapses. Thus, it would be of interest to use electron 
microscopy to measure the width of the synaptic cleft and compare the synaptic morphology of 
artificial synapses with that of native neuronal synapses. This has been achieved with GABAergic 
artificial synapses where it was shown that the presynaptic terminals were similar to native 
GABAergic synapses in that they exhibited close apposition between pre- and postsynaptic 
membranes, together with a high density of presynaptic membrane-bound vesicles and 
mitochondria	 (Fuchs et al., 2013). It would be of interest to employ this approach on artificial 
glycinergic synapses.  
 
An additional means of comparing artificial with real synapses would be to employ high resolution 
imaging. Superresolution photoactivation localization microscopy (sptPALM) measurements on 
live cells could be employed to monitor the diffusion rate of individual GlyRs in both the synaptic 
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and extrasynaptic compartments in neurons and in HEK cells containing artificial synapses	 (Manley 
et al., 2010). By comparing the relative abilities of the respective synapses to restrain GlyR 
movement, it would be possible to determine whether the synaptic clustering mechanisms are 
similar in strength between the two systems. PALM imaging on fixed neurons or HEK cells could 
also be used to compare both synaptic cluster sizes and the densities of GlyRs within individual 
synaptic clusters. Finally, it would be useful to probe the relative expression levels and functional 
roles of specific proteins that might contribute to synaptogenesis and synaptic clustering 
mechanisms in artificial and native synapses. Together, this information would greatly enhance our 
ability to determine the extent to which glycinergic ‘artificial’ synapses recapitulate their native 
neuronal counterparts. 
 
2. α1- and α1β-mediated IPSCs exhibit identical kinetic profiles. 
Incorporation of the β subunit into α2 and α3-containing GlyRs accelerates IPSC rise and decay 
times. This result is consistent with the notion that β subunit is essential for clustering GlyRs at the 
postsynaptic sites via directly binding to gephyrin (Fritschy et al., 2008). In contrast, incorporation 
of the β subunit into α1 containing GlyRs does not alter the kinetic properties, implying that GlyR 
α1 can be localized to postsynaptic sites by a gephyrin-dependent or a gephyrin-independent 
mechanism. Single particle tracking studies have shown that the GlyR α1 diffused much faster and 
was less confined in both Hela cell and neuron membrane compared to that of GlyR α1 containing 
the gephyrin-binding motifs (Ehrensperger et al., 2007). Therefore, if gephyrin is the sole means of 
clustering GlyRs at synapses, the diffusion and clustering properties of α1 and α1β GlyRs should be 
different. We hypothesize that α1 homomer-mediated fast IPSCs is independent of the regulation of 
mobility and clustering by gephyrin. If this is the case, disruption of gephyrin clusters by either 
gephyrin shRNAs or gene knockout should lead to a specific disruption of the function of the α1β 
GlyR-mediated synapses but not of α1 GlyR-mediated synapses. Furthermore, search for proteins 
interacting with GlyR α1 subunit would provide additional details concerning the mechanisms of 
efficient synaptic transmission mediated by α1 GlyRs. 
 
Chimeras of GlyR α1 and α3 subunits have been used in our laboratory to identify the structural 
determinants of their efficacy differences (Chen et al., 2009), and the structural domains influencing 
conformational variations in the glycine-binding site (Han et al., 2013). The predicted intrinsic 
channel closing rates from the simulation were relatively fast for both α1 and α3 GlyRs. However, 
in artificial synapses, the time course of α3 GlyR-mediated IPSCs was considerably longer than α1 
GlyR-mediated IPSCs, yet the basis for difference in kinetics remains unknown. Chimera 
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approaches using GlyR α1 and α3 subunits provide a plausible way to investigate the structural 
basis of their different IPSC characteristics. 
 
3. α1β- and α3β-mediated IPSCs exhibit similar IPSC characteristics. 
The glycine sensitivity differs between the α1 and α3 GlyRs, with the EC50 for glycine being 10-
fold higher in α3-containing GlyRs (~300 µM) than in α1-containing GlyRs (~30 µM). As the 
glycine EC50 for α3β GlyRs is comparable with that of the α1A52Sβ mutant GlyR, we expected to 
observe faster decay rates in α3β-mediated IPSCs compared to the α1β-mediated IPSCs. However, 
we observed remarkably similar IPSC rise and decay rates in α1β and α3β-mediated 
heterosynapses. Although α3β-mediated IPSCs have yet to be recorded in isolation in native 
synapses, their kinetic properties appear indistinguishable from those of α1β GlyRs (Harvey et al., 
2004). This fits well with the results from our artificial synapses. However, the mechanisms by 
which α1 and α3 GlyRs with drastically different glycine sensitivities are capable of generating 
IPSCs with identical kinetic properties still need to be determined.  
 
4. Gain-of-function GLRA1 mutations prolong the decay of IPSCs. 
Hyperekplexia, or startle disease, is most commonly caused by hereditary GLRA1 and GLRB 
mutations that reduce the efficacy of glycinergic transmission. Previous studies have identified 
several GLRA1 mutations that result in spontaneous channel activation, suggesting gain-of-function 
GLRA1 mutations can also cause hyperekplexia. In my study, we identified two new GLRA1 gain-
of-function hyperekplexia mutations (I43F and W170S) and characterized these along with known 
gain-of-function mutations (Q226E, V280M and R414H). Using artificial synapses, all gain-of-
function mutations exhibit prolonged decay of glycinergic IPSCs. The longer and more complex 
spontaneous bursts induced by α1I43Fβ, α1Q226Eβ and α1V280Mβ most likely underlie the observed 
drastically slow IPSC decay rates. Conversely, the short-lived spontaneous bursts induced by 
α1W170Sβ and α1R414Hβ most likely underlie their faster IPSC decay rates, compared to those 
mediated by other gain-of-function mutations.  
 
As to how GLRA1 gain-of-function mutations cause hyperekplexia, we proposed several possible 
mechanisms. First, we considered the spontaneous Cl- current may deplete the Cl- gradient in adult 
neurons leading to reduced efficacy of glycinergic inhibition. However, we consider this unlikely as 
it should also lead to pain sensitization and a hyperekplexia phenotype that correlates with mutation 
severity, neither of which is observed in patients with gain-of-function mutations. Second, we 
considered that even small increases in IPSC decay time constants (as seen in W170S and R414H) 
may directly elicit hyperekplexia, perhaps by a presynaptic effect on motor neurons on an upstream 
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effect on an excitatory or inhibitory input onto motor neurons. We also rule out this possibility 
given that the clinically-important drug, tropisetron, increases glycinergic IPSC decay times 
without causing motor side effects. Third, we considered whether a neurodevelopmental defect may 
result in fewer glycinergic synapses in adult motor neurons. This idea stemmed from a recent study 
that concluded that an elevated intracellular chloride concentration late during development ablates 
α1β glycinergic synapses but spares GABAergic synapses (Schwale et al., 2016). As this 
mechanism satisfies all our considerations, we propose it is primarily responsible for the gain-of-
function hyperekplexia phenotype. To test our hypothesis, overexpression of GLRA1 gain-of-
function mutations in neuronal cultures followed by imaging experiments to quantitate changes in 
GlyR synapse numbers could provide further insights into the morphological correlates of these 
functional alterations in glycinergic synapses. 
 
5. Autism-causing α2R350L mutation increases IPSC time courses. 
We have characterized the functional properties of a newly identified autism-causing mutation, 
R350L, which located in the intracellular loop of GlyR α2 subunit. Using artificial synapses, the 
R350L mutation was found to slow rise and decay times of glycinergic IPSCs. The increased IPSC 
decay time is mainly due to the prolonged intrinsic channel closing rate. As mutation of Arg-350 to 
Ala, Lys or Ile did not affect the IPSC decay time, we propose the Leu mutation specifically affects 
a molecular interaction responsible for the prolonged IPSC time courses. Thus, it would be of 
interest to identify this molecular interaction.  
 
The importance of α2 GlyR activation in neuronal migration and cortical network formation has 
already been established. Thus, mutations that affect a2 glyR activation might lead to aberrant 
neurodevelopment, and hence could conceivably lead to autism.  Further experiments are required 
to establish whether the aberrant glycinergic signaling caused by the R350L mutation may lead to 
cortical neuronal migration and maturation defects that account for the etiology of autism. 
 
6. Probing the Zn2+ concentration in glycinergic synaptic cleft. 
It is generally accepted that free Zn2+ is concentrated into presynaptic vesicles at many brain 
glutamatergic synapses and is co-released with neurotransmitter into the synaptic cleft by nerve 
terminal stimulation. However, phasically released Zn2+ at glycinergic synapses is more 
questionable and the peak Zn2+ concentration in the synaptic cleft is more debatable. We generated 
‘artificial’ synapses expressing α1β, α1H107Nβ and α1W170Sβ GlyRs with different Zn2+ sensitivities. 
By comparing the effects of Zn2+ chelator, tricine, on IPSCs to the effects of co-applied glycine plus 
free Zn2+ to macropatches, we inferred that synaptic Zn2+ rises to at least 1 µM following a single 
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presynaptic stimulation. Moreover, using the fast high-affinity chelator, ZX1, we found no evidence 
for tonic Zn2+ bound constitutively to high affinity GlyR sites, indicating diffusible Zn2+ is likely to 
be phasically released at glycinergic synapses. 
 
Our experiments provide a preliminary estimation of free Zn2+ concentration in the glycinergic 
synaptic cleft, and a most likely mechanism for Zn2+ modulation of glycinergic neurotransmission. 
Clearly, more detailed investigations are needed. Most importantly, where does the Zn2+ come from 
at glycinergic synapses? Whether the Zn2+ and glycine are co-released from presynaptic terminals, 
or through spillover of Zn2+ from neighbouring glutamatergic synapses in the mammalian spinal 
cord remains unsolved. Whether extrasynaptic GlyRs are also subject to Zn2+ modulation is unclear. 
In addition, the time course of Zn2+ in the synapse still needs to be determined and this could help 
us better evaluate the Zn2+ effects on neuronal physiology. 
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Abstract: Fast inhibitory neurotransmission in the brain is mediated by wide range of GABAA 
receptor (GABAAR) and glycine receptor (GlyR) isoforms, each with different physiological and 
pharmacological properties. Because multiple isoforms are expressed simultaneously in most 
neurons, it is difficult to define the properties of inhibitory postsynaptic currents mediated by 
individual isoforms in vivo. Although recombinant expression systems permit the expression of 
individual isoforms in isolation, they require exogenous agonist application which cannot mimic the 
dynamic neurotransmitter profile characteristic of native synapses. We describe a neuron-HEK293 
cell co-culture technique for generating inhibitory synapses incorporating defined combinations of 
GABAAR or GlyR subunits. Primary neuronal cultures, prepared from embryonic rat cerebral 
cortex or spinal cord, are used to provide presynaptic GABAergic and glycinergic terminals, 
respectively. When the cultures are mature, HEK293 cells expressing the subunits of interest plus 
neuroligin 2A are plated onto the neurons, which rapidly form synapses onto HEK293 cells. Patch 
clamp electrophysiology is then used to analyze the physiological and pharmacological properties 
of the inhibitory postsynaptic currents mediated by the recombinant receptors. The method is 
suitable for investigating the kinetic properties or the effects of drugs on inhibitory postsynaptic 
currents mediated by defined GABAAR or GlyR isoforms of interest, the effects of hereditary 
disease mutations on the formation and function of both types of synapses, and synaptogenesis and 
synaptic clustering mechanisms. The entire cell preparation procedure takes 2 – 5 weeks.  
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INTRODUCTION 
 
The central nervous system is comprised of circuits of interconnected neurons that serve to 
process specific types of information. These circuits regulate their own output by feedback and 
feedforward connections. Knowledge of the physiological properties of the inhibitory and 
excitatory synapses that mediate these connections is crucial for understanding the electrical 
behavior of circuits and ultimately of brain function. Fast inhibitory neurotransmission in these 
circuits is mediated by GABA type-A receptor (GABAAR) and glycine receptor (GlyR) chloride 
channels.  
GABAARs exhibit a particularly broad range of heterogeneity. As members of the 
pentameric ligand-gated ion channel (pLGIC) family, five subunits are required to form a single 
functional oligomer. There are 19 GABAAR genes (a1 – 6, b1 – 3, g1 – 3, d, e, q, p and r1 – 3) 
with the most common synaptic isoform comprising a1, b2 and g2 subunits in a 2:2:1 
stoichiometry. Although many hundreds of other subunit combinations are theoretically possible, it 
is thought that around one hundred exist naturally in the brain (Olsen and Sieghart, 2009). GlyRs 
exhibit far less diversity with only four genes (a1 – 3, b) in humans (Lynch, 2009). They also 
belong to the pLGIC family and synaptic GlyR isoforms comprise heteromeric assemblies of a and 
b subunits in a 2:3 or 3:2 stoichiometry (Durisic et al., 2012; Yang et al., 2012).   
Each GABAAR or GlyR isoform has a unique physiological and pharmacological profile 
and it is the unique properties of a particular isoform that are important for the appropriate 
functioning of a particular network. Disruptions to these properties can result in neurological 
disorders. For example, hereditary mutations that affect the function of GABAARs or GlyRs can 
lead to epilepsy (Macdonald et al., 2010) or human hyperekplexia (Bode and Lynch, 2014), 
respectively. Other disruptive mechanisms are also possible. For example, a post-transcriptional 
RNA editing mechanism that is upregulated in temporal lobe epilepsy increases the prevalence of 
a3 GlyRs incorporating the P185L mutation (Meier et al., 2005; Eichler et al., 2008; Eichler et al., 
2009). Finally, a range of neurological disorders is known to result from aberrant changes to pLGIC 
phosphorylation status (Talwar and Lynch, 2014). For example, chronic pain sensitization is caused 
by prostaglandin-induced phosphorylation of α3 GlyRs (Harvey et al., 2004; Zeilhofer, 2005; 
Lynch and Callister, 2006) and ethanol-induced phosphorylation of the g2 GABAAR subunit 
contributes to alcoholism (Qi et al., 2007).   
Thus, characterising the physiological and pharmacological properties of defined GABAAR 
and GlyR isoforms under synaptic activation conditions is essential for understanding how neuronal 
circuits function in health and disease. However, it is difficult to study individual isoforms in their 
native neuronal environment due to the multitude of other isoforms present, and the difficulty in 
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pharmacologically or genetically isolating the receptor isoform of interest. The neuron-HEK293 
cell co-culture protocols we describe here solve this problem by providing a simple, efficient means 
of generating functional recombinant inhibitory synapses that selectively incorporate the 
recombinant GABAAR or GlyR isoform of interest. A key step is to express neuroligin 2A in the 
HEK293 cells in order to promote synaptogenesis (Bemben et al., 2015). To generate glycinergic 
synapses, we also expressed gephyrin, a postsynaptic microtubular-binding protein essential for 
anchoring GlyRs to synapses (Meyer et al., 1995; Meier et al., 2000). 
Co-culture approaches have previously been developed to understand the roles of synaptic 
adhesion molecules (including neurexin and neuroligin) in the formation of glutamatergic or 
GABAergic synapses	 (Scheiffele et al., 2000; Biederer et al., 2002; Dean et al., 2003; Graf et al., 
2004; Sara et al., 2005; Kim et al., 2006; Dong et al., 2007; Fuchs et al., 2013) or to investigate the 
impact of disease-causing neuroligin mutations on GABAergic synaptogenesis (Chubykin et al., 
2005; Sun et al., 2011). They have also been employed to characterise the functional properties of 
inhibitory post-synaptic currents (IPSCs), and have revealed kinetic differences among different 
GABAAR isoforms (Wu et al., 2012; Dixon et al., 2014) and GlyR isoforms (Zhang et al., 2014).  
The original co-culture protocol, involving postnatal hippocampal neurons and transfected 
HEK293 cells, was optimized for the immunohistochemical analysis of glutamatergic and 
GABAergic synapse development (Biederer and Scheiffele, 2007). A more recent protocol outlined 
an improved procedure for generating recombinant GABAergic synapses between striatal medium 
spiny GABAergic neurons and transfected HEK293 cells (Brown et al., 2014). However, this was 
also optimized for monitoring synapse development rather than for recording IPSCs in mature 
synapses. We have extended the co-culture approach in three ways. First, we describe the first 
spinal neuron-HEK293 cell co-culture preparation suitable for the efficient generation of 
recombinant glycinergic synapses. Second, we have simplified the technique for creating 
GABAergic synapses by using embryonic cortical neurons grown in serum-free media that does not 
promote the growth of glia (Brewer et al., 1993; Brewer, 1995). We have also have optimized the 
technique to facilitate the electrophysiological analysis of GABAergic and glycinergic IPSCs. 
 
MATERIALS AND METHODS 
 
Overview 
Protocols for all procedures described in this study are detailed in the supplementary 
information. Lists of reagents and equipment are also provided. An overview of the co-culture 
procedure is presented in Figure 1. The cerebral cortex contains large populations of GABAergic 
interneurons that were used to provide presynaptic GABAergic terminals onto HEK293 cells that 
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recombinantly express the GABAAR subunits of interest. Similarly, spinal neurons contain large 
populations of glycinergic interneurons that were used to provide glycinergic presynaptic terminals 
onto HEK293 cells expressing GlyR subunits of interest. The main steps in preparing the neuronal 
cultures are summarized in Figure 1 (blue box). The steps involved in HEK293 cell transfection are 
also described in Figure 1 (green box).  
 
Figure 1. Overview of the co-culture method. The blue box describes the steps involved in preparing neuronal cultures 
(GABAergic in upper row, glycinergic in lower row). The green box describes the steps involved in transfecting 
HEK293 cells. The unshaded section (right) illustrates the final step involving HEK293 cells being plated onto the 
cultured neurons. 
 
Preparation of neuron cultures 
Euthanasia of timed-pregnant rats was performed via CO2 inhalation, in accordance with 
procedures approved by the University of Queensland Animal Ethics Committee. To produce 
GABAergic interneuron cultures, E18 rat embryos were surgically removed from timed-pregnant 
rats and placed into chilled Ca-Mg-free Hank’s Balanced Salt Solution (CMF-HBSS) under sterile 
conditions. The cortical neuronal tissue was then pinched off using fine forceps, taking care to peel 
away the meninges to keep glial cell numbers down. The dissected neurons were then triturated, 
centrifuged and resuspended in Dulbecco’s Modified Eagles Medium supplemented with 10 % fetal 
bovine serum (DMEM-FBS). To produce glycinergic interneuron cultures, E15 rat embryos were 
surgically removed and placed into ice cold CMF-HBSS under sterile conditions. The spinal cords 
were then removed and pinned at the wider proximal end while meninges were carefully detached. 
The dissected neurons were then triturated, centrifuged and resuspended in DMEM-FBS. 
In both cases, the cells were then counted and between 40,000 – 80,000 neurons were plated 
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onto each 12 mm poly-D-lysine-coated coverslip in 4-well plates. As previously noted, neuronal 
density is a key consideration: if it is too low it impairs neuronal survival and if it is too high it 
encourages neuron clumping	 (Fuchs et al., 2013). Neuronal cultures were always maintained in a 5 
% CO2 incubator at 37 oC. After 24 h the entire DMEM-FBS medium was replaced with 
Neurobasal medium including 2 % B27 and 1 % GlutaMAX supplements. A second (and final) 
feed 1 wk later replaced half of this medium. In contrast to a previous protocol	 (Fuchs et al., 2013), 
we found that antibiotics were unnecessary. Neurons were used in co-culture experiments between 
3 – 6 wk later (for GABAergic co-cultures) or 1 – 4 wk later (for glycinergic co-cultures).  
 
Culture and transfection of HEK293 cells 
HEK293 cells were cultured in T75 flasks in DMEM-FBS and maintained in a 5 % CO2 
incubator at 37 oC. The cells were passaged weekly. Prior to transfection, they were trypsinized and 
plated onto 35 mm culture dishes at a density of 5000 cells/dish. Following overnight incubation, 
the cells were transfected via a calcium phosphate co-precipitation protocol, using a total of 0.5 – 
2.5 µg DNA per dish. Then, following incubation for 5 – 20 hr in a 3% CO2 incubator, the 
transfection was terminated by washing twice with divalent cation-free phosphate buffered saline. 
The cells were then trypsinized, centrifuged and resuspended in Neurobasal medium (including 2% 
B27 and 1% GlutaMAX supplements) then seeded onto the neurons. One 35 mm dish of HEK293 
cells was sufficient to seed 4 coverslips of neurons. Once seeded with HEK293 cells, the co-
cultures were returned to the incubator overnight to allow synapses to form. Cultures were used for 
patch clamp recording over the following 2 – 3 days. 
 
Plasmid DNA 
A total of 0.5 – 2.5 µg plasmid DNA should be added to each 35 mm dish of HEK293 cells. 
This amount may vary according to the individual plasmid expression efficiency, the number and 
ratios of plasmids to be transfected and the transfection method. When using a calcium phosphate 
co-precipitation protocol, our recommendations are as follows. When expressing synaptic GlyRs, 
the total plasmid DNA should comprise: 0.2 µg neuroligin 2A, 0.2 µg gephyrin, 0.1 µg EGFP, with 
the remainder comprising GlyR subunit DNA that varies according to the number of subunits and 
the ratio of subunit DNA required. For example, when transfecting GlyR a subunits as homomers, 
add 0.5 µg DNA. When transfecting a and b GlyR subunits in 1:10 or 1:50 ratios add a total of 2 
µg DNA. We recommend transfecting a1:b, a2:b and a3:b subunits in 1:50, 1:50 and 1:10 ratios, 
respectively	 (Zhang et al., 2014). When expressing a1b2g2 GABAARs, the a1, b2, g2, EGFP and 
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neuroligin 2A plasmid DNAs should be transfected in a 1:1:4:1:1 ratio with a combined total of 0.5 
µg DNA. 
In experiments described in Figures 2 and 3, we employed plasmid DNAs encoding the 
human a1 (pCIS), rat a3L (pcDNA3.1) and human b (pcDNA3.1) GlyR subunits, plus mouse 
neuroligin 2A (pNice) and rat gephyrin P1 (pCIS). In experiments described in Figure 4, we 
employed human a2 (pcDNA3.1), human a4 (pCIS), b2 (pcDNA3.1) and g2L (pcDNA3.1) 
GABAAR subunits, plus mouse neuroligin 2A (pNice). Site-directed mutagenesis was performed 
using the QuikChange mutagenesis kit (Agilent Technologies) according to manufacturers’ 
instructions and the successful incorporation of mutations was confirmed by DNA sequencing. 
 
Patch clamp electrophysiology and data analysis 
Standard patch-clamp electrophysiology equipment can be used, with the only specific 
requirement being a fluorescence microscope for identifying GFP fluorescent cells. Coverslips 
containing the co-cultured cells were placed gently into the recording chamber on the microscope 
stage and perfused continuously with an extracellular solution comprising (in mM): 140 NaCl, 5 
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with NaOH. Patch 
pipettes were filled with an intracellular solution containing (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 
10 HEPES, 10 EGTA and 2 MgATP, adjusted to pH 7.4 with NaOH. HEK293 cell selection is 
largely a matter of trial and error. A good starting point is to select large, strongly fluorescent green 
cells that are closely surrounded by many neurons, especially small clumps of neurons. Cells with a 
textured (rather than smooth) appearance often yield abundant IPSCs.  
The electrophysiological techniques may vary according to the experimental requirements. 
For example, if precise quantitation of rise times is required, it is extremely important that the 
filtering and digitisation rates are high and that pipette series resistance is low to avoid artefactually 
slowing down the event. In contrast, testing the effect of a drug on IPSC decay rate is less sensitive 
to filtering, and it may be necessary to use higher resistance pipettes to obtain a membrane seal that 
is stable enough to permit recordings that are long enough to apply and wash out the drug. 
In all experiments described below, series resistance was compensated to 60 % of maximum 
and was monitored throughout the recording. Spontaneous and action potential-evoked IPSCs in 
HEK293 cells were recorded at a holding potential −60 mV and currents were filtered at 4 kHz and 
sampled at 10 kHz.  Only cells with a stable series resistance of <25 MΩ throughout the recording 
period were included in the analysis. Patch pipettes (4 – 8 MΩ resistance) were made from 
borosilicate glass (GC150F-7.5, Harvard Apparatus). Analyses of IPSC amplitude, 10 – 90% rise 
time, and decay time constant (single-exponential) were performed using Axograph X (Axograph 
Scientific). Single peak IPSCs with amplitudes of at least three times above the background noise 
 	 116	
were detected using a semi-automated sliding template. Each detected event was visually inspected 
and only well-separated IPSCs with no inflections in the rising or decay phases (suggestive of 
superimposed events) were included. The respective parameters from all selected events from a 
single cell were averaged and are presented as a single data point in Figures 2 – 4. The averages 
from multiple cells were then pooled to obtain group data. Statistical analysis and plotting were 
performed on group data with Prism 5 (GraphPad Software). All data are presented as mean ± 
SEM. One-way and two-way ANOVA were employed for multiple comparisons. For all tests, the 
number of asterisks corresponds to level of significance: *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
 
RESULTS 
 
Glycinergic IPSCs 
While we found that some co-cultures exhibited spontaneous activity in almost all green 
fluorescent HEK293 cells, it was more typical to observe spontaneous glycinergic IPSCs in around 
20 % of cells. This success rate is adequate for most experiments. 
It is important to establish that the spontaneous IPSCs produced by the co-culture synapses 
exhibit similar characteristics to those mediated by native synapses incorporating the same subunits. 
Figure 2a shows sample IPSC recordings from HEK293 cells expressing a1b GlyRs. An IPSC 
averaged from >200 events recorded from multiple cells is shown in Figure 2b. Mean amplitudes, 
10 – 90 % rise times and decay time constants are presented in Figure 2c. Frequency distributions 
of IPSC amplitudes, 10 – 90% rise times and decay time constants all exhibit monotonic 
distributions suggesting a single functional population of synapses (Figure 2c). In adult hypoglossal 
motor neurons, where the α1β GlyR isoform predominates (Lynch, 2009), the 10 – 90 % rise times 
and decay time constants range between 0.6 – 1.8 and 4.9 – 7.7 ms, respectively	 (Singer et al., 1998; 
Graham et al., 2006; Hirzel et al., 2006; Muller et al., 2006). The mean decay time constant (9.3 ms) 
and the 10 – 90 % rise time (1.9 ms) recorded in our co-culture synapses correspond well with these 
results.  
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Figure 2. Comparison of the properties of spontaneous glycinergic IPSCs mediated by a1b GlyRs (in black) and 
a1A288Gb GlyRs (in pink). (a) Sample voltage-clamp recordings at three different time scales for both isoforms. (b) 
Mean IPSC waveforms, each averaged from >200 events from a single cell. (c) Mean values and distribution 
histograms for the peak amplitudes, 10 – 90% rise times and decay time constants of IPSCs recorded from a1b and 
a1A288Gb GlyRs. Each data point represents the mean of all IPSCs recorded from a single cell. *p < 0.05, ****p < 
0.0001 relative to a1b GlyRs.  
 
We performed a similar analysis on a3b co-culture synapses and found the mean IPSC rise 
and decay times to be remarkably similar to those mediated by a1b GlyRs (Figure 3a – c). These 
parameters were also distributed monotonically, again suggesting a single population of synapses 
(Figure 3c). Although a3b-mediated IPSCs have yet to be recorded in isolation in native neurons, 
evidence to date suggests their rise and decay times are indistinguishable from those mediated by 
a1b GlyRs	(Harvey et al., 2004). This fits well with the results from our engineered synapses.  
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Figure 3. Comparison of the properties of spontaneous glycinergic IPSCs mediated by a3b GlyRs (in black) and 
a3185Lb GlyRs (in blue). (a) Sample voltage-clamp recordings at three different time scales for both isoforms. (b) Mean 
IPSC waveforms, each averaged from >200 events from a single cell. (c) Mean values and distribution histograms for 
the peak amplitudes, 10 – 90% rise times and decay time constants of IPSCs recorded from a1b and a3185Lb GlyRs. 
Each data point represents the mean of all IPSCs recorded from a single cell. *p < 0.05, ****p < 0.0001 relative to a3b 
GlyRs. 
 
The a1 GlyR subunit D80A and A52S mutations result in startle disease phenotypes in mice 
(Graham et al., 2006; Hirzel et al., 2006). We previously demonstrated that engineered synapses 
incorporating α1D80Aβ and α1A52Sβ GlyRs exhibited accelerated IPSC decay rates closely 
resembling those recorded in native synapses from mutant mice homozygous for these mutations 
(Zhang et al., 2014). This provides an important validation of our technique. In this study we sought 
to determine whether GlyRs may be located both synaptically and peri-synaptically in HEK293 
cells by introducing mutations that dramatically enhanced the glycine sensitivity. We reasoned that 
if GlyRs are located peri-synaptically then enhancing their glycine sensitivity may render them 
susceptible to activation by synaptically released glycine, and if so this should be detectable as an 
additional slow rise time component (Wu et al., 2012). As noted above, a3185L results from a post-
transcriptional RNA editing mechanism that is upregulated in (and is causative of) human temporal 
lobe epilepsy (Eichler et al., 2009; Winkelmann et al., 2014). This mutation reduces the glycine 
EC50 from 70.9 to 7.4 µM	 (Legendre et al., 2009). We also investigated the a1A288G mutation 
(which is not associated with a disease) because it reduces the glycine EC50 from 30.9 to 6.0 µM 
(Lynagh and Lynch, 2010). 
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As shown in Figure 2a – c, IPSCs mediated by a1A288Gb GlyRs exhibited significantly 
slower rise times and decay time constants, although additional slow components suggestive of 
peri-synaptic receptors were never observed on the rising phase of IPSCs. As with unmutated a1b 
GlyRs, the rise and decay times were monotonically distributed (Figure 2c) suggesting a single 
postsynaptic receptor population. Similarly, Figure 3a – c shows that IPSCs mediated by a3185Lb 
GlyRs also exhibited significantly slower rise times and decay time constants that were distributed 
monotonically. We were not able to unequivocally distinguish a putative peri-synaptic GlyR 
population in either case.  
 
GABAergic IPSCs 
As with glycinergic IPSCs, we typically observed GABAergic IPSCs in around 20 % of 
HEK293 cells. The rise times and decay time constants of IPSCs recorded from the dominant 
(a1b2g2) synaptic subtype (1.2 and 4.0 ms, respectively) are in close accordance with those 
recorded from neurons known to predominantly express this subtype (Dixon et al., 2014). The co-
culture system has revealed that other GABAAR subunit combinations can yield IPSCs with 
dramatically different rise and decay times (Wu et al., 2012; Dixon et al., 2014), although it is as 
yet unclear how these properties relate to those of the same isoforms when expressed in native 
neuronal synapses.  
We have previously demonstrated that the effects of some clinically important drugs on co-
culture GABAergic synaptic IPSCs are similar to those recorded at corresponding neuronal 
synapses. For example, 1 µM diazepam or 0.1 µM flunitrazepam significantly increased the decay 
time constants of IPSCs mediated by a2-containing GABAARs (Dixon et al., 2014) and 1 µM 
zolpidem or 1 µM eszopiclone increased IPSC magnitudes and decay time constants of IPSCs 
mediated by a1-containing GABAARs (Dixon et al., 2015). Here we extended this characterisation 
by performing a ‘reciprocal’ pharmacological comparison of a2b2g2 and a4b2g2 GABAARs, based 
on the knowledge that a4-containing GABAARs are highly sensitive to ethanol and insensitive to 
benzodiazepines, whereas a2-containing GABAARs have the opposite profile (Knoflach et al., 
1996; Wallner et al., 2006). As shown in Figure 4a and b, IPSCs mediated by recombinant a2b2g2 
and a4b2g2 GABAARs exhibit identical amplitudes, 10 – 90 % rise times and decay time constants. 
A physiologically relevant (10 mM) ethanol concentration significantly increased the IPSC decay 
time constant in a4b2g2 GABAARs whereas 1 µM diazepam had no effect (Figure 4c, d). On the 
other hand, 1 µM diazepam significantly prolonged the IPSC decay time constant in a2b2g2 
GABAARs (Dixon et al., 2014), whereas even a very high (30 mM) ethanol concentration had no 
effect (Figure 4d). 
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Figure 4. Comparison of kinetics and pharmacological properties of IPSCs mediated by a2b2g2 and a4b2g2 
GABAARs. (a) Cumulative probability data averaged from 4 cells expressing a4b2g2 GABAARs were compared to 
previously published data for a2b2g2 GABAARs (n = 7) (Dixon et al., 2014). We found no significant differences in 
IPSC amplitudes, 10 – 90 % rise times or decay time constants. (b) Sample recordings of spontaneous IPSCs mediated 
by a4b2g2 GABAARs before and after the application of 10 mM ethanol and 1 µM diazepam. (c) Examples of mean 
IPSC waveforms mediated by a4b2g2 GABAARs, each averaged from >100 events from a single cell, before and after 
the application of 10 mM ethanol or 1 µM diazepam. (d) The decay time constants of IPSCs mediated by a4b2g2 
GABAARs were significantly prolonged by 10 mM ethanol but not by 1 µM diazepam (left panel). In contrast, IPSCs 
mediated by a2b2g2 GABAARs were significantly prolonged by 1 µM diazepam but not by 30 mM ethanol (right 
panel). Diazepam data for a2b2g2 GABAARs were reproduced from (Dixon et al., 2014). *p < 0.05 relative to drug-
free control in same cell. 
 
 
 
 	 121	
DISCUSSION 
Applications of the protocol 
We have described protocols for reliably generating recombinant inhibitory synapses that 
incorporate defined GlyR or GABAAR isoforms of interest. These are suitable for investigating (1) 
the kinetics of IPSCs mediated by defined GABAAR or GlyR isoforms, (2) the effects of drugs on 
IPSCs mediated by defined GABAAR or GlyR isoforms, (3) the effect of posttranslational 
modifications (e.g., phosphorylation) and hereditary disease mutations on the formation and 
function of both types of synapses, and (4) synaptogenesis and synaptic clustering mechanisms in 
both types of synapses. We now expand on each of these points. 
 
IPSC kinetics 
IPSCs mediated by different synaptic GABAAR or GlyR isoforms exhibit unique 
physiological and pharmacological profiles. It is useful to quantitate these properties because they 
may help in identifying the presence, or even the role, of a particular isoform in a particular neuron 
and also because accurate parameters provide key inputs into computational models of neuron or 
network function. Although studying recombinant receptors in standard heterologous expression 
systems such as HEK293 cells or Xenopus oocytes allows the electrophysiological properties of a 
single isoform to be studied in isolation, this approach is limited because the neurotransmitter must 
be applied artificially and it cannot mimic the fast (µs) dynamic neurotransmitter concentration 
profile that exists in the synaptic cleft.  
 
Investigating drug efficacy and selectivity 
The GABAAR is an established therapeutic target for clinical indications including epilepsy, 
anxiolysis, muscle spasms, sedation and anaesthesia. GABAAR-targeted drugs currently in clinical use 
are not strongly subtype-selective and this can lead to dose-limiting side effects. For example, diazepam 
produces effective anxiolysis by positively modulating a2-containing GABAARs, although it also elicits 
the side effect of sedation by modulating a1-containing GABAARs (Trincavelli et al., 2012). Drugs 
specific for other isoforms are also being sought. For example, selective modulators of a5-containing 
GABAARs are being developed for a range of indications including stroke, cognitive impairment and 
schizophrenia (Soh and Lynch, 2015). Although GlyRs are not currently targeted by clinically useful 
drugs, molecules that selectively enhance a3-containing GlyRs are considered promising as new 
generation treatments for chronic pain (Zeilhofer, 2005; Lynch and Callister, 2006). When evaluating 
new molecules as potential therapeutic lead compounds for synaptically-localised receptors, it is 
important to test their potency, efficacy and subtype-selectivity under realistic synaptic activation 
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conditions. The system we describe provides the most definitive means available of evaluating drug 
efficacy and selectivity at IPSCs mediated by defined receptor isoforms. 
 
Investigating disease mutations 
Engineered synapses have yet to be used to study disease-causing GABAAR mutations or 
modifications, and hence, the method has not realised its full potential as a model system for 
understanding the molecular pathology of neurological disorders. Mutations in GABAAR a1 and g2 
subunits have long been associated with genetic epilepsy syndromes (Macdonald et al., 2010). Thus 
far, the function and pharmacology of epilepsy-causing mutant GABAARs have only been 
investigated using whole-cell recordings of steady-state GABA-activated currents in heterologous 
expression systems. The differing approaches that have been used to analyze the effects of these 
mutations have led to controversy, particularly in the case of the g2R43Q mutation (Petrou and Reid, 
2012). Moreover, of all the identified epilepsy-causing mutant GABAARs that exhibit partial or full 
expression at the cell membrane, there is an animal knock-in model of only one (Petrou and Reid, 
2012). Transgenic animal models are afflicted by compensatory mechanisms that can obfuscate 
data, especially those involving ion channel genetic manipulations that affect GABAergic 
transmission (Harris et al., 2011). Because engineered a1b2g2 GABAAR synapses successfully 
recapitulate the kinetics of neuronal IPSCs (Dixon et al., 2014), they may provide a promising 
means of investigating the synaptic signaling defects induced by hereditary epilepsy mutations to 
a1 and g2 subunits.  
Glycinergic co-culture synapses incorporating a1D80Ab and a1A52Sb GlyRs have been 
shown to exhibit accelerated IPSC decay rates that strongly resemble those recorded in native 
synapses from mutant mice homozygous for the same mutations (Zhang et al., 2014). This suggests 
that the co-culture system should be useful for modelling the effects of hyperekplexia mutations to 
a1 and b subunits (Bode and Lynch, 2014) and autism mutations to a2 subunits	 (Pilorge et al., 
2015).  
Here we investigated the disease-relevant a3185L GlyR under synaptic activation conditions. 
The P185L substitution results from an RNA-editing mechanism and the incidence of the edited 
receptors in the hippocampus is increased in patients with temporal lobe epilepsy (Meier et al., 
2005; Eichler et al., 2008; Eichler et al., 2009). Although glycinergic synapses are absent in the 
hippocampus, a3L GlyRs are located presynaptically at glutamatergic synapses (Eichler et al., 2009; 
Kubota et al., 2010; Winkelmann et al., 2014). As these GlyRs are excitatory due to the collapsed 
transmembrane chloride gradient, upregulation of RNA-edited a3185L GlyRs would increase the 
depolarisation of presynaptic terminals (and thus increase glutamate release) due to longer channel 
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open times (Winkelmann et al., 2014). The resulting alteration in network activity not only leads to 
recurrent epileptiform discharge but also to cognitive dysfunction and memory deficits (Meier et al., 
2014; Winkelmann et al., 2014). Our results demonstrate that the synaptically-localised RNA-
edited GlyRs remain open for longer during each synaptic event.  
Synaptogenesis and synaptic clustering mechanisms 
Co-culture synapses have been used extensively to probe the roles of synaptic adhesion 
molecules in the formation of glutamatergic or GABAergic synapses	 (Scheiffele et al., 2000; 
Biederer et al., 2002; Dean et al., 2003; Graf et al., 2004; Sara et al., 2005; Kim et al., 2006; Dong 
et al., 2007; Fuchs et al., 2013) or to investigate the impact of disease-causing neuroligin mutations 
on GABAergic synaptogenesis (Chubykin et al., 2005; Sun et al., 2011). The strengths and 
weaknesses of co-cultures in this respect have recently been reviewed	(Fuchs et al., 2013). 
 
Conclusions 
As the presynaptic terminals of our engineered synapses are provided by neurons, their 
function is likely to resemble those of synapses in vivo. Indeed, serial electron microscopic 
reconstructions of GABAergic terminals onto HEK293 cells have confirmed that their 
ultrastructures are similar to those of native neurons	 (Fuchs et al., 2013). However, the postsynaptic 
specializations of our engineered synapses may not resemble those of neurons given that HEK293 
cells do not express all necessary postsynaptic clustering proteins at appropriate levels for 
synaptogenesis. Moreover, some proteins that they do express may lack neuron-specific post-
translational modifications required for correct synaptic function. These factors could ultimately 
alter the geometry of the synaptic cleft and the postsynaptic receptor clustering density, leading to 
non-physiological changes in the neurotransmitter concentration profile that could affect IPSC 
kinetics. This uncertainty is the main limitation of the technique. To address this, we have 
ascertained using as many subunit combinations as possible that the physiological properties of our 
engineered synapses resemble those of real synapses. On the other hand, the non-physiological 
nature of our engineered synapses could also offer opportunities to investigate new clustering or 
synaptogenesis mechanisms. If, for example, substitution of a particular pLGIC subunit results in a 
drastic, unexpected slowing of the IPSC rise time, it is possible that synaptic receptors have been 
de-clustered in a manner that does not occur in neurons. This could in turn lead to the identification 
of novel clustering molecules and mechanisms. HEK293 cells are ideal for investigating such 
questions: they do not express all proteins necessary for synaptogenesis, but they do provide a high 
efficiency of transfection, faithful protein translation and a small, electronically-compact shape 
appropriate for accurate quantitation of IPSC rise and decay times	(Thomas and Smart, 2005).  
 	 124	
 
Supplementary information: Yes. 
 
Acknowledgements: This research was supported by project grants from the Australian Research 
Council (DP120104373) and the National Health and Medical Research Council (APP1062183). 
JWL is supported by a Principal Research Fellowship from the National Health and Medical 
Research Council (APP1058542). We thank Dr. Nela Durisic for critical review of the manuscript. 
We thank Prof. Jochen Meier and Dr. Aline Winkelmann for kindly supplying the rat GlyR a3L185L 
plasmid DNA and Prof. Rob Harvey for the rat gephyrin P1 plasmid DNA. 
 
Author contributions: C.L.D., Y.Z and J.W.L. conceived the project and developed the protocols; 
C.L.D. and Y.Z. performed experiments and analysed the data; and C.L.D., Y.Z and J.W.L. wrote 
the manuscript. 
 
Competing financial interests: The authors declare no competing financial interests. 
 
 
REFERENCES 
 
Bemben, M. A., Shipman, S. L., Nicoll, R. A., and Roche, K. W. (2015). The cellular and 
molecular landscape of neuroligins. Trends Neurosci 38, 496-505. 
Biederer, T., Sara, Y., Mozhayeva, M., Atasoy, D., Liu, X., Kavalali, E. T., and Sudhof, T. C. 
(2002). SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297, 
1525-31. 
Biederer, T., and Scheiffele, P. (2007). Mixed-culture assays for analyzing neuronal synapse 
formation. Nat Protoc 2, 670-6. 
Bode, A., and Lynch, J. W. (2014). The impact of human hyperekplexia mutations on glycine 
receptor structure and function. Mol Brain 7, 2. 
Brewer, G. J. (1995). Serum-free B27/neurobasal medium supports differentiated growth of 
neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate 
gyrus. J Neurosci Res 42, 674-83. 
Brewer, G. J., Torricelli, J. R., Evege, E. K., and Price, P. J. (1993). Optimized survival of 
hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium 
combination. J Neurosci Res 35, 567-76. 
Brown, L. E., Fuchs, C., Nicholson, M. W., Stephenson, F. A., Thomson, A. M., and Jovanovic, J. 
N. (2014). Inhibitory synapse formation in a co-culture model incorporating GABAergic 
medium spiny neurons and HEK293 cells stably expressing GABAA receptors. J Vis Exp 
e52115. 
Chubykin, A. A., Liu, X., Comoletti, D., Tsigelny, I., Taylor, P., and Sudhof, T. C. (2005). 
Dissection of synapse induction by neuroligins: effect of a neuroligin mutation associated 
with autism. J Biol Chem 280, 22365-74. 
Dean, C., Scholl, F. G., Choih, J., DeMaria, S., Berger, J., Isacoff, E., and Scheiffele, P. (2003). 
Neurexin mediates the assembly of presynaptic terminals. Nat Neurosci 6, 708-16. 
 	 125	
Dixon, C., Sah, P., Lynch, J. W., and Keramidas, A. (2014). GABAA receptor alpha and gamma 
subunits shape synaptic currents via different mechanisms. J Biol Chem 289, 5399-411. 
Dixon, C. L., Harrison, N. L., Lynch, J. W., and Keramidas, A. (2015). Zolpidem and eszopiclone 
prime alpha1beta2gamma2 GABAA receptors for longer duration of activity. Br J 
Pharmacol 172, 3522-36. 
Dong, N., Qi, J., and Chen, G. (2007). Molecular reconstitution of functional GABAergic synapses 
with expression of neuroligin-2 and GABAA receptors. Mol Cell Neurosci 35, 14-23. 
Durisic, N., Godin, A. G., Wever, C. M., Heyes, C. D., Lakadamyali, M., and Dent, J. A. (2012). 
Stoichiometry of the Human Glycine Receptor Revealed by Direct Subunit Counting. J 
Neurosci 32, 12915-12920. 
Eichler, S. A., Forstera, B., Smolinsky, B., Juttner, R., Lehmann, T. N., Fahling, M., Schwarz, G., 
Legendre, P., and Meier, J. C. (2009). Splice-specific roles of glycine receptor alpha3 in the 
hippocampus. Eur J Neurosci 30, 1077-91. 
Eichler, S. A., Kirischuk, S., Juttner, R., Schaefermeier, P. K., Legendre, P., Lehmann, T. N., 
Gloveli, T., Grantyn, R., and Meier, J. C. (2008). Glycinergic tonic inhibition of 
hippocampal neurons with depolarizing GABAergic transmission elicits histopathological 
signs of temporal lobe epilepsy. J Cell Mol Med 12, 2848-66. 
Fuchs, C., Abitbol, K., Burden, J. J., Mercer, A., Brown, L., Iball, J., Anne Stephenson, F., 
Thomson, A. M., and Jovanovic, J. N. (2013). GABA(A) receptors can initiate the 
formation of functional inhibitory GABAergic synapses. Eur J Neurosci 38, 3146-58. 
Graf, E. R., Zhang, X., Jin, S. X., Linhoff, M. W., and Craig, A. M. (2004). Neurexins induce 
differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell 
119, 1013-26. 
Graham, B. A., Schofield, P. R., Sah, P., Margrie, T. W., and Callister, R. J. (2006). Distinct 
physiological mechanisms underlie altered glycinergic synaptic transmission in the murine 
mutants spastic, spasmodic, and oscillator. J Neurosci 26, 4880-90. 
Harris, R. A., Osterndorff-Kahanek, E., Ponomarev, I., Homanics, G. E., and Blednov, Y. A. 
(2011). Testing the silence of mutations: Transcriptomic and behavioral studies of 
GABA(A) receptor alpha1 and alpha2 subunit knock-in mice. Neurosci Lett 488, 31-5. 
Harvey, R. J., Depner, U. B., Wassle, H., Ahmadi, S., Heindl, C., Reinold, H., Smart, T. G., 
Harvey, K., Schutz, B., Abo-Salem, O. M., Zimmer, A., Poisbeau, P., Welzl, H., Wolfer, D. 
P., Betz, H., Zeilhofer, H. U., and Muller, U. (2004). GlyR alpha3: an essential target for 
spinal PGE2-mediated inflammatory pain sensitization. Science 304, 884-7. 
Hirzel, K., Muller, U., Latal, A. T., Hulsmann, S., Grudzinska, J., Seeliger, M. W., Betz, H., and 
Laube, B. (2006). Hyperekplexia phenotype of glycine receptor alpha1 subunit mutant mice 
identifies Zn(2+) as an essential endogenous modulator of glycinergic neurotransmission. 
Neuron 52, 679-90. 
Kim, S., Burette, A., Chung, H. S., Kwon, S. K., Woo, J., Lee, H. W., Kim, K., Kim, H., Weinberg, 
R. J., and Kim, E. (2006). NGL family PSD-95-interacting adhesion molecules regulate 
excitatory synapse formation. Nat Neurosci 9, 1294-301. 
Knoflach, F., Benke, D., Wang, Y., Scheurer, L., Luddens, H., Hamilton, B. J., Carter, D. B., 
Mohler, H., and Benson, J. A. (1996). Pharmacological modulation of the diazepam-
insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and 
alpha 6 beta 2 gamma 2. Mol Pharmacol 50, 1253-61. 
Kubota, H., Alle, H., Betz, H., and Geiger, J. R. (2010). Presynaptic glycine receptors on 
hippocampal mossy fibers. Biochem Biophys Res Commun 393, 587-91. 
Legendre, P., Forstera, B., Juttner, R., and Meier, J. C. (2009). Glycine Receptors Caught between 
Genome and Proteome - Functional Implications of RNA Editing and Splicing. Front Mol 
Neurosci 2, 23. 
Lynagh, T., and Lynch, J. W. (2010). A glycine residue essential for high ivermectin sensitivity in 
Cys-loop ion channel receptors. Int J Parasitol 40, 1477-81. 
 	 126	
Lynch, J. W. (2009). Native glycine receptor subtypes and their physiological roles. 
Neuropharmacology 56, 303-9. 
Lynch, J. W., and Callister, R. J. (2006). Glycine receptors: a new therapeutic target in pain 
pathways. Curr Op Investig Drugs 7, 48-53. 
Macdonald, R. L., Kang, J. Q., and Gallagher, M. J. (2010). Mutations in GABAA receptor 
subunits associated with genetic epilepsies. J Physiol 588, 1861-9. 
Meier, J., Meunier-Durmort, C., Forest, C., Triller, A., and Vannier, C. (2000). Formation of 
glycine receptor clusters and their accumulation at synapses. J Cell Sci 113, 2783-95. 
Meier, J. C., Henneberger, C., Melnick, I., Racca, C., Harvey, R. J., Heinemann, U., Schmieden, V., 
and Grantyn, R. (2005). RNA editing produces glycine receptor alpha3(P185L), resulting in 
high agonist potency. Nat Neurosci 8, 736-44. 
Meier, J. C., Semtner, M., Winkelmann, A., and Wolfart, J. (2014). Presynaptic mechanisms of 
neuronal plasticity and their role in epilepsy. Front Cell Neurosci 8, 164. 
Meyer, G., Kirsch, J., Betz, H., and Langosch, D. (1995). Identification of a gephyrin binding motif 
on the glycine receptor beta subunit. Neuron 15, 563-72. 
Muller, E., Le Corronc, H., Triller, A., and Legendre, P. (2006). Developmental dissociation of 
presynaptic inhibitory neurotransmitter and postsynaptic receptor clustering in the 
hypoglossal nucleus. Mol Cell Neurosci 32, 254-73. 
Olsen, R. W., and Sieghart, W. (2009). GABA A receptors: subtypes provide diversity of function 
and pharmacology. Neuropharmacology 56, 141-8. 
Petrou, S., and Reid, C. A. (2012). The GABAAgamma2(R43Q) mouse model of human genetic 
epilepsy. in: Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W., Delgado-Escueta, 
A.V., editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda 
(MD): National Center for Biotechnology Information (US). 
Pilorge, M., Fassier, C., Le Corronc, H., Potey, A., Bai, J., De Gois, S., Delaby, E., Assouline, B., 
Guinchat, V., Devillard, F., Delorme, R., Nygren, G., Rastam, M., Meier, J. C., Otani, S., 
Cheval, H., James, V. M., Topf, M., Dear, T. N., Gillberg, C., Leboyer, M., Giros, B., 
Gautron, S., Hazan, J., Harvey, R. J., Legendre, P., and Betancur, C. (2015). Genetic and 
functional analyses demonstrate a role for abnormal glycinergic signaling in autism. Mol 
Psychiatry. 
Qi, Z.-H., Song, M., Wallace, M. J., Wang, D., Newton, P. M., McMahon, T., Chou, W.-H., Zhang, 
C., Shokat, K. M., and Messing, R. O. (2007). Protein Kinase Cϵ Regulates γ-
Aminobutyrate Type A Receptor Sensitivity to Ethanol and Benzodiazepines through 
Phosphorylation of γ2 Subunits. J Biol Chem 282, 33052-33063. 
Sara, Y., Biederer, T., Atasoy, D., Chubykin, A., Mozhayeva, M. G., Sudhof, T. C., and Kavalali, 
E. T. (2005). Selective capability of SynCAM and neuroligin for functional synapse 
assembly. J Neurosci 260-70. 
Scheiffele, P., Fan, J., Choih, J., Fetter, R., and Serafini, T. (2000). Neuroligin expressed in 
nonneuronal cells triggers presynaptic development in contacting axons. Cell 101, 657-69. 
Singer, J. H., Talley, E. M., Bayliss, D. A., and Berger, A. J. (1998). Development of glycinergic 
synaptic transmission to rat brain stem motoneurons. J Neurophysiol 80, 2608-20. 
Soh, M. S., and Lynch, J. W. (2015). Selective Modulators of alpha5-Containing GABAA 
Receptors and their Therapeutic Significance. Curr Drug Targets 16, 735-46. 
Sun, C., Cheng, M. C., Qin, R., Liao, D. L., Chen, T. T., Koong, F. J., Chen, G., and Chen, C. H. 
(2011). Identification and functional characterization of rare mutations of the neuroligin-2 
gene (NLGN2) associated with schizophrenia. Hum Mol Genet 20, 3042-51. 
Talwar, S., and Lynch, J. W. (2014). Phosphorylation mediated structural and functional changes in 
pentameric ligand-gated ion channels: implications for drug discovery. Int J Biochem Cell 
Biol 53, 218-23. 
Thomas, P., and Smart, T. G. (2005). HEK293 cell line: a vehicle for the expression of recombinant 
proteins. J Pharmacol Toxicol Methods 51, 187-200. 
 	 127	
Trincavelli, M. L., Da Pozzo, E., Daniele, S., and Martini, C. (2012). The GABAA-BZR complex 
as target for the development of anxiolytic drugs. Curr Top Med Chem 12, 254-69. 
Wallner, M., Hanchar, H. J., and Olsen, R. W. (2006). Low dose acute alcohol effects on GABA A 
receptor subtypes. Pharmacol Ther 112, 513-28. 
Winkelmann, A., Maggio, N., Eller, J., Caliskan, G., Semtner, M., Haussler, U., Juttner, R., 
Dugladze, T., Smolinsky, B., Kowalczyk, S., Chronowska, E., Schwarz, G., Rathjen, F. G., 
Rechavi, G., Haas, C. A., Kulik, A., Gloveli, T., Heinemann, U., and Meier, J. C. (2014). 
Changes in neural network homeostasis trigger neuropsychiatric symptoms. J Clin Invest 
124, 696-711. 
Wu, X., Wu, Z., Ning, G., Guo, Y., Ali, R., Macdonald, R. L., De Blas, A. L., Luscher, B., and 
Chen, G. (2012). gamma-Aminobutyric acid type A (GABAA) receptor alpha subunits play 
a direct role in synaptic versus extrasynaptic targeting. J Biol Chem 287, 27417-30. 
Yang, Z., Taran, E., Webb, T. I., and Lynch, J. W. (2012). Stoichiometry and subunit arrangement 
of alpha1beta glycine receptors as determined by atomic force microscopy. Biochemistry 51, 
5229-31. 
Zeilhofer, H. U. (2005). The glycinergic control of spinal pain processing. Cell Mol Life Sci 62, 
2027-35. 
Zhang, Y., Dixon, C. L., Keramidas, A., and Lynch, J. W. (2014). Functional reconstitution of 
glycinergic synapses incorporating defined glycine receptor subunit combinations. 
Neuropharmacology 89C, 391-397. 
	 128	
Supplementary Information 
Protocol for generating functional inhibitory synapses between 
neurons and HEK293 cells expressing defined combinations of 
GABA(A) or glycine receptor subunits 
 
REAGENTS 
• Timed-pregnant rats at E15 (for spinal cord) or E18 (for cerebral cortex).  
• Trypsin 0.05 % in EDTA with phenol red (Gibco 25300-054, Life Technologies) 
• Divalent cation free Phosphate-buffered saline solution (PBS) 
• Poly-D-lysine (P6407-5MG, Sigma-Aldrich) 
• Fetal Bovine Serum (FBS, sterile filtered, Batch number 28301107, Moregate Biotech) 
• Dulbecco’s modified Eagle’s medium (DMEM; Gibco 11995-065, Life Technologies) 
• Neurobasal media (Gibco 21103-049, Life Technologies) 
• B27 (Gibco 17504-44, Life Technologies) 
• Glutamax (Gibco 35050-61, Life Technologies) 
• HEK293 cells. We usually use the HEK293 variant AD-293 (240085, Agilent), but have 
also successfully used Cos9 cells and HEK293T cells. 
• Plasmids for: Neuroligin 2A (plasmid 15259, Addgene), green fluorescent protein (GFP), 
and receptor subunits of interest. 
• Hank’s Balanced Salt Solution (HBSS; Gibco 14025, Life Technologies) 
• Calcium-magnesium free HBSS (CMF-HBSS; H9394, Sigma-Aldrich) 
• Trypan blue 0.4 % solution (Fluka 93595 Sigma-Aldrich) 
• DNase Ι (10104159001, Roche Applied Science) 
• CaCl2, 250 mM in milliQ water, sterile filtered 
• N,N-bis(2-hydroxyethyl)-2-aminoethane- sulfonic acid (BES) buffered saline (BBS; 14280, 
Sigma-Aldrich) 
 
EQUIPMENT 
• 4-well plates (e.g. 176740, Nunclon). We find that multi-well plates are less vulnerable to 
infection than 35 mm dishes. 
• Circular glass coverslips (12 mm diameter, Menzel #1.5, Thermo Fisher Scientific) 
• Fine forceps, curved forceps and dissection scissors for embryonic dissection. 
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• Dissection tools for adult rat 
• CO2 supply and chamber for euthanasia 
• 70 % ethanol in spray bottle 
• Lab	wipes	
• Tube rack 
• Ice bed 
• 100 mm petri dishes 
• 50 ml tubes 
• 15 ml tubes 
• 1.5 ml microcentrifuge tubes 
• Pipettes and tips 
• Glass pasteur pipettes 
• Cigarette lighter 
• Rubber bulb for pasteur pipette 
• Haemocytometer 
• 35 mm dishes for HEK293 cells 
• T75 flasks 
• Dissecting microscope with light 
• Cell culture cabinet (Class II biological safety cabinet or laminar flow hood) 
• Centrifuge with rotor for 15 ml tubes 
• Bottle/tube roller 
• Humidified cell culture incubator at 37 °C, with 5 % CO2 
• Humidified cell culture incubator at 37 °C, with 3 % CO2 (If unavailable, transfection will 
still be partly effective at 5 % CO2) 
• A standard patch-clamp electrophysiology rig incorporating either an upright or an inverted 
fluorescence microscope.  
 
EQUIPMENT SETUP 
• Clean glass coverslips: Clean coverslips in bulk by rinsing for 10 min in concentrated 
hydrochloric or nitric acid.  
CAUTION: When handling acid wear gloves, safety glasses and a lab gown and work in a 
fume hood. Remove the acid and wash coverslips in running distilled water until the pH 
returns to neutral (usually 1 – 2 h). Pour off water and store coverslips in a sealed glass 
container under 100 % ethanol. 
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REAGENT SETUP 
All reagent setup steps should be performed in a cell culture cabinet. 
• DMEM-FBS media: DMEM plus 10 % FBS. 
• Aliquot B27 in 1 ml tubes and freeze for up to 4 months. Once thawed use aliquots within 1 
week. 
• Neuron media: In a 50 ml tube combine 1 ml B27, 0.5 ml Glutamax supplement and top up 
to 50 ml with Neurobasal medium. Loosen the lid and equilibrate to 37 °C and 5 % CO2 in 
the cell incubator before use. 
• Dilute DNAse I to 10 mg/mL in CMF-HBSS, and stored frozen 1 mL aliquots for up to 6 
months. 
• Coated coverslips: Make poly-D-lysine stock solution by adding 5 ml cell-culture water to 5 
mg of poly-D-lysine, and freeze as 0.5 ml aliquots for up to 6 months. Remove ~40 cleaned 
coverslips from the ethanol (see equipment setup) and, in a 50 mL tube, rinse with cell 
culture water. Dilute 1 aliquot of poly-D-lysine stock to 5 ml, and incubate the coverslips on 
a tube roller for at least 1 h at room temperature. Pour off poly-D-lysine solution and use 
forceps to spread coverslips out to dry on sterile lab tissue in the cell culture cabinet. 
PAUSE POINT: Poly-D-lysine solution can be refrigerated and re-used within 1 wk. 
Coated coverslips are best used within 1 wk, but can be stored in a dry sterile tube at room 
temperature for 1 month. 
 
PROCEDURE 
Primary culture 
1. Coat coverslips and place one coverslip in each well of 16 x 4-well plates. 
2. Outside of the biological safety cabinet, euthanize the pregnant rat with CO2, open the 
abdomen and quickly recover the embryos into tubes of chilled CMF-HBSS. If necessary, 
the embryos can remain on ice for 2-3 h prior to the rest of the procedure. 
CAUTION: Euthanasia of animals must be carried out in accordance with national and 
institutional guidelines. 
3. Steps 3–16 below are carried out within a cell culture cabinet using sterile techniques. Begin 
with option A for cortical cultures or option B for spinal cord cultures. 
 
A) Isolating cortical neurons (for GABAergic synapses) 
i) Remove the heads from 3 embryos and rinse in a 100 mm petri dish containing 
chilled CMF-HBSS. Fixing each head with straight forceps, use curved forceps to 
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peel back the skin and skull. Pinch off the top 1 mm of cortical tissue, and place in a 
fresh dish of CMF-HBSS. 
ii) Use fine forceps to peel off the meninges, by grasping blood vessels at the edge of 
the tissue and teasing them away.  
CRITICAL STEP: Failure to remove the meninges will increase glia cell numbers 
in the culture, decreasing the health and lifespan of the neurons. 
iii) Use the flame from a cigarette lighter to lightly polish the tip of a sterile glass 
Pasteur pipette. Suck up a little fresh CMF-HBSS and gently rinse the cortices, then 
suck them up and place in a sterile 15 ml tube. 
  
B) Isolating spinal cord neurons (for glycinergic synapses) 
i) Remove the head and tail of each E15 embryo using forceps, and transfer it to a 
100 mm petri dish filled with ice-cold CMF-HBSS under a dissecting microscope.  
CRITICAL STEP: The dissection procedure should be performed on ice. 
ii) Place the embryo in the prone position and stabilize the embryo with straight 
forceps. Slide the other pair of forceps to cut the skin and meninges along midline 
to open the spinal cord.  
iii) Poke the tissue closed to the dorsal lip of the spinal cord with closed forceps. Open 
the forceps to tear dorsal tissue away. Repeat this operation to detach surrounding 
tissue from both sides of the spinal cord.  
iv) Pin the wider, proximal end of spinal cord with forceps and peel off meninges from 
the spinal cord.  
CRITICAL STEP: Slowly and evenly peel off the meninges and avoid breakage of the 
spinal cord or the meninges. Failure to remove the meninges will increase the 
numbers of glial cells in the culture. 
v) Use fire-polished glass Pasteur pipette to transfer the isolated dorsal strips to a fresh 
petri dish containing ice-cold CMF-HBSS. 
vi) Collect 7 intact dorsal strips into a 15 ml tube containing 4 ml of 0.05 % trypsin 
and 1 ml DNase I. 
vii)  Incubate at 37 oC in the water bath for 20 min with intermittent agitation. 
viii) Stop the digestion by adding 5 ml of trypsin inhibitor (or DMEM/FBS media), and 
centrifuge at 100 g for 3 min at room temperature. 
ix) Discard the supernatant. Wash the tissue pellet by adding 2 ml CMF-HBSS.  
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4. Use a fire-polished glass pipette to triturate the tissue, gently pipetting up and down 5 to 10 
times, taking care to avoid bubbles. Small chunks of tissue should still remain, but the 
media will become cloudy as cells are released.  
CRITICAL STEP: Pipetting speed needs to be low and the inside diameter of the 
glass pipette tip is critical. If it is too large it will not dissociate the cells effectively, and if it 
is too small it will increase cell damage. The optimal size depends on the size of tissue 
chunks. One solution is to sequentially triturate with three pipettes with decreasing 
diameters. 
5. Allow tissue pieces to settle for 1 min. Then aspirate the supernatant into a fresh 15 ml tube 
and centrifuge for 3 min at 100 g at room temperature.  
CRITICAL STEP: Be careful not to aspirate the settled debris. 
6. Remove supernatant. Gently resuspend pellet in 1 ml of DMEM-FBS. 
7. In a 1.5 ml tube, mix 10 µl trypan blue with 10 µl of cell suspension. Load 10 µl into the 
haemocytometer and count the viable (non-blue) cells, remembering to multiply the final 
count by 2 to account for the trypan blue dilution. Typically, cortices from 3 embryos or 
spinal cords from 7 embryos will result in 200-500 cells per 0.1 µl.  
8. Dilute cells in DMEM-FBS so that 80 – 100 µl can be plated on each coverslip of 8 dishes, 
resulting in 80,000 cells per coverslip. Dilute the remaining cells 2-fold, and plate the 
remaining 8 dishes at 40,000 cells per coverslip. 
9. Incubate overnight, and then change media by aspirating the DMEM-FBS and replacing 
with 500 µl neuron media. Return dishes to the incubator  
10. After 1 week in vitro, perform a half media change by removing 250 µl media and topping 
up with a further 500 µl of fresh neuron media. This is the final feed and will allow the cells 
to remain healthy for up to 6 weeks. 
 
Preparation of HEK293 cells 
11. Trypsinize HEK293 cells in a T75 flask and plate in DMEM-FBS onto 35 mm culture 
dishes (suggested starting density: 5000 cells per dish). Incubate overnight at 5 % CO2. 
12. To transfect, combine 0.5 – 3 µg total plasmid DNA, with 100 µl of 250 mM CaCl2, then 
add 100 µl BBS. Vortex and incubate for 10 min at room temperature, then add dropwise to 
one 35 mm dish of HEK293 cells. When expressing GlyRs, the total plasmid DNA should 
comprise: 200 ng neuroligin 2A, 200 ng gephyrin, 100 ng GFP, with the remainder 
comprising GlyR subunit DNA that varies according to the number of subunits and the ratio 
of subunit DNA required. For example, when transfecting GlyR a subunits as homomers, 
add 0.5 µg DNA. When transfecting a and b GlyR subunits in 1:10 or 1:50 ratios add a total 
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of 2 µg DNA. When expressing a1b2g2 GABAARs, the a1, b2, g2, GFP and neuroligin 2A 
DNAs should be transfected in a 1:1:4:1: ratio with a combined total of 0.5 µg DNA.   
13. Incubate for 5 to 20 h in a 3% CO2 incubator. 
14. Thoroughly rinse each plate with PBS, then incubate in 0.5 ml trypsin until most cells 
detach (typically 3 min). Quench with 2 ml DMEM-FBS, and remove cell suspension into 
15 ml tube. Centrifuge at 100 g for 3 min at room temperature. 
Discard supernatant.  
15. Take mature neuron cultures from the incubator and remove around 50 µl from each dish to 
combine with the HEK293 cell pellet. One 35 mm dish of HEK293 cells can be used to seed 
about 4 coverslips of neurons.  
CRITICAL STEP Thoroughly resuspend the HEK293 cell pellet in neuron media so that 
all cells are completely isolated. Well isolated cells are essential for allowing the efficient 
formation of synaptic contacts and to facilitate electrophysiological recording from 
identified cells.  
16. Return the co-cultures to the incubator overnight to allow synapses to form. Cultures can 
then be used for 2 – 3 d. 
 
Electrophysiological analysis of spontaneous activity 
17.  Using fine forceps, place a coverslip gently into an electrophysiological recording bath on 
the stage of the fluorescence microscope that forms part of the patch-clamp 
electrophysiology rig. The cells should be perfused continuously with an extracellular 
solution comprising (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-
glucose, adjusted to pH 7.4 with NaOH. Depending on the experiment, pharmacological 
agents may be added or the ionic composition may be varied. Because drugs that affect 
IPSCs may also change the rate of spontaneous activity in the neurons, it is advisable to 
apply drugs directly to the patch-clamped cell, and expose the rest of the coverslip to control 
saline as much as possible. We achieve this using a small array of plastic tubes glued 
together, with control solution flowing through all but the central tube. 
18. Patch pipettes (4−8 MΩ resistance), made from borosilicate glass (GC150F-7.5, Harvard 
apparatus), should be filled with an intracellular solution containing (in mM): 145 CsCl, 2 
CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA and 2 MgATP, adjusted to pH 7.4 with NaOH. The 
ionic composition can be varied according to experimental requirements. Heat polishing the 
pipette tips can help with seal formation, but be aware of the effect of increased series 
resistance on rapid events (see next step).  
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CRITICAL STEP: As IPSCs exhibit rise times in the microsecond range, it is important to 
filter and digitise currents at a high rate (at least 4 and 10 kHz, respectively) and to apply the 
maximum possible series resistance compensation. 
19. Choosing a cell for electrophysiological recording is a matter of trial and error. A good 
starting point is to select large, strongly-fluorescent green cells that are closely surrounded 
by many neurons, especially clumps of neurons. HEK293 cells with a textured (rather than 
smooth) appearance often yield abundant IPSCs. A good rule of thumb is to target cells that 
look similar to those that have previously yielded successful recordings. 
20. Voltage clamp cells at -70 mV to -50 mV to record spontaneous events for several minutes, 
or until more than 100 putative events have been collected.  
21. The coverslip should be viable for 1 − 2 h. Discard it sooner if cell viability starts to appear 
degraded. Unused coverslips in 4-well plates should be returned to the incubator as soon as 
possible to maintain the pH of the medium. 
22. Analyses of IPSC amplitudes, 10 − 90% rise times, and decay time constants can performed 
using a range of analysis software packages including Axograph X (Axograph Scientific), 
Minianalysis (Synaptosoft) and pClamp10 (Axon Instruments, Molecular Devices).  
 
TIMING 
See Figure 1 for an overview of the procedure. Set-up and culturing of primary neurons takes 2 to 3 
h (the dissection for spinal cord cultures is longer). Then the neurons must be cultured until 
maturity, at least 3 wk for cortical neurons and 1 – 1.5 wk for spinal cord neurons. Preparing the 
HEK293 cells and adding them to the neurons takes about 2 h spread across 3 d. Once HEK293 
cells have been added to the neurons, the synapses form within 24 h and at this point the 
electrophysiological experiments can be commenced.  
 
TROUBLESHOOTING 
• Not enough neurons for plating: If there are not enough cells to fill the intended plates, 
trituration may have been too vigorous (more then 50 % of cells trypan positive) or too 
gentle (few trypan positive cells and few negative) Experiment with trituration of different 
strengths. As noted above, the tip size of the flame-polished glass pipette is crucial: a very 
small opening will damage more cells, but a large opening will not dissociate the cells 
effectively. 
• Massive cell death after seeding: Check the incubator CO2 level, temperature, and water 
levels; check the temperature of the trypsin incubation; make fresh neuron media or 
coverslip coating solution.  
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• Difficulty forming seals on HEK293 cells: Co-cultured cells are often more difficult to 
record from than HEK293 cells that have been cultured in isolation. Fire polishing the patch 
pipette tip can help to form high resistance seals, but be aware of increasing the series 
resistance. 
• Unhealthy neuron cultures leading to little spontaneous activity: Too many glia present in 
the final cultures (take more care to remove the meninges), or plating density too high or too 
low. 
• Non-transfected HEK293 cells: Adjust DNA ratios, or try fresh BBS. Alternately, other 
methods of transfecting HEK293 cells could also be applied. 
• No detectable spontaneous IPSCs in the HEK293 cells: Check that the cells are expressing 
functional receptors by directly applying the appropriate neurotransmitter agonist. If there is 
no current, trouble-shoot the transfection. If agonist-evoked currents are present, check that 
the neurons exhibit spontaneous spiking activity by recording from a few. If they are not 
active, the neuronal cultures may be too young or too old, the neuron density may be too 
high or too low (leading to cell death) or excess glial growth may be impairing neuronal 
activity. Check that neuroligin is being successfully expressed using immunofluorescent 
labelling for the HA tag (as shown in Figure 1, inset). If all of these things seem normal but 
brightly fluorescent HEK293 cells still do not have currents, consider patching cells with 
different appearances, including those with low fluorescence. We find that large or brightly 
fluorescent HEK293 cells next to clumps of neurons have the highest probability of showing 
synaptic activity. 
 
 
